PosterSessionOnline

EUROPEAN HEMATOLOGY ASSOCIATION

20th Congress of EHA

11-14 June 2015 Vienna

N. Poster

Poster title

Applicant name

Status


151-P	DISTINCTIVE GENOTYPES WITH PRENATAL ORIGINS IN INFANT T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA	Anthony Ford	Received

152-P	DETAILED GENOME ANALYSES REVEAL EXTENSIVE RAG-MEDIATED REARRANGEMENTS IN ADULT ACUTE LEUKEMIA SUBSETS	Mathijs Sanders	Received

153-P	AGE SPECIFIC INCIDENCE OF PARTNER GENE AND SECONDARY ABNORMALITIES IN MLL POSITIVE ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)	Alem Gabriel	Received

154-P	PROGNOSTIC AND THERAPEUTIC IMPLICATIONS OF RAS/RTK PATHWAY MUTATIONS IN DIFFERENT AGE COHORTS OF B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITHOUT KNOWN FUSION TRANSCRIPTS	Monica Messina	Received

155-P	DUAL SMALL MOLECULE INHIBITORS TARGETING G9A AND DNMTS: A NOVEL STRATEGY FOR TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA	Edurne San Jose	Received

157-P	RESTORING IKAROS TUMOR SUPPRESSION AS A THERAPY FOR HIGH-RISK LEUKEMIA	Chunhua song	Received

158-P	THE STEMNESS INHIBITOR, BBI608, REDUCES THE SELF-RENEWAL OF BCR-ABL1 POSITIVE LEUKEMIA CELLS.	Tetsuzo Tauchi	Received

159-P	TP53 MUTATIONS IN PHILADELPHIA NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) DEFINE A GROUP OF VERY HIGH RISK PATIENTS: A NEXT GENERATION SEQUENCING (NGS) STUDY.	Marie Lorena Guinea	Received

161-P	INFLUENCE OF BASELINE FACTORS ON OUTCOMES IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL) TREATED WITH BLINATUMOMAB	Max S.Topp	Received

162-P	CHARACTERIZATION OF LEF1 HIGH EXPRESSION AND NOVEL MUTATIONS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA	Zheng Ge Jose	Received

163-P	HIGH RATE OF COMPLETE HEMATOLOGICAL RESPONSE IN ELDERLY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS BY INNOVATIVE SEQUENTIAL USE OF NILOTINIB AND IMATINIB: A GIMEMA CLINICAL TRIAL LAL 1408	Cristina Papayannidis Guinea	Received

164-P	INTERNATIONAL MULTI-LABORATORY NEXT-GENERATION SEQUENCING FOR MRD ANALYSIS IN ALL. A PILOT STUDY BY THE EUROCLONALITY-NGS CONSORTIUM.	Monika BRÜGGEMANN Jose	Received

165-P	RETREATMENT WITH BLINATUMOMAB AFTER CD19-POSITIVE RELAPSE: EXPERIENCE FROM 3 TRIALS IN PATIENTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL)	Max S.Topp	Received

166-P	CENTRAL NERVOUS SYSTEM AS AN IMMUNOLOGICAL SANCTUARY FOR ACUTE LYMPHOBLASTIC LEUKEMIA: ROLE OF NATURAL KILLER CELLS.	Shai Izraeli	Received

169-P	ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO HAD CENTRAL NERVOUS SYSTEM INVOLVEMENT: A STUDY FROM THE ADULT ALL WORKING GROUP OF THE JSHCT	Akio Shigematsu Guinea	Received

170-P	REDEFINE CLINICAL RISK CLASSIFICATION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA USING INITIAL ABSOLUTE LYMPHOCYTE COUNT	Koramit Suppipat	Received

171-P	THE CXCR4 ANTAGONIST BL-8040 DIRECTLY AFFECTS AML BLASTS BY INDUCING THEIR TERMINAL DIFFERENTIATION AND BLOCKING SURVIVAL SIGNALS	Yaron Pereg Sehn	Received

172-P	TARGETING ABERRANT NCAM (NEURAL CELL ADHESION MOLECULE; CD56) EXPRESSION IN ACUTE MYELOID LEUKEMIA	Daniel Sasca Sehn	Received

173-P	GENETIC AND EPIGENETIC EVOLUTION DURING THE PROGRESSION OF CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA (CN-AML)	Sebastian Vosberg Sehn	Received

174-P	GENOTOXIC STRESS MODULATES EVI1 INTERACTION WITH CTBP1 IN ACUTE MYELOID LEUKAEMIA CELLS	Marion Schneider Jose	Received

175-P	COMBINING IMMUNE CHECKPOINT INHIBITION WITH AMG 330 TO ENHANCE T CELL MEDIATED LYSIS OF PRIMARY AML CELLS	Christina Krupka Sehn	Received

176-P	DIFFERENTIAL RESPONSIVENESS OF PML-RARA CARRYING VARIOUS POINT MUTATIONS TO ARSENIC TRIOXIDE	Jiangying Liu	Received

177-P	SURVIVAL PREDICTION AND IDENTIFICATION OF KEY PROGNOSTIC PROTEINS IN ACUTE MYELOID LEUKEMIA USING REVERSE PHASE PROTEIN ARRAY	Erel Joffe Guinea	Received

178-P	MICRORNA-182, C/EBP? AND E2F GENERATE AN AUTOREGULATORY FEEDBACK NETWORK WHICH IS DYSREGULATED IN ACUTE MYELOID LEUKEMIA	Alexander Arthur Wurm	Received

179-P	THE LEUKEMIA-ASSOCIATED RUNX1/ETO ONCOPROTEIN CONFERS A MUTATOR PHENOTYPE	Victoria Forster	Received

180-P	EVALUATION OF MINIMAL RESIDUAL DISEASE IN CHILDREN WITH CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA â€" RESULTS OF THE FRENCH MULTICENTER ELAM02 TRIAL	Hélene Lapillonne Sehn	Received

181-P	HIGH PROGNOSTIC VALUE OF PRE TRANSPLANT MINIMAL RESIDUAL DISEASE ASSESSMENT BY COMBINED WT1 EXPRESSION AND FLOW CYTOMETRY IN ACUTE MYELOID LEUKEMIA PATIENTS	Fabio Guolo Guinea	Received

182-P	A COMPARISON OF DAUNORUBICIN/ CLOFARABINE AND FLAG-IDA IN HIGH RISK ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 TRIAL	Alan Burnett Sehn	Received

183-P	FLUDARABINE-CONTAINING INDUCTION INCREASES MINIMAL RESIDUAL DISEASE CLEARENCE AND IMPROVES SURVIVAL IN AML PATIENTS WITH CONCOMITANT NPM1 AND FLT3-ITD MUTATIONS	Fabio Guolo Guinea	Received

185-P	DEFINITION OF CURE IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA	Gevorg Tamamyan Guinea	Received

186-P	RESIDUAL HEMATOPOIETIC STEM CELLS REFLECT MINIMAL RESIDUAL DISEASE AND PREDICT OUTCOME IN ACUTE MYELOID LEUKEMIA	Wenwen Wang Guinea	Received

187-P	ALLOGENEIC TRANSPLANT IN PATIENTS =60 YEARS OF AGE WITH FIRST RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA AFTER TREATMENT WITH VOSAROXIN OR PLACEBO PLUS CYTARABINE: RESULTS FROM VALOR	Diana Talag Wurm	Received

188-P	RELAPSE CHARACTERISTICS AND RISK FACTORS FOR CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ACUTE PROMYELOCYTIC LEUKAEMIA IN THE ORAL ARSENIC TRIOXIDE ERA – A 13-YEAR FOLLOW-UP STUDY	Harinder Gill	Received

192-P	NOVEL FUSIONS AND POINT MUTATIONS DETECTED IN NEWLY DIAGNOSED AML PATIENTS BY RNA-SEQ IDENTIFY POTENTIAL NEW TREATMENT OPTIONS	Caterina Cecchetti Sehn	Received

193-P	SALVAGE REGIMENT WITH FRACTIONATED GEMTUZUMAB OZOGAMICIN, INTERMEDIATE DOSE CYTARABINE AND MITOXANTRONE (MYLODAM) FOR REFRACTORY AND RELAPSED AML: A SINGLE CENTER EXPERIENCE.	Anne-Claire Mamez Sehn	Received

195-P	MICRODUPLICATION 17Q21.31 AND 17P11.2 ASSOCIATE WITH AML DIAGNOSIS OR RESPONSE TO THE THERAPY	Emilia Jaskula Guinea	Received

196-P	THE SIGNIFICANCE OF RELATIVE MUTANT LEVEL FOR C-KIT MUTATION IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA BY ALLELE-SPECIFIC REAL-TIME PCR	Eunhee Han Sehn	Received

197-P	IMPROVED SURVIVAL IN PATIENTS â‰¥60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY	Farhad Ravandi-Kashani Sehn	Received

198-P	IMPORTANCE OF THE B-CELL RECEPTOR ISOTYPE FOR SIGNALING AND FUNCTIONAL RESPONSES IN B CELLS FROM PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Jan Burger Wurm	Received

199-P	HIGHER-ORDER IMMUNOGLOBULIN SEQUENCE RELATIONS FOR MAJOR SUBSETS OF CHRONIC LYMPHOCYTIC LEUKEMIA: UNIQUENESS VERSUS EQUIVALENCE	Andreas Agathangelidis Guinea	Received

200-P	SPECIFIC T-CELL IMMUNE RESPONSES AGAINST AUTOANTIGENS RECOGNIZED BY CHRONIC LYMPHOCYTIC LEUKEMIA CELLS	Joanna Zaleska Guinea	Received

201-P	STEM CELL FACTOR KLF4 IS EPIGENETICALLY INACTIVATED AND REPRESSED BY NOTCH SIGNALING IN CLL	Daniel Mertens	Received

202-P	NOTCH2 AND NOTCH3 HAVE OPPOSITE ROLES IN THE REGULATION OF APOPTOSIS IN CLL CELLS	Rainer Hubmann Guinea	Received

203-P	EXPRESSION AND FUNCTIONAL ROLE OF CORTACTIN IN AGRESSIVENESS AND DIFFUSION OF CHRONIC LYMPHOCYTIC LEUKEMIA	Veronica Martini Wurm	Received

204-P	ROLE OF HAUSP/PTEN NETWORK IN CHRONIC LYMPHOID LEUKEMIA PATHOGENESIS AND THERAPY	Giovanna carrà Guinea	Received

205-P	UPREGULATED COBLL1 IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) PATIENTS WITH UNMUTATED IGHV IDENTIFIES A COHORT WITH INFERIOR PROGNOSIS	Hana Plešingerová Guinea	Received

206-P	EXTRACELLULAR VESICLES FROM MESENCHYMAL STROMAL CELL MICROENVIRONMENT PROTECT CHRONIC LYMPHOCYTIC LEUKEMIA B-CELLS FROM APOPTOSIS	Emerence Crompot Wurm	Received

207-P	FUNCTIONAL INVOLVEMENT OF THE SRC KINASE LYN IN THE SURVIVAL OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS VIA MAINTENANCE OF ANTI-APOPTOTIC B CELL RECEPTOR SIGNALING	Günter Krause Guinea	Received

209-P	REFINING PROGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH SOMATICALLY HYPERMUTATED B-CELL RECEPTORS: A NOVEL PROGNOSTIC INDEX ON BEHALF OF THE EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC)	Panagiotis Baliakas Guinea	Received

210-P	LONG-TERM FOLLOW-UP OF A PHASE IB TRIAL OF IDELALISIB IN COMBINATION WITH CHEMOIMMUNOTHERAPY (CIT) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CLL INCLUDING PATIENTS WITH DEL17P/TP53 MUTATION	Jacqueline Barrientos Sehn	Received

211-P	A RANDOMISED DE-ESCALATION STUDY OF ORAL FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB IN FIT ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA: WELL TOLERATED AND SUPERIOR OUTCOMES WITH FCR	Stephen Mulligan Wurm	Received

215-P	CHRONIC LYMPHOCYTIC LEUKEMIA MD ANDERSON CANCER CENTER PROGNOSTIC INDEX IS SUCCESSFUL BUT STILL CAN BE IMPROVED BY INCORPORATING SERUM LDH LEVEL	Gursel Gunes Guinea	Received

216-P	GENETIC BASIS OF HAIRY CELL LEUKEMIA (BRAF) REVEALS HIGH FREQUENCIES OF MUTATIONS IN BRAF V600E, U2AF1 AND MAP2K1 GENES	Sheetal GAWARE	Received

217-P	LLC-LENAR-08 A PHASE I/II STUDY LENALIDOMIDE-RITUXIMAB IN RELAPSE/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA	Adolfo De La	Received

218-LB	IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY	Paula Cramer Salinas	Received

218-P	NON GENOMIC LOSS OF FUNCTION OF TUMOR SUPPRESSORS IN CML: BCR-ABL PROMOTES P53 NUCLEAR EXCLUSION THROUGH THE INTERACTION WITH IKB-ALPHA	Sabrina Crivellaro Wurm	Received

219-LB	OFATUMUMAB (O) IN COMBINATION WITH FLUDARABINE (F) AND CYCLOPHOSPHAMIDE (C) (OFC) VS. FC IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): RESULTS OF THE PHASE III STUDY COMPLEMENT 2	Tadeusz Robak Salinas	Received

219-P	TRANSCRIPTION FACTOR MEF2C IS UPREGULATED DURING CML DISEASE PROGRESSION AND INHIBITS C/EBP? EXPRESSION	Soumen Chakraborty Wurm	Received

221-P	DO ENDOTHELIAL CELLS BELONG TO THE PRIMITIVE LEUKEMIC CLONE IN CML? ¬ ROLE OF EXTRACELLULAR VESICLES	Teresa Ramos	Received

222-P	PPAR-GAMMA LIGANDS INCREASE ANTILEUKEMIC ACTIVITY OF 2ND AND 3RD GENERATION TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA CELLS	Eliza Glodkowska-Mrowka Guinea	Received

223-P	IDENTIFICATION OF BRD4 AS A NOVEL MOLECULAR TARGET IN PH+ CML	Barbara Peter	Received

224-P	QUANTITATIVE EVALUATION OF BOTH POINT MUTATED AND ALTERNATIVELY SPLICED BCR-ABL IN CML-CP PATIENT WITH SUBOPTIMAL MOLECULAR RESPONSE TO IMATINIB: RESULT OF HIGHLY-SENSITIVE, DEEP SEQUENCING STUDY	Junichiro Yuda Guinea	Received

225-P	AN ITALIAN MULTICENTRIC EVALUATION OF THE Q-LAMP TECHNOLOGY APPLIED TO THE MOLECULAR DETECTION OF BCR-ABL TRANSCRIPTS IN ARCHIVED RNA FROM PHILADELPHIA POSITIVE ONSET SAMPLES	Maria Teresa Bochicchio	Received

226-P	DYNAMIC EXPANSION AND FUNCTIONAL TUNING OF NATURAL KILLER CELLS IN CHRONIC MYELOID LEUKEMIA	Paulo Rodrigues Santos	Received

227-P	IS THE HIGH-THROUGHPUT DROPLET DIGITAL PCR A NEXT-GENERATION TECHNOLOGY FOR ACCURATE AND SENSITIVE BCR-ABL1 QUANTIFICATION FOR DEEP MOLECULAR RESPONSE MONITORING IN CML?	Hana Zizkova La	Received

228-P	EFFICACY AND SAFETY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: 6-YEAR FOLLOW-UP OF ENESTND	Timothy Hughes La	Received

229-P	ENESTCMR 4-Y RESULTS: PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND RESIDUAL DISEASE MORE LIKELY TO ACHIEVE DEEP MOLECULAR RESPONSE FOLLOWING SWITCH TO NILOTINIB (NIL)	Timothy Hughes La	Received

230-P	DEEP MOLECULAR RESPONSE TO NILOTINIB AS FIRST-LINE TREATMENT OF BCR-ABL+ CML	Fausto Castagnetti	Received

231-P	SMOOTHENED (SMO) INHIBITOR LDE225 COMBINED WITH NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT (R/I) TO AT LEAST 1 PRIOR TYROSINE KINASE INHIBITOR: A PHASE 1B STUDY	Oliver Ottmann La	Received

232-P	FINAL LASOR RESULTS: SWITCH TO NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND SUBOPTIMAL CYTOGENETIC RESPONSE (CYR) TO FRONTLINE IMATINIB (IM)	Philipp Le Coutre	Received

233-P	HEALTH-RELATED QUALITY OF LIFE IN CML PATIENTS UNDER NILOTINIB FIRST-LINE TREATMENT: RESULTS OF A GERMAN SUB-STUDY WITHIN THE ENEST1ST TRIAL	Insa Luetge Coutre	Received

234-P	PONATINIB EFFICACY AND SAFETY IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 3-YEAR RESULTS OF THE PACE TRIAL	Jorge Cortes Coutre	Received

235-P	RESPONSES AT EARLY LANDMARK TIME POINTS ARE ASSOCIATED WITH OUTCOMES IN HEAVILY PRETREATED CP-CML PATIENTS (PTS) TREATED WITH PONATINIB	Martin Mueller Coutre	Received

236-P	LONG-TERM FOLLOW-UP OF PONATINIB EFFICACY AND SAFETY IN PATIENTS (PTS) WITH THE T315I MUTATION IN THE PHASE 1 AND PHASE 2 (PACE) TRIALS	Michele Baccarani Coutre	Received

237-P	MINIMUM FOLLOW-UP OF 4 YEARS FOR ONGOING PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN A PHASE 1 TRIAL OF PONATINIB	Moshe Talpaz Coutre	Received

238-P	HYPOPLASTIC MYELODYSPLASTIC SYNDROME (H-MDS): DISTINCT CLINICO-BIOLOGICAL FEATURES AND PROGNOSTIC RELEVANCE	Chi-Yuan Yao	Received

239-P	LONG-TERM OUTCOME OF LOWER RISK MDS PATIENTS RECEIVING ESA, AND IMPACT OF POST ESA TREATMENTS ON SURVIVAL: A RETROSPECTIVE STUDY FROM THE GFM, DUSSELDÖRF, AND GESMD REGISTRIES	Sophie PARK	Received

240-P	EVALUATION OF DYSPLASIAS IN 1979 PATIENTS WITH MYELODYSPLASTIC SYNDROMES COLLECTED IN A GERMAN-AUSTRIAN DATA SET TO APPROACH THE HETEROGENEITY OF THE DISEASE	Michael Pfeilstöcker	Received

241-P	RANDOMIZED, PLACEBO (PBO)-CONTROLLED, PHASE I/II TRIAL OF THE THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG (EPAG) IN THROMBOCYTOPENIC PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS)	Uwe Platzbecker	Received

243-P	IMPACT OF MDS ON HEALTH-RELATED QUALITY OF LIFE: A COMPARISON OF IPSS LOW- AND INT-1 RISK MDS PATIENTS FROM THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY AND EUROPEAN REFERENCE POPULATIONS	Reinhard STAUDER MSc	Received

244-P	SPRESAS (SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY): THE LARGEST RETROSPECTIVE STUDY OF TREATMENT WITH ESAS IN LOWER RISK MDS	María Díez	Received

246-P	PROGNOSTIC IMPACT OF CHROMOSOMAL TRANSLOCATIONS IN MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA PATIENTS. A STUDY BY THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROMES.	Meritxell Nomdedeu	Received

247-P	SUPERIOR LONG-TERM OUTCOMES OF LOWER RISK MDS PATIENTS WHEN TRANSPLANTED IN RESPONSE COMPARED TO RELAPSED OR REFRACTORY TO HMA	Yoo JinLee	Received

248-P	ABERRANT EXPRESSION PROFILES OF HLA-G AND IMMUNOGLOBULIN-LIKE TRANSCRIPTS (ILTS) IN ACQUIRED APLASTIC ANEMIA.	Yuanxin Sun Campelo	Received

249-P	THE MTOR SIGNALING PATHWAY IS ACTIVIVED IN T CELLS OF APLASTIC ANEMIA	Guangsheng He Coutre	Received

250-P	THE PREVALENCE OF GATA-2 MUTATION AMONG PEDIATRIC PATIENTS WITH MYELODYSPLASTIC SYNDROME IN CZECH REPUBLIC	Michaela Novakova Coutre	Received

252-P	IMMUNOPHENOTYPIC PROFILING OF ERYTHROID PROGENITOR-DERIVED EXTRACELLULAR VESICLES IN DIAMOND-BLACKFAN ANAEMIA: A NEW DIAGNOSTIC STRATEGY	Serena Macri Coutre	Received

253-P	ALTERATION OF HEME METABOLISM IN A CELLULAR MODEL OF DIAMOND-BLACKFAN ANEMIA	Deborah CHIABRANDO	Received

254-P	AUTOIMMUNE NEUTROPENIA OF INFANCY: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY	Piero Farruggia Coutre	Received

256-P	SOLUBLE CD163 AS A MARKER FOR MACROPHAGE ACTIVATION IN CHILDREN AND ADOLESCENTS WITH GAUCHER DISEASE: RELATION TO PULMONARY AND BONE INVOLVEMENT	Amira Adly MSc	Received

257-P	THE PROGNOSIS OF ACQUIRED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN ADULTS IS HEAVILY AFFECTED BY A COEXISTING VIRAL INFECTION: ANALYSIS OF A SINGLE INSTITUTION SERIES OF 35 PATIENTS	Chiara CATTANEO MSc	Received

258-P	A COMPREHENSIVE GENOME-WIDE COPY NUMBER ALTERATIONS (CNAS) ANALYSIS OF HOMOGENEOUSLY TREATED, NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS.	Carolina Terragna MSc	Received

259-P	RELATIONSHIP BETWEEN INHIBITION PROFILE OF ?1, ?2 AND ?5 PROTEASOME SUBUNITS AND CYTOTOXIC ACTIVITY OF PROTEASOME INHIBITORS IN MULTIPLE MYELOMA	Andrej Besse MSc	Received

260-P	LSD1 IMPAIRS OSTEOCLASTOGENESIS AND EPITHELIAL-MESENCHYMAL TRANSITION IN MM AND ENHANCES HDAC INHIBITORS ACTIVITY	Maria Gkotzamanidou MSc	Received

261-P	S1P MODULATOR FTY720 TARGETS OSTEOCLASTOGENESIS IN CXCR4-BASED MULTIPLE MYELOMA SYSTEMIC XENOGRAFT MODEL	Katia Beider MSc	Received

262-P	PTC-209, A TRANSCRIPTIONAL SMALL MOLECULE INHIBITOR OF BMI-1, DEMONSTRATES POTENT ANTI-MYELOMA ACTIVITY IN VITRO	Arnold Bolomsky Coutre	Received

263-P	POMALIDOMIDE ENHANCES THE ACTIVATION OF ANTI-MYELOMA SPECIFIC T CELLS IN HEALTHY DONORS AND MULTIPLE MYELOMA PATIENTS	Jingying Dai	Received

264-P	LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES.	Nicola GIULIANI MSc	Received

265-P	P21-ACTIVATED KINASE 4 (PAK4) REGULATES MULTIPLE MYELOMA (MM) CELL GROWTH AND SURVIVAL BY MODULATION OF CRITICAL TRANSCRIPTIONAL PATHWAYS: THERAPEUTIC APPLICATION OF PAK4 ALLOSTERIC INHIBITORS	Stefania Oliva MSc	Received

267-P	FDG-PET/CT FOCAL LESIONS IN THE ABSENCE OF OSTEOLYSES AS A NEW MARKER OF PROGRESSION OF SMOLDERING MULTIPLE MYELOMA INTO SYMPTOMATIC DISEASE	Elena ZAMAGNI	Received

268-P	ANALYSIS OF OUTCOMES BY RESPONSE FOR PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PHASE 3 PANORAMA 1 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE	Philippe Moreau Coutre	Received

269-P	WEEKLY CARFILZOMIB WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 STUDY CHAMPION-1 (NCT01677858)	James Berenson Coutre	Received

270-P	EARLY MORTALITY IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS: A POOLED ANALYSIS OF TWO LARGE RANDOMIZED PHASE III TRIALS	Alessandra Larocca MSc	Received

271-P	MAINTENANCE THERAPY WITH LENALIDOMIDE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST-HOC ANALYSIS OF THE EMN01 TRIAL.	Valeria Magarotto MSc	Received

272-P	OUTCOMES FOR OLDER PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE IN THE STRATUS (MM-010) TRIAL, A SINGLE-ARM, PHASE 3B STUDY	Antonio Palumbo Coutre	Received

273-P	THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE + LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA	Meletios A Dimopoulos	Received

274-P	IMPACT OF RENAL IMPAIRMENT ON OUTCOMES AFTER TREATMENT WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: FIRST TRIAL RESULTS	Meletios Dimopoulos Dimopoulos	Received

275-P	AN OPEN-LABEL, MULTICENTER, PHASE 1B STUDY OF DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE AND WITH BACKBONE REGIMENS IN PATIENTS WITH MULTIPLE MYELOMA	Maria-Victoria Mateos Campelo	Received

276-P	OUTCOMES OF PATIENTS WITH PRIMARY REFRACTORY MULTIPLE MYELOMA IN THE ERA OF NOVEL THERAPIES	Neil Majithia Campelo	Received

277-P	ASSESSING THE BENEFIT OF CONTINUOUS TREATMENT IN THE FIRST TRIAL (MM-020): IMPACT OF RESPONSE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA	Nizar Bahlis Dimopoulos	Received

278-P	LACK OF RESPONSE IMPROVEMENT BEYOND DAY +100 AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN ABSENCE OF MAINTENANCE THERAPY IN MULTIPLE MYELOMA	Carlos Fernández	Received

279-P	RICOLINOSTAT (ACY-1215) THE FIRST SELECTIVE HDAC6 INHIBITOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED & REFRACTORY MULTIPLE MYELOMA: PHASE 1B & EARLY PHASE 2 RESULTS	Tyce Havens MSc	Received

280-P	PROGRESSION-FREE SURVIVAL 2 (PFS2) IS THE MOST SIGNIFICANT PROGNOSTIC FACTOR OF LONG-TERM SURVIVAL IN THE ERA OF NOVEL AGENTS: A SINGLE GREEK MYELOMA CENTER EXPERIENCE.	Eirini Katodritou Dimopoulos	Received

281-P	OBESITY AND RISK OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: A POPULATION-BASED STUDY	Marianna Thordardottir	Received

282-P	POST AUTOLOGOUS STEM CELL TRANSPLANTATION MAINTENANCE IN MULTIPLE MYELOMA. SINGLE CENTER EXPERIENCE OF 18 YEARS: A MARKED SURVIVAL ADVANTAGE WITH INTERFERON.	Gergely Varga	Received

283-P	WHOLE BODY DIFFUSION WEIGHTED MRI SCANNING IN PATIENTS WITH MYELOMA. INCIDENTAL FINDINGS - THE ROYAL MARSDEN EXPERIENCE.	Anita Wale MSc	Received

284-P	PATTERNS OF TOTAL COST OF CARE BY AGE GROUP FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)	Steven Arikian Dimopoulos	Received

285-P	ENCOURAGING PRELIMINARY DATA IN ONGOING OPEN-LABEL PHASE 1/2 STUDY OF SAFETY AND EFFICACY OF MELFLUFEN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA	Eva Nordström	Received

286-P	ANALYSIS OF PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT TREATED WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE IN THE PHASE 3B STRATUS TRIAL (MM-010)	Katja Weisel Dimopoulos	Received

287-P	PROGNOSTIC VALUE AND USEFULNESS OF SERUM-FREE-LIGHT-CHAINS-RATIO (SFLCR) AND SERUM HEAVY-LIGHT-CHAINS-RATIO (SHLCR) IN SYMPTOMATIC MULTIPLE MYELOMA IN THE CONTEXT OF THREE GEM/PETHEMA CLINICAL TRIALS	Lucia Lopez-Anglada	Received

288-P	RISK OF VARICELLA-ZOSTER VIRUS INFECTION IN MYELOMA PATIENTS WITHOUT BORTEZOMIB TREATMENT	Chia-Jen Liu MSc	Received

289-P	VENETOCLAX (ABT-199/GDC-0199) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA : PHASE 1B RESULTS	Philippe Moreau Dimopoulos	Received

290-P	RETROSPECTIVE REFINING OF DIAGNOSIS IN 286 MGUS AND SMM PATIENTS ACCORDING TO THE UPDATED IMWG CRITERIA. CLINICAL IMPLICATIONS	Eftychia Nikolaou	Received

291-P	IS A DEEP RESPONSE THE KEY TO SUCCESSFUL TREATMENT OF MULTIPLE MYELOMA?	Johan Liwing MSc	Received

292-P	FAMILY HISTORY OF LYMPHOPROLIFERATIVE DISEASE ASSOCIATED WITH A SUPERIOR SURVIVAL IN MULTIPLE MYELOMA: A POPULATION-BASED STUDY	Kristrún Aradóttir MSc	Received

293-P	PARENTAL LONGEVITY AND SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA AND MGUS.	Ingigerdur Solveig Sverrisdottir	Received

294-P	SERUM B-CELL MATURATION ANTIGEN IS A NOVEL PROGNOSTIC INDICATOR FOR MULTIPLE MYELOMA PATIENTS AND CORRELATES WITH CLINICAL STATUS AND SURVIVAL	James Berenson Dimopoulos	Received

296-P	INCREASED AND PROLONGED STAT5 ACTIVATION DETECTED FOR A JAK2 E846D GERMLINE MUTATION IN THE SPECIFIC CONTEXT OF EPO RECEPTOR	Katarina Kapralova	Received

297-P	PH-NEGATIVE MPN RED BLOOD CELLS DISPLAY DEREGULATION OF IQGAP1-RHO GTPASE SIGNALING DEPENDING ON CALR/JAK2 STATUS	Nuria SOCORO	Received

298-P	CRITICAL ROLE OF HIS499 IN REGULATING THE DIMERIZATION AND FUNCTION OF THE HUMAN THROMBOPOIETIN RECEPTOR AND RESTRAINING THE REPERTOIRE OF ASPARAGINE PATHOGENIC MUTATIONS.	Emilie Leroy Sverrisdottir	Received

299-P	COMBINED CONSTITUTIVE CANONICAL AND NON-CANONICAL HH SIGNALING CAUSED BY DEPLETION OF PATCHED 2 INDUCES A MYELOPROLIFERATIVE PHENOTYPE AND TRANSFORMS CHRONIC MPNS INTO ACUTE LEUKEMIAS	Claudius Klein	Received

300-P	PROSPECTIVE ISOLATION OF NOVEL POPULATIONS OF MEGAKARYOCYTE- AND ERYTHROID-PRIMED MEGAKARYOCYTE-ERYTHROID PROGENITORS DEMONSTRATES MEGAKARYOCYTE-BIASED LINEAGE COMMITMENT IN PRIMARY MYELOFIBROSIS	Beth Psaila Sverrisdottir	Received

301-P	HIGH RESOLUTION CYTOGENETIC MAPPING AND WHOLE EXOME SEQUENCING REVEAL A COMPLEX PATTERN OF CHROMOSOME 6P ABERRATIONS IN PATIENTS WITH MYELOID MALIGNANCIES	Ana Pudja Sverrisdottir	Received

302-P	DNA METHYLATION PROFILING OF SORTED CELLS FROM MYELOFIBROSIS PATIENTS REVEALS ABERRANT EPIGENETIC REGULATION OF IMMUNE PATHWAYS AND IDENTIFIES EARLY MPN DRIVER GENES	Helene Myrtue Nielsen	Received

303-P	SEQUENTIAL EVALUATIONS OF CALR MUTANT BURDEN IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS	Chiara Cavalloni	Received

304-P	NDEL1-PDGFRB FUSION GENE IN JUVENILE MYELOMONOCYTIC LEUKEMIA ASSOCIATED WITH RESISTANCE TO TYROSINE KINASE INHIBITORS	Konstantin Byrgazov Nielsen	Received

305-P	IDENTIFICATION AND CHARACTERIZATION OF PUTATIVE NEOPLASTIC STEM CELLS IN PATIENTS WITH MAST CELL LEUKEMIA	Gregor Eisenwort Nielsen	Received

306-P	COMORBIDITY AND ITS IMPACT ON ALL-CAUSE MORTALITY IN DANISH PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS FROM 1994-2013: A POPULATION-BASED MATCHED COHORT STUDY	Marie bak Nielsen	Received

307-P	IMPACT OF JAK2, CALR OR MPL MUTATION STATUS ON PREGNANCY OUTCOME IN PATIENTS WITH ESSENTIAL THROMBOCYTEMIA	Elisa Rumi	Received

308-P	QUALITY OF LIFE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS COMPARED TO NORMAL INDIVIDUALS â€" CASE-CONTROL EVIDENCE OF SIGNIFICANT IMPAIRMENT	Andrew Duncombre Dimopoulos	Received

309-P	PREDICTORS OF SURVIVAL IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA	Danijela Lekovic Dimopoulos	Received

310-P	ELEVATED HEMOGLOBIN CONCENTRATION AND RISK OF ACUTE MYOCARDIAL INFARCTION AND VENOUS THROMBOEMBOLISM	M Hultcrantz Nielsen	Received

311-P	IMPACT OF DYNAMIC BLOOD COUNT FOLLOW-UP ON VASCULAR COMPLICATIONS IN 217 PV PATIENTS	Anneli Enblom Dimopoulos	Received

312-P	SPLEEN ENLARGEMENT IS A RISK FACTOR FOR THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA: EVALUATION ON 1097 PATIENTS AND VALIDATION ON 792 PATIENTS	Alessandro Andriani Dimopoulos	Received

313-P	CLINICAL VALUE OF SPLENIC VOLUME MEASURED BY COMPUTED TOMOGRAPHY AS A NOVEL PROGNOSTIC FACTOR IN PATIENTS WITH PRIMARY MYELOFIBROSIS	Moo-Kon Song	Received

314-LB	PERSIST-1: A PHASE III STUDY OF PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (PPV-MF) OR POST-ESSENTIAL THROMBOCYTHEMIA MF (PET-MF)	Claire Harrison Salinas	Received

315-P	DYNAMIC ROLE OF THE IRF4-PU.1 AXIS IN IBRUTINIB-RESISTANT WALDENSTROMS MACROGLOBULINEMIA	Kasyapa Chitta Dimopoulos	Received

316-P	KDM5 INHIBITION LEADS TO INCREASED H3K4ME3 LEVELS AND CELL DEATH IN GERMINAL CENTRE LYMPHOMA CELL LINES INDEPENDENT OF MLL2 MUTATION STATUS	Lola Koniali Dimopoulos	Received

317-P	MICRORNA 203 CONTROLS T-CELL LYMPHOMAGENESIS BY TARGETING IL-2 RECEPTOR SIGNALING	Ulrik Ralfkiaer Nielsen	Received

319-P	COMBINED 3D IMMUNO-FISH ANALYSIS OF PRIMARY HODGKIN (H) AND REED-STERNBERG (RS) CELLS REVEALS DISRUPTION OF TELOMERE-TRF2 INTERACTION AND IDENTIFIES HODGKIN´S LYMPHOMA SHELTERIN ASSOCIATED DISEASE	Hans Knecht Nielsen	Received

320-P	A NOVEL ULTRA-DEEP SEQUENCING METHOD FOR TRACKING OF DRIVER MUTATIONS IDENTIFIES THE MYD88 L265P MUTATION IN EARLY HAEMOPOIETIC PRECURSORS IN DIFFUSE LARGE B CELL LYMPHOMA	Dipti Talaulikar	Received

323-P	COMBINED CHEMOIMMUNOTHERAPY (R-CVP) IS AN EFFECTIVE TREATMENT FOR HIV-NEGATIVE, HHV-8 POSITIVE PATIENTS WITH MULTICENTRIC CASTLEMAN´S DISEASE	Alberto FRAGASSO	Received

324-P	SINGLE ARM NCRI FEASIBILITY PHASE II STUDY OF CHOP IN COMBINATION WITH OFATUMUMAB IN INDUCTION AND MAINTENANCE FOR PATIENTS WITH NEWLY DIAGNOSED RICHTERâ€™S SYNDROME	Toby Eyre Dimopoulos	Received

324-LB	GENETIC ALTERATIONS OF IMPORTANCE FOR THE TRANSFORMATION OF FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA	Anna Kwiecinska	Received

325-LB	THE TYK2 PATHWAY AS A NOVEL THERAPEUTIC INTERVENTION SITE IN AGGRESSIVE T-CELL LYMPHOMA	Nicole Prutsch Salinas	Received

326-P	A PHASE 1 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES TREATED WITH A PI3K DELTA INHIBITOR (INCB040093) ALONE OR IN COMBINATION WITH A SELECTIVE JAK1 INHIBITOR (INCB039110)	Moshe Talpaz Dimopoulos	Received

328-P	BENDAMUSTINE COMBINED WITH RITUXIMAB (BR) IN ELDERLY FRAIL PATIENTS WITH NEWLY DIAGNOSED DLBCL	Sergio Storti	Received

331-P	CD56 NEGATIVE EXTRANODAL NK/T CELL LYMPHOMA SHOULD BE REGARDED AS A DISTINCT SUBTYPE WITH POOR PROGNOSIS	Liang Wang Dimopoulos	Received

332-P	DEFINING IMMUNOGLOBULIN SOMATIC HYPERMUTATION IN DE NOVO DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: POTENTIAL APPLICATION FOR PROGNOSIS AND RISK STRATIFICATION	Catherine Sanders Nielsen	Received

333-P	A PHASE 1 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH A PI3K DELTA INHIBITOR (INCB040093) ALONE OR IN COMBINATION WITH A SELECTIVE JAK1 INHIBITOR (INCB039110)	Moshe Talpaz Dimopoulos	Received

334-P	ROUTINE BONE MARROW BIOPSY IN PET/TC ERA FOR HODGKIN LYMPHOMA STAGING.	Lopez Irene Nielsen	Received

335-P	THE PROGNOSTIC VALUE OF BIOLOGICAL MARKERS IN PEDIATRIC HODGKIN LYMPHOMA	Piero Farruggia Dimopoulos	Received

336-P	EVI1 EXPRESSION ASSOCIATES WITH HIGHER CUMULATIVE INCIDENCE OF RELAPSE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING HEMATOPOIETIC CELL TRANSPLANTATION WITH NON-MYELOABLATIVE CONDITIONING	Marius Bill Nielsen	Received

338-P	AUGMENTED CONDITIONING WITH TARGETED MOLECULAR RADIOTHERAPY PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN MYELOMA: RESULTS OF A PHASE II RANDOMISED CONTROL TRIAL WITH IMPROVED CR RATE POST ASCT.	Kim Orchard	Received

339-P	ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS REQUIRING INTENSIVE CARE: DELAY BETWEEN ORGAN DYSFUNCTION AND REFERRAL TO THE INTENSIVE CARE UNIT AND TIME SPENT ON ORGAN SUPPORT IMPACT SURVIVAL	Aurélien Sutra	Received

340-P	OUTCOME AND PROGNOSTIC FACTORS IN FLAMSA SEQUENTIAL CHEMOTHERAPY FOLLOWED BY RIC AND HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIGHER RISK AML AND MDS PATIENTS	Aurélien SUTRA DEL	Received

341-P	PRE-TRANSPLANT QUANTITATIVE MONITORING OF NPM1 MUTATION SIGNIFICANTLY PREDICTS OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN NORMAL KARYOTYPE AML IN COMPLETE REMISSION.	Michal KARAS	Received

342-P	EARLY RELAPSE FOR FOLLICULAR LYMPHOMA (FL) AFTER AUTOLOGOUS STEM CELL TRASPLANTATION (HDT/ASCT) CARRIED OUT IN 1ST OR SUBSEQUENT COMPLETE RESPONSES (CRS) DEFINES PATIENTS AT HIGH RISK FOR DEATH.	Ana Jiménez DEL	Received

343-P	HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA: A RETROSPECTIVE STUDY OF THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION (EBMT).	Tony MARCHAND DEL	Received

344-P	UPDATED RESULTS OF THE MAYO CLINIC RISK ADAPTED ALGORITHM FOR PERIPHERAL BLOOD STEM CELL MOBILIZATION UTILIZING G-CSF AND PLERIXAFOR	Raina Ferzoco	Received

347-P	NO NEGATIVE IMPACT OF AGE ON OUTCOME OF REDUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ELDERLY PATIENTS WITH ACUTE MYELOID	Jun Aoki	Received

349-P	TCR REPERTOIRE DIVERSITY ASSESSED WITH IMMUNOSEQUENCING IS ASSOCIATED WITH PATIENT MORTALITY FOLLOWING CORD BLOOD TRANSPLANT	Catherine Sanders DEL	Received

350-P	NEUROREGENERATIVE POTENTIAL OF INTRAVENOUS INFUSION OF G-CSF FOLLOWED BY MOBILIZED PERIPHERAL BLOOD MONONUCLEAR CELLS IN CHILDREN WITH CEREBRAL PALSY	Young-Ho Lee	Received

352-P	OUTCOME AFTER RELAPSE OR PROGRESSION FOLLOWING FIRST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ACUTE LEUKEMIA. A RETROSPECTIVE ANALYSIS FROM THE SFGM-TC	Clémence ROUX DEL	Received

353-P	BENDA-BEAM HIGH-DOSE THERAPY PRIOR TO AUTO-SCT IS EFFECTIVE IN RESISTANT/RELAPSED DLBCL: A PHASE II MULTICENTER STUDY.	Alessandro Isidori	Received

354-P	TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH A COMBINATION OF B-CELL DEPLETION AND TYROSINE KINASE INHIBITION, PRELIMINARY RESULTS	Lotte VAN DER	Received

355-P	LOW-DOSE DECITABINE COMBINED WITH MODIFIED BUCY AS CONDITIONING REGIMENT FOLLOW BY ALLOGENEIC STEM CELL TRANSPLANTATION FOR THE TREATMENT OF ADVANCED AML/MDS PATIENTS	Xiaowen Tang	Received

356-P	STUDY OF PERIPHERAL STEM CELLS MOBILIZATION AS A TREATMENT LINE FOR PEDIATRIC IDIOPATHIC DILATED CARDIOMYOPATHY	Mohamed El-Shanshory	Received

357-P	IKAROS CONTRIBUTES TO B CELL TOLERANCE BY MODULATING MAPK ACTIVITY	Beate Heizmann	Received

358-P	HIGH-THROUGHPUT SIRNA SCREENING REVEALS GATA-2 UPSTREAM TRANSCRIPTIONAL MECHANISMS IN HEMATOPOIETIC CELLS	Tohru Fujiwara DEL	Received

359-P	FUMARATE HYDRATASE IS AN ESSENTIAL REGULATOR OF EMBRYONIC AND ADULT HAEMATOPOIETIC STEM CELL	Amélie Guitart DEL	Received

360-P	DECODING THE CENTRAL ROLE OF RCOR1 IN PROLIFERATION AND DIFFERENTIATION OF HAEMATOPOIETIC STEM AND PROGENITOR CELLS IN ZEBRAFISH	Ana Cvejic DEL	Received

361-P	DUVELISIB (IPI-145) INHIBITS MALIGNANT B-CELL PROLIFERATION AND DISRUPTS SIGNALING FROM THE TUMOR MICROENVIRONMENT THROUGH MECHANISMS THAT ARE DEPENDENT ON PI3K-DELTA AND PI3K-GAMMA	Jeffery Kutok	Received

362-P	BONE MARROW ADIPOGENESIS BY ACTIVATING PPARG SIGNALING INHIBITS POSTINJURY RECOVERY OF MOUSE HEMATOPOIETIC STRESS MODEL	Wenyi Lu	Received

364-P	A CRITICAL ROLE FOR O-GLCNACYLATION IN MURINE FETAL LIVER AND ADULT HEMATOPOIESIS	Shunsuke Soma DEL	Received

365-P	DEREGULATION OF GENES RELATED TO IRON AND MITOCHONDRIAL METABOLISM IN REFRACTORY ANEMIA WITH RING SIDEROBLASTS	Mónica del Rey	Received

366-P	THE PRESENCE OF HEMOGLOBIN S IS ASSOCIATED WITH MIRNA DEREGULATION INCD34+-DERIVED ERYTHROID CELLS	Thais Fornari	Received

367-P	ORAL IRON SUPPLEMENTS INCREASE HEPCIDING AND DECREASE ABSORPTION FROM DAILY OR TWICE DAILY DOSES: STUDIES WITH STABLE IRON ISTOPIC LABELS IN YOUNG WOMEN	Diego Moretti DER	Received

368-P	RED BLOOD CELL GLYCOLYTIC INHIBITION ALTERS INTRACELLULAR ION CONCENTRATIONS, LEADS TO DECREASED DEFORMABILITY, AND UPREGULATES EXPRESSION OF CLEARANCE SIGNALS.	Rick Huisjes Rey	Received

369-P	MODIFIED ACTRIIB-MFC FUSION PROTEIN (RAP-536) INCREASES FUNCTIONAL RED BLOOD CELLS AND IMPROVES SICKLE CELL DISEASE PATHOLOGY WITH OR WITHOUT HYRDOXYUREA IN A MURINE MODEL	Rajasekhar NVSSuragani	Received

370-P	QUANTIFICATION AND VISUALIZATION OF DIETARY IRON UTILIZATION UNDER ERYTHROPOIETIC STIMULATION BY USING STABLE IRON ISOTOPE 57FE AND MASS SPECTROMETRY	Yukari Tezuka	Received

371-P	FIVE NEW CASES OF HEXOKINASE DEFICIENCY: BIOCHEMICAL AND MOLECULAR CHARACTERIZATION OF A NOVEL SPLICE SITE MUTATION AND 2 NOVEL MISSENSE MUTATIONS IN HK1.	Pavla Koralkova	Received

372-P	CHRONIC PSYCHOLOGICAL STRESS STIMULATES MEDULLARY ERYTHROPOIESIS BY MODULATING LOCAL NITRIC OXIDE PRODUCTION	Mirela Budec	Received

375-LB	POSSIBLE INTERPLAY OF MICRORNA AND TRANSCRIPTION FACTORS DURING IN VITRO ERYTHROID CULTURE OF CD34+ CELLS IN SICKLE CELL ANEMIA	Regiane Ferreira Salinas	Received

375-P	CATEGORIZATION OF CLINICAL SEVERITY IN PYRUVATE KINASE DEFICIENCY (PKD) IN AN INTERNATIONAL, OBSERVATIONAL COHORT	Rachael Grace DER	Received

376-P	EFFICACY AND SAFETY OF VITAMIN C AS AN ADJUVANT TO IRON CHELATION THERAPY IN YOUNG PATIENTS WITH ?-THALASSEMIA MAJOR: A RANDOMIZED PROSPECTIVE TRIAL	Amira Adly Rey	Received

377-P	TREATMENT OF IRON DEFICIENCY ANAEMIA OF LATE PREGNANCY WITH A SINGLE INTRAVENOUS IRON POLYMALTOSE OR FERRIC CARBOXYMALTOSE VERSUS ORAL IRON SULPHATE: A PROSPECTIVE RANDOMIZED CONTROLLED STUDY (TIDAL)	Alhossain Khalafallah Rey	Received

378-P	HYDROXIUREA PRESCRIPTION, AVAILABILITY AND USE FOR CHILDREN WITH SICKLE CELL DISEASE IN ITALY:RESULTS OF THE ITALIAN ASSOCIATION OF PEDIATRIC HEMATOLOGY ONCOLOGY (AIEOP) MULTICENTER SURVEY	Raffaella Colombatti Rey	Received

379-P	NOVEL SICKLE CELL DISEASE DIAGNOSTIC DEVICE DEMONSTRATES HIGH PERFORMANCE AT THE POINT OF CARE	Julie Kanter Rey	Received

380-P	TRANSCRANIAL DOPPLER IN A EUROPEAN COHORT OF SICKLE SC PEDIATRIC PATIENTS	Raffaella Colombatti Rey	Received

381-P	INTRAVENOUS IRON CARBOXYMALTOSE VERSUS STANDARD CARE IN THE MANAGEMENT OF POSTOPERATIVE ANAEMIA: A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL	Alhossain Khalafallah Rey	Received

382-P	ORAL HIGH DOSE LIPOSOMIAL IRON SUPPORT IS SAFE, FAST, WELL TOLERATED AND COST-EFFECTIVE AS INTRAVENOUS IRON IN SIDEROPENIC ANEMIA. MULTICENTRIC RANDOMIZED STUDY.	Giulio Giordano del	Received

383-P	SURVIVAL AND CAUSES OF DEATH IN PATIENTS WITH Î´LPHA- AND Î´ETA-THALASSAEMIA IN A DEVELOPING COUNTRY: THE FIRST REPORT FROM THAILAND	Vip Viprakasit del	Received

384-P	LONG-TERM FOLLOW-UP ON YOUNG PEDIATRIC PATIENTS TREATED WITH DEFERASIROX	Elliot Vichinsky del	Received

385-P	COMPARISON OF MICAFUNGIN AND LIPOSOMAL AMPHOTERICIN B FOR EMPIRICAL ANTIFUNGAL THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED CONTROLLED TRIAL	Tatsuo Oyake Rey	Received

386-P	CAN THERAPEUTIC DRUG MONITORING OPTIMISE EXPOSURE OF PIPERACILLIN IN FEBRILE NEUTROPENIC PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES? A RANDOMISED CONTROLLED TRIAL	Fekade Bruck Sime	Received

388-P	THE ASSOCIATION OF COMBINED ANTIBODY DEFICIENCY AND CHEMOTHERAPY REPRESENTS A HIGH-RISK FACTOR OF NON-NEUTROPENI MAJOR INFECTION IN CLL	Andrea Visentin Sime	Received

389-P	EMERGING RESISTANT BACTERIA STRAINS IN ACUTE LEUKAEMIA PATIENTS: IS THERE STILL A ROLE FOR FLUOROQUINOLONE PROPHYLAXIS? RESULTS OF A PROSPECTIVE STUDY BY THE RETE EMATOLOGICA LOMBARDA (REL)	Chiara CATTANEO Rey	Received

390-P	PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND ACUTE RESPIRATORY FAILURE FROM UNDETERMINED ETIOLOGY ARE AT HIGHEST RISK OF DYING: A GRRR-OH STUDY.	Adrien Contejean Rey	Received

393-P	STREAMLINING THE MANAGEMENT OF BLOOD GROUP O RH NEGATIVE BLOOD STOCK: A SINGLE CENTRE IRISH EXPERIENCE	Emma Groarke Rey	Received

394-P	CELL SALVAGE DURING CARDIAC SURGERY MAY DECREASE RED BLOOD CELL TRANSFUSION: A SYSTEMATIC REVIEW AND META-ANALYSIS	Murtadha Al-Khabori Sime	Received

395-P	IMMUNOGLOBULIN PROPHYLAXIS AGAINST HUMAN T CELL LYMPHOTROPIC VIRUS TYPE I PREVENTS INFECTION IN A HUMANIZED MOUSE MODEL.	Takuo Mizukami Sime	Received

396-P	ENDOGENOUS THROMBIN POTENTIAL FOLLOWING HEMOSTATIC THERAPY WITH 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE: A 7-DAY OBSERVATIONAL STUDY OF TRAUMA PATIENTS	Georgios Papakitsos	Received

397-P	HIGH LEVEL OF UNDERSTANDING FOR BLOOD TRANSFUSIONS IN PATIENTS CAN BE ACHIEVED BY EXPERT STAFF FROM THE TRANSFUSION UNIT.	Hiroaki Furumaki	Received

399-P	MORTALITY REDUCTION WITH A MASSIVE TRANSFUSION PROTOCOL IN A NON-TRAUMA UNIVERSITY MEDICAL CENTER	Nicolas Martinez Rey	Received

400-P	THE TAIL MUTATIONS OF MYH9 INHIBIT THE DISASSEMBLY OF NON-MUSCLE MYOSIN IIA	Koji Miyazaki Rey	Received

401-P	PLATELET PROGENITORS AFTER LEAVING BONE MARROW	Shugo Kowata Sime	Received

404-P	OUTCOMES OF 65 PREGNANCIES IN 34 WOMEN WITH 5 DIFFERENT FORMS OF INHERITED PLATELET FUNCTION DISORDERS ENROLLED IN A RETROSPECTIVE AND MULTICENTRIC STUDY	Patrizia Noris	Received

405-P	PREDICTION OF SEVERE ADAMTS13 DEFICIENCY IN PATIENTS WITH THROMBOTIC MICROANGIOPATHIES	Jorge Nieto Sime	Received

407-P	EFFICACY OF PROPHYLACTIC SINGLE DONOR PLATELETS (SDP) TRANSFUSION IS RELATED TO THE TIME OF STORAGE AND NOT TO THE ABO COMPATIBILITY IN CHILDREN WITH MALIGNANCY	Despoina Adamidou Sime	Received

408-P	IMPACT OF HIGH ON-TREATMENT PLATELET REACTIVITY ON 5-YEAR MORTALITY IN PATIENTS AFTER MYOCARDIAL INFARCTION	Martin Jakl Rey	Received

409-P	NEUTROPHILS CONTRIBUTE TO THE GENERATION OF PROCOAGULANT PLATELETS BY A MYELOPEROXIDASE INDEPENDENT MECHANISM	Leonardo Pasalic Rey	Received

410-P	RELEVANT ROLE OF VON WILLEBRAND FACTOR IN EXPERIMENTAL SEPSIS BY CECAL LIGATION AND PUNCTURE IN MOUSE	Mitsuhiko Sugimoto	Received

411-P	A NOVEL ASSAY DEMONSTRATES PROCOAGULANT PLATELETS ARE INCREASED IN PATIENT UNDERGOING CORONARY ANGIOGRAPHY WITH DIFFERENTIAL EFFECTS BY ANTI-PLATELET AND ANTI-COAGULANT THERAPY	Leonardo Pasalic Rey	Received

412-P	SUITABILITY OF THE CAPE BABOON IN HUMAN-TARGETED ANTI-PLATELET STUDIES	Walter Janse Van	Received

413-P	CHARACTERIZATION OF PROCOAGULANT PLATELETS IN WHOLE BLOOD USING A NOVEL CELL DEATH MARKER	Leonardo Pasalic Rey	Received

414-P	NO DIRECT ASSOCIATION BETWEEN ON-TREATMENT PLATELET REACTIVITY AND BLEEDING EVENTS FOLLOWING CORONARY INTERVENTION AND DUAL ANTIPLATELET THERAPY: A POST HOC ANALYSIS OF THE PRASFIT-ACS STUDY	Masakatsu Nishikawa Sime	Received

415-P	CYSTATHIONINE BETA SYNTHASE (CBS) GENE 844INS68 POLYMORPHISM IN SICKLE CELL DISEASE PATIENTS: FREQUENCY OF VASO-OCCLUSIVE CRISIS	Ghada Ezzat Rey	Received

416-P	THE DANISH LYMPHOMA REGISTRY HAS A HIGH COVERAGE AND HIGH DATA QUALITY.	Bente Arboe Rey	Received

418-P	QUALITY OF LIFE AND SYMPTOM PROFILE IN LYMPHOMA PATIENTS IN COMPLETE REMISSION AFTER AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT)	Kira Kurbatova Van	Received

419-P	GERMAN PATIENT AND PHYSICIAN PREFERENCES FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA TREATMENT OUTCOMES: A DISCRETE CHOICE EXPERIMENT	Patience Musingarimi del	Received

420-P	COST EFFECTIVENESS OF BORTEZOMIB, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR THE FIRST-LINE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION	Marjolijn van Keep	Received

422-P	CROSS-CULTURAL DEVELOPMENT OF FOUR EORTC QUESTIONNAIRES TO ASSESS QUALITY OF LIFE IN PATIENTS WITH HODGKIN LYMPHOMA, NON-HODGKIN LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKAEMIA	Sandra Malak Van	Received

425-P	A COST-UTILITY ANALYSIS OF DEFERIPRONE COMPARED TO DESFERRIOXAMINE AND DEFERASIROX FOR THE TREATMENT OF CHRONIC IRON OVERLOAD IN PEOPLE WITH THALASSAEMIA: AN ITALIAN ADAPTATION OF THE UK MODEL	Antonella Meloni Keep	Received

521-P	SPHINGOSINE KINASES ARE REQUIRED FOR IL-7-MEDIATED SIGNALING IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Alice Melao Rey	Received

522-P	MIR-146B IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A POSSIBLE TUMOR SUPPRESSOR ROLE	Rita Fragoso Keep	Received

523-P	IL-7 ACTIVATES THE JAK/STAT5/PIM1 KINASE AXIS THEREBY MEDIATING VIABILITY AND GROWTH OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELLS	Daniel Ribeiro Keep	Received

524-P	JAK2 MUTATIONS ARE HIGHLY ENRICHED IN CRLF2-REARRANGED B-ALL CASES WITH A PH-LIKE GENE SIGNATURE	Teresa Sadras Rey	Received

525-P	CLONAL ORIGINS OF HIGH-HYPERDIPLOID ACUTE LYMPHOBLASTIC LEUKEMIA	Donat Alpar Van	Received

526-P	INTEGRATED ANALYSIS OF JAK/STAT, RAS/AKT AND NOTCH1 PATHWAYS IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS	Valentina Gianfelici Rey	Received

527-P	DISTINCT ALL-ASSOCIATED JAK3 MUTANTS EXHIBIT DIFFERENT CYTOKINE-RECEPTOR REQUIREMENTS AND JAK-INHIBITOR SPECIFICITIES	Elisabeth Losdyck Rey	Received

528-P	XIAP EXHIBITS AN ESSENTIAL ROLE FOR PATIENTS´ ALL CELLS GROWING IN VIVO AS SHOWN BY A NOVEL TECHNIQUE FOR STABLE KNOCKDOWN IN PATIENT-DERIVED XENOGRAFT (PDX) ALL CELLS	Michela Carlet Van	Received

529-P	EXPRESSION OF GATA3 DEPENDS ON GENOTYPE VARIANT AT RS3824662 AND IS ASSOCIATED WITH CLINICAL COURSE OF B-CELL CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA	Joanna Madzio Rey	Received

530-P	PATIENT´S SINGLE STEM CELL CLONES OF ACUTE LYMPHOBLASTIC LEUKEMIA SHOW DRUG RESISTANCE AND SLOW PROLIFERATION IN MICE IN VIVO	Cornelia Finkenzeller del	Received

531-P	A RARE SUBPOPULATION OF QUIESCENT, DRUG RESISTANT STEM CELLS IN PATIENTS´ ALL CELLS GROWING IN MICE	Irmela Jeremias del	Received

532-P	PROGNOSIS IN OLDER/ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA DIAGNOSED 2005-2012: RESULTS FROM A SWEDISH POPULATION-BASED STUDY	Emma BERGFELT Keep	Received

533-P	GENOME-WIDE ANALYSIS OF WDR5 BINDING REVEALS ITS EFFECT ON TUMORIGENESIS IN ACUTE LEUKEMIA	Zheng Ge Keep	Received

534-P	IMPACT OF STEROID DOSE AT INDUCTION PHASE OF PEDIATRIC ALL ON MINIMAL RESIDUAL DISEASE AND SURVIVAL OF THE PATIENTS: A PROSPECTIVE RANDOMIZED STUDY	Sule Unal	Received

535-P	IKZF1 DELETION AND PROGNOSIS OF ADULTS WITH COMMON B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Guo-Rui Ruan Van	Received

536-P	EXTENSIVE PHENOTYPIC CHARACTERIZATION AND CYTOKINE PRODUCTION OF WHOLE BLOOD AT DAY 29 OF INDUCTION CHEMOTHERAPY FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA	Nina Rolf Rey	Received

537-P	NONE OF THE COMMON RISK FACTORS IS SIGNIFICANT IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED ACCORDING TO NON-INTENSIVE BUT NON-INTERRUPTIVE PROTOCOL ALL-2009: RESULTS OF THE RUSSIAN ALL STUDY GROUP	Mikhail Drokov Rey	Received

538-P	OSTEONECROSIS IN AIEOP ALL 2000 AND 2006R TRIALS	Rosanna Parasole Rey	Received

539-P	HDAC EXPRESSION PATTERNS ASSOCIATE WITH HIGH-RISK FEATURES IN PEDIATRIC LEUKEMIA	Nerea Vega-Garcia Rey	Received

541-P	SIGNIFICANCE OF RECURRENCE OF MINIMAL RESIDUAL DISEASE (MRD) DETECTED BY MULTI-PARAMETER FLOW CYTOMETRY (MFC) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN MORPHOLOGICAL REMISSION	Naveen Pemmaraju Rey	Received

542-P	IMPROVED SURVIVAL IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN THE NETHERLANDS: A POPULATION-BASED STUDY ON TREATMENT, TRIAL PARTICIPATION AND SURVIVAL, 1989-2012	Aniko Szabo	Received

543-P	A DISTINCTIVE LONG-NON CODING RNA SIGNATURE CHARACTERIZES ACUTE MYELOID LEUKEMIA WITH TRANSLOCATION T(8;16)(P11;P13) AND MYST3-CREBBP REARRANGEMENT	Marina Diaz-Beya del	Received

544-P	NEW JAK2 HETEROZYGOUS LOSS: A ROLE IN OVERALL SURVIVAL IN ACUTE MYELOID LEUKEMIA PATIENTS	Viviana Guadagnuolo Keep	Received

545-P	SELECTIVE DEATH OF LEUKEMIC STEM CELLS INDUCED BY DEFERASIROX	Saar Shapira del	Received

546-P	ADDITIONAL MOLECULAR ABERRATIONS LEADING TO LEUKEMIC TRANSFORMATION IN PATIENTS WITH FAMILIAL PLATELET DISORDER	Nicolas Duployez Van	Received

548-P	GENOMIC LANDSCAPE OF CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA	Nicolas Duployez Van	Received

549-P	PRO-METASTASIS PHOSPHATASE PRL-3 TRANSFORMS LEUKEMIA STEM CELLS AND PROMOTES LEUKEMOGENESIS IN AML VIA ACTIVATION OF SOX4/LIN28B/LET-7 SIGNALING	Jianbiao Zhou Van	Received

550-P	RATIONAL TARGETING OF NOTCH SIGNALLING IN ACUTE MYELOID LEUKAEMIA	Paul Takam Kamga	Received

551-P	ARSENIC TRIOXIDE AND ALL-TRANS-RETINOIC ACID TARGET NPM1 MUTANT ONCOPROTEIN LEVELS AND INDUCE APOPTOSIS IN NPM1-MUTATED AML CELLS	Maria Paola MARTELLI	Received

552-P	OVEREXPRESSION OF INTEGRIN ?9 COOPERATES WITH THE LOSS OF RUNX1 AND RUNX3 IN LEUKEMOGENESIS	Desmond Chin Kamga	Received

553-P	EUROPEAN NETWORK NGS-PTL PRELIMINARY DATA: WHOLE EXOME SEQUENCING IDENTIFIES MUTATIONS OF ALDH2, RETSAT, HSPG2, CHPF, AND OTHER METABOLIC GENES AS A NOVEL FUNCTIONAL CATEGORY IN ACUTE MYELOID LEUKEMIA	Giorgia Simonetti del	Received

554-P	THE PAN-CLASS I PI3 KINASE INHIBITOR, NVP-BKM120, DEMONSTRATES ANTI-LEUKEMIC ACTIVITY IN ACUTE MYELOID LEUKEMIA	Matteo Allegretti MARTELLI	Received

555-P	ACUTE MYELOID LEUKEMIA DERIVED MACROPHAGE MIGRATION INHIBITORY FACTOR DRIVES INTERLEUKIN-8 PRO-SURVIVAL SIGNALS IN THE TUMOR MICROENVIRONMENT	Amina Abdul-Aziz Kamga	Received

556-P	XPO1 INHIBITION USING SELINEXOR SYNERGIZES WITH CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA (AML) BY TARGETING DNA REPAIR GENES	Ramiro Garzon Kamga	Received

557-P	MAPPING WHOLE-EXOME SEQUENCING DATA OF ACUTE MYELOID LEUKEMIA PATIENTS INTO KEGG PATHWAYS	Antonella Padella Rey	Received

559-P	THE MODULAR NETWORK STRUCTURE OF THE MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA	Mariam Ibañez del	Received

560-P	INVESTIGATING THE ROLE OF BONE MARROW ADIPOCYTES IN REGULATING SURVIVAL AND PROLIFERATION OF ACUTE MYELOID LEUKEMIA	Manar Shafat Rey	Received

561-P	COMPARATIVE FUNCTIONAL ANALYSIS OF THE MOLECULAR NETWORK OF 7 SELECTED MLL FUSION PROTEINS	Anna Skucha Rey	Received

563-P	CLINICAL SAFETY AND ACTIVITY OF AG-120, A FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF PATIENTS WITH ADVANCED IDH1-MUTANT HEMATOLOGIC MALIGNANCIES	Malia Prahl Rey	Received

564-P	TOSEDOSTAT PLUS LOW DOSE CYTARABINE COMBO INDUCES A HIGH RATE OF RESPONSES THAT CAN BE PREDICTED BY GENETIC PROFILING IN AML: FINAL RESULTS OF A PHASE II MULTICENTER STUDY	Giuseppe Visani Kamga	Received

565-P	LOW-DOSE LENALIDOMIDE AND CYTARABINE COMBO PRODUCES A HIGH COMPLETE REMISSION RATE THAT CAN BE PREDICTED BY GENETIC PROFILING IN AML PATIENTS AGED =70 YEARS: FINAL RESULTS OF A PHASE II STUDY.	Alessandro Isidori MARTELLI	Received

569-P	AG-221, AN ORAL, SELECTIVE, FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH2 MUTANT ENZYME, INDUCED DURABLE RESPONSES IN A PHASE 1 STUDY OF IDH2 MUTATION-POSITIVE ADVANCED HEMATOLOGIC MALIGNANCIES	Eyal Attar Rey	Received

570-P	ORAL TETRA-ARSENIC TETRA-SULFIDE FORMULA IS BETTER THAN INTRAVENOUS ARSENIC TRIOXIDE IN TREATING ACUTE PROMYELOCYTIC LEUKEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS	Gan-Lin He Rey	Received

571-P	LATE RESPONSES AND OVERALL SURVIVAL (OS) FROM LONG TERM FOLLOW UP OF A RANDOMIZED PHASE 2 STUDY OF SGI-110 (GUADECITABINE) 5-DAY REGIMEN IN ELDERLY AML WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY	Patricia Kropf del	Received

572-P	PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF AG-120, A POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF IDH1-MUTANT ADVANCED HEMATOLOGIC MALIGNANCIES	Bin Fan Rey	Received

573-P	CHARACTERISATION OF TP53 MUTATIONS IN ADULT ACUTE MYELOID LEUKEMIA (AML) PATIENTS: MUTUAL EXCLUSIVITY WITH FLT3 AND NPM MUTATIONS STRONG ASSOCIATION WITH COMPLEX KARYOTYPE AND POOR OUTCOME	Anna Ferrari Rey	Received

574-P	PHASE 1 TRIAL OF G-CSF, CLADRIBINE, CYTARABINE, AND DOSE-ESCALATED MITOXANTRONE (G-CLAM) IN ADULTS WITH NEWLY DIAGNOSED AML OR HIGH-RISK MDS	Roland Walter Kamga	Received

576-P	ABSOLUTE QUANTIFICATION OF THE PRETREATMENT PML-RARA MOLECULAR TRANSCRIPT BY DROPLET DIGITAL PCR DEFINES THE RELAPSE RISK IN ACUTE PROMYELOCYTIC LEUKEMIA	Francesco Albano Kamga	Received

577-P	PREVALENCE AND CLINICAL CHARACTERISTICS OF SETBP1 MUTATIONS IN MYELOID DISORDERS	Nils Winkelmann Rey	Received

578-LB	PRELIMINARY PHASE II RESULTS OF ARA-C AND IDARUBICIN IN COMBINATION WITH SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND SELINEXOR (KPT-330) IN PATIENTS WITH RELAPSED OR REFRACTORY AML	Anne Kranich	Received

578-P	NOTCH1 MUTATIONS ARE ASSOCIATED WITH LOW CD20 EXPRESSION LEVELS IN CHRONIC LYMPHOCYTIC LEUKEMIA: EVIDENCE FOR A NOTCH1-MEDIATED EPIGENETIC MECHANISM	Federico Pozzo Kamga	Received

579-P	MYD88 L265P SOMATIC MUTATIONS INFLUENCE GENE EXPRESSION AND THERAPEUTIC RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA	Jennifer Brown Kamga	Received

580-P	THE GAIN OF THE SHORT ARM OF CHROMOSOME 2 (2P) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RESULTS IN XPO1 OVEREXPRESSION AND DRUG RESISTANCE.	Adrien COSSON Rey	Received

581-P	A LONGITUDINAL STUDY OF NEXT GENERATION SEQUENCING IN CHRONIC LYMPHOCYTIC LEUKEMIA SHOWS EVIDENCE OF CHEMOTHERAPY-INDUCED MUTAGENESIS AND SNOWBALLING EFFECT DUE TO LOSS OF P53/ATM-MEDIATED DNA REPAIR	Sozan Karim Kamga	Received

583-P	TP53 MUTATIONS ARE EARLY EVENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) DISEASE PROGRESSION AND PRECEDE CLONAL EVOLUTION TO COMPLEX KARYOTYPES.	Fanny Baran-Marszak Rey	Received

584-P	EXPRESSION OF DNA HYDROXYMETHYLATION-RELATED GENES IS ASSOCIATED WITH PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA	Michaël Van Damme	Received

585-P	SF3B1 MUTATIONS AND ALTERATIONS OF FOXP1 TRANSCRIPTION IN CHRONIC LYMPHOCYTIC LEUKAEMIA	Rémi Letestu Rey	Received

586-P	ADDITIONAL TRISOMIES AMONGST PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA CARRYING TRISOMY 12: THE PARTNER CHROMOSOME MAKES A DIFFERENCE	Panagiotis Baliakas Rey	Received

587-P	MUTATIONS IN THE TP53 GENE SHOW FEATURES OF SOMATIC HYPERMUTATION PROCESS WITH PROMINENT DIFFERENCE BETWEEN IGHV MUTATED AND UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA	Nikola Tom Rey	Received

589-P	PHASE I, FIRST-IN-HUMAN TRIAL OF BI 836826 (AN ANTI-CD37 ANTIBODY) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Stephan Stilgenbauer Kamga	Received

590-P	TELOMERE LENGTH AND POT1 MUTATIONS IN CLL: INCIDENCE, ASSOCIATIONS AND CLINICAL IMPACT IN THE COMPLEMENT 1 TRIAL	Billy Jebaraj Rey	Received

591-P	PREVALENCE AND CHARACTERISTICS OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Paolo Strati Damme	Received

592-P	MAKING THE RIGHT CHOICE: THE ROLE OF FITNESS STATUS IN THE MANAGEMENT OF FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL FITNESS STUDY)	Lydia Scarfo´ Rey	Received

593-P	EFFICACY OF PHOSPHATIDYLINOSITOL-3 KINASE INHIBITORS WITH DIVERSE ISOFORM SELECTIVITY PROFILES FOR INHIBITING THE SURVIVAL OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS	Elisa Göckeritz Rey	Received

595-P	GENOMIC PROFILE OF CHRONIC LYMPHOCYTIC LEUKEMIA IN KOREA: ETHNIC DIFFERENCE IN RECURRENT MUTATIONS IDENTIFIED BY TARGETED EXOME SEQUENCING	Jung-Ah Kim Rey	Received

596-P	CYTOTOXICITY FOR CHRONIC LYMPHOCYTIC LEUKEMIA CELLS OF THE CD37 ANTIBODY BI 836826 IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS OR PI3K INHIBITORS	Guenter Krause del	Received

597-P	SOLUBLE CALRETICULIN PREDICTS FOR TIME TO FIRST TREATMENT OF PATIENTS WITH EARLY CHRONIC LYMPHOCYTIC LEUKEMIA.	Stefano molica Damme	Received

598-P	INDIVIDUALIZED IMATINIB THERAPY BASED ON [C]MIN LEVELS MONITORING IN NEWLY DIAGNOSED CML PATIENTS RESULTED IN HIGHER MAJOR MOLECULAR RESPONSE RATES AT 12 MONTHS. RESULTS OF THE OPTIM-IMATINIB STUDY.	Philippe Rousselot del	Received

598-LB	RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB (IDELA) IN COMBINATION WITH OFATUMUMAB (OFA) FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Timothy Dichiara Salinas	Received

599-P	ATTEMPT TO EARLY DISCONTINUE DASATINIB FIRST LINE IN CHRONIC PHASE CML PATIENTS IN EARLY MOLECULAR RESPONSE AND INCLUDED IN THE PROSPECTIVE OPTIM-DASATINIB TRIAL.	Philippe Rousselot del	Received

600-P	REAL LIFE ANALYSIS OF CML MANAGEMENT DEMONSTRATES THAT SECOND-LINE THERAPY IS FREQUENTLY USED BUT IS PREMATURELY DISCONTINUED FOR INTOLERANCE: REPORT OF THE GROUPE QUÃ‰BÃ‰COIS DE RECHERCHE EN LMC-NMP	Lambert Busque del	Received

601-P	CARDIOVASCULAR (CV) AND PULMONARY ADVERSE EVENTS (AES) IN PATIENTS (PTS) TREATED WITH BCR-ABL TYROSINE KINASE INHIBITORS (TKIS): UPDATED ANALYSIS FROM THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)	Jorge Cortes del	Received

602-P	LONG-TERM BOSUTINIB IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) AFTER PRIOR IMATINIB FAILURE	Tim H. Bruemmendorf	Received

603-P	IMATINIB DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS ON PATIENTS IN CLINICAL PRACTICE	Giovanna Rege-Cambrin Bruemmendorf	Received

604-P	VALIDATION OF A NEW PROGNOSTIC SCORE AIMED TO IDENTIFY THREE GROUPS WITH DIFFERENT PROBABILITIES OF DYING OF CHRONIC MYELOID LEUKAEMIA IN 1,120 PATIENTS WITH FIRST-LINE IMATINIB TREATMENT	Markus Pfirrmann Damme	Received

605-P	PROGRESSION OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO ADVANCED PHASE ON TKI THERAPY: A POPULATION BASED ANALYSIS FROM THE SWEDISH CML REGISTER	Stina Söderlund Rey	Received

606-P	INTERFERON-Î´LPHA REVISITED: INDIVIDUALIZED IMMUNE-MODULATION EASED UP SELECTION PRESSURE OF TKI ON BCR-ABL MUTATED CLONES AND IMPROVES MOLECULAR RESPONSE IN HIGH-RISK CML PATIENTS	Katerina MachovaPolakova Bruemmendorf	Received

607-P	PREDICTION OF THE NUMBER OF CML– PATIENTS IN GERMANY: UP TO 20,000 ARE TO BE EXPECTED IN THE NEAR FUTURE	Michael Lauseker Damme	Received

608-P	KILLER IMMUNOGLOBULIN-LIKE RECEPTORS CAN PREDICT TKI TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS	Giovanni Caocci Damme	Received

609-P	AML1-EVI-1 FUSION GENE INHIBITED DIFFERENTIATION AND APOPTOSIS IN ZEBRAFISH MYELOPOIESIS	Li-Jing Shen Damme	Received

610-P	THE INFLUENCE OF SF3B1 MUTATIONS ON THE RESPONSIVENESS OF BLOOD CANCERS TO MOLECULAR THERAPEUTICS	Fabio Liberante Rey	Received

611-P	POLYMORPHISMS OF DNMTS AND FOLATE/METHIONINE METABOLISM GENES INFLUENCE DNA METHYLATION, GENETIC SUSCEPTIBILITY AND PROGNOSIS OF MYELOID NEOPLASIA PATIENTS	Ana Cristina Gonçalves	Received

614-P	REPOPULATING PROGENITOR CELLS IN PRIMARY MDS BONE MARROW CELL CULTURE IN SEVERE HYPOXIC CONDITIONS	Erico Masala Kamga	Received

616-P	OVERALL SURVIVAL (OS) AND BASELINE DISEASE CHARACTERISTICS IN MDS PATIENTS WITH PRIMARY HMA FAILURE IN A RANDOMIZED, CONTROLLED, PHASE III STUDY OF RIGOSERTIB	Nozar Azarnia Gonçalves	Received

617-P	INFERIOR LONG-TERM OUTCOME OF FRONT-LINE HYPOMETHYLATING AGENT COMPARED TO SUPPORTIVE CARE IN PATIENTS WITH LOWER RISK MDS: PROPENSITY SCORE MATCHED ANALYSIS	Joon Ho	Received

619-P	AZACITIDINE (AZA) IN HIGHER RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES (ABN 7): RESULTS OF A RETROSPECTIVE STUDY FROM THE GFM AND GESMD REGISTRIES.	María Díez Campelo	Received

621-P	TREATMENT OF HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) WITH AZACITIDINE: A 4-YEAR POPULATION-BASED ANALYSIS FROM BRITISH COLUMBIA, CANADA	Thomas Nevill Campelo	Received

622-P	ASSOCIATION OF AZACITIDINE AND LENALIDOMIDE (COMBINATION VS SEQUENTIAL TREATMENT) IN HIGH-RISK MYELODYSPLASTIC SYNDROMES. UPDATE OF THE RESULTS OF A RANDOMIZED PHASE II MULTICENTER STUDY	Carlo Finelli Campelo	Received

623-P	CLINICAL IMPACT OF DEL (11Q) IN PATIENTS WITH DE NOVO AND SECONDARY MYELODYSPLASTIC SYNDROMES- A SINGLE INSTITUTION EXPERIENCE	Mrinal Patnaik	Received

624-P	A PROGNOSTIC MODEL FOR PREDICTING SURVIVAL AFTER STOPPING HYPOMETHYLATING AGENT IN MYELODYSPLASTIC SYNDROME	Hawk KIM	Received

625-P	CORRELATION OF OVERALL SURVIVAL (OS) WITH BONE MARROW BLAST (BMBL) RESPONSE IN PATIENTS (PTS) WITH MYELODYSPLASTIC SYNDROMES (MDS)	Michael Petrone Campelo	Received

627-P	HYPOMEGAKARYOCYTIC THROMBOCYTOPENIA (HMT): AN IMMUNE-MEDIATED BONE MARROW FAILURE CHARACTERIZED BY AN INCREASED NUMBER OF PNH-PHENOTYPE CELLS AND PLASMA THROMBOPOIETIN LEVELS	Ken Ishiyama Moon	Received

629-P	PEARSON SYNDROME: MULTISYSTEM MITOCHONDRIAL DISORDER WITH BONE MARROW FAILURE	Ayami YOSHIMI Damme	Received

630-P	PEARSON SYNDROME: A RETROSPECTIVE COHORT STUDY FROM THE MARROW FAILURE STUDY GROUP OF THE AIEOP (ASSOCIAZIONE ITALIANA EMATO-ONCOLOGIA PEDIATRICA).	Piero Farruggia Moon	Received

631-P	SCREENING OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CLONES BY MULTICOLOR FLOW CYTOMETRY USING FLUORESCENT AEROLYSIN (FLAER) –A SINGLE CENTRE STUDY OF 212 PATIENTS	Khaliqur Rahman Campelo	Received

632-P	LONG TERM OUTCOME OF IMMUNOSUPPRESSIVE THERAPY IN A LARGE COHORT OF 1430 PATIENTS OF APLASTIC ANEMIA FROM A SINGLE TERTIARY CARE CENTRE IN INDIA.	Pawan Kumar SINGH	Received

633-P	COMBINED IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH APLASTIC ANEMIA WITH REPEATED COURSES OF ATG	Zalina Fidarova Kamga	Received

634-P	PRELIMINARY DATA ON L-LEUCINE THERAPY OF DBA PEDIATRIC PATIENTS	Galina Ovsyannikova SINGH	Received

636-P	EFFECT OF IMID COMPOUNDS ON CD38 EXPRESSION ON MULTIPLE MYELOMA CELLS: MOR202, A HUMAN CD38 ANTIBODY IN COMBINATION WITH POMALIDOMIDE	Rainer Boxhammer Moon	Received

637-P	CENTROSOME ASSOCIATED GENES PATTERN FOR RISK SUBSTRATIFICATION IN MULTIPLE MYELOMA	Fedor Kryukov Moon	Received

638-P	BONE MARROW MESENCHYMAL STROMAL CELLS FROM HEALTHY DONORS SECRETE EXOSOMES THAT INHIBIT IN VIVO TUMOR GROWTH AND ANGIOGENESIS IN MULTIPLE MYELOMA	Tomohiro UMEZU Campelo	Received

639-P	ANTITUMORAL ACTIVITY OF AMILORIDE IN MULTIPLE MYELOMA THROUGH APOPTOSIS INDUCTION, REGARDLESS OF TP53 MUTATIONAL STATUS	Elizabeta Rojas SINGH	Received

640-P	BORTEZOMIB-RESISTANCE OF BONE MARROW FIBROBLASTS IN MULTIPLE MYELOMA IS CLOSELY CONNECTED TO ACTIVATION OF AUTOPHAGY AS SURVIVAL MACHINERY	Lucia di marzo	Received

641-P	POLYMORPHISMS WITHIN THE CEREBLON AND BETA-CATENIN ENCODING GENES IN PATIENTS WITH MULTIPLE MYELOMA	Aleksandra Butrym Moon	Received

642-P	A NEW NEXT GENERATION SEQUENCING STRATEGY TO EVALUATE GENETIC ABNORMALITIES IN MULTIPLE MYELOMA	Cristina Jiménez marzo	Received

643-P	HUMAN MYELOMA CELL ENGRAFTMENT IN NEXT GENERATION HUMANIZED MICE EXPRESSING HUMAN INTERLEUKIN 6	Tobias Silzle Campelo	Received

644-P	OVEREXPRESSION OF SALIVARY-TYPE AMYLASE REDUCES THE SENSITIVITY TO BORTEZOMIB IN MULTIPLE MYELOMA CELLS	Shohei Mizuno marzo	Received

645-P	A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF TREATMENTS FOR PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA	Weisel Katja Moon	Received

646-P	UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT OPROZOMIB (OPZ) IN PATIENTS (PTS) WITH HEMATOLOGIC MALIGNANCIES, INCLUDING MULTIPLE MYELOMA (MM)	Ravi Vij Moon	Received

647-P	MULTIPLE MYELOMA MANAGEMENT: PRACTICE PATTERNS ACROSS EUROPE	Marc. S Raab	Received

648-P	MULTIPLE INFUSIONS OF AUTOLOGOUS ACTIVATED AND EXPANDED NATURAL KILLER CELLS: A NEW THERAPEUTIC OPTION FOR MULTIPLE MYELOMA	Alejandra Leivas Campelo	Received

649-P	MULTIPLE MYELOMA MANAGEMENT: OUTCOMES IN REAL-WORLD PRACTICE	Kwee Yong Raab	Received

650-P	EUROPEAN POST-APPROVAL SAFETY STUDY (PASS) OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): VTE INCIDENCE, RISK FACTORS, AND USE OF ANTITHROMBOTIC PROPHYLAXIS IN MM PATIENTS TREATED WITH LENALIDOMIDE	Igor Wolfgang Blau	Received

651-P	MANAGEMENT OF ADVERSE EVENTS IN THE STRATUS TRIAL, A PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE+LOW-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA	Michele Cavo Blau	Received

652-P	SINGLE CENTER EXPERIENCE WITH EARLY VERSUS LATE AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA	Gergely Varga marzo	Received

653-P	OPROZOMIB (OPZ) AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM DOSE ESCALATION IN A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY	Parameswaran Hari Blau	Received

654-P	PROGNOSTIC IMPACT OF IMMUNOPHENOTYPIC RESPONSE AND NORMALIZATION OF SERUM FREE LIGHT CHAIN AMONG PATIENTS WITH MULTIPLE MYELOMA	Kota fukumoto	Received

655-P	A PRIOR CANCER DIAGNOSIS IS NOT A RISK FACTOR FOR THE DEVELOPEMENT OF SUBSEQUENT CANCERS IN MULTIPLE MYELOMA PATIENTS	Gudbjörg Jónsdóttir Campelo	Received

656-P	MELPHALAN IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE (BMDEX) PRODUCES MORE DURABLE RESPONSES THAN CYCLOPHOSPHAMIDE (CYBORD): A MATCHED CASE-CONTROL STUDY	Paolo Milani Campelo	Received

657-P	EVALUATION OF CURRENT CLINICAL MODELS FOR RISK OF PROGRESSION FROM SMOLDERING MULTIPLE MYELOMA TO MULTIPLE MYELOMA IN 287 PATIENTS FOLLOWED IN THE CZECH REPUBLIC	Vera Sandecka Campelo	Received

658-P	VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE I SAFETY AND EFFICACY	Shaji K Kumar	Received

659-P	IMPACT OF FISH ABNORMALITIES ON RISK OF PROGRESSION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE	Samith Kochuparambil marzo	Received

660-P	POST RELAPSE OUTCOMES IN YOUNG PATIENTS WITH MULTIPLE MYELOMA IN THE ERA OF NOVEL AGENTS	Nishanth vallumsetla Campelo	Received

661-P	SKY92 GEP, IFISH AND ISS COMPARISONS FOR RISK STRATIFICATION IN MULTIPLE MYELOMA	Erik van Beers	Received

662-P	MARKERS OF DISEASE EVOLUTION IN SMOLDERING MULTIPLE MYELOMA (SMM)	Eftychia Nikolaou marzo	Received

663-P	EFFICIENCY AND TOXICITY OF CYCLOPHOSPHAMIDE BASED STEM CELL MOBILIZATION IN RELAPSED MULTIPLE MYELOMA PATIENTS: OBSERVATIONS FROM THE ONGOING PHASE III TRIAL RELAPSE	Marc-A. Baertsch Beers	Received

664-P	HEAVY LIGHT CHAIN RATIO NORMALIZATION ALLOWS IDENTIFICATION OF ELECTROPHORETIC NON-COMPLETE RESPONSE PATIENTS WITH IMPROVED OUTCOMES: A LONG TERM FOLLOW UP UPDATE FOR BMT CTN 0102 CORRELATIVE STUDY.	Anita D´Souza marzo	Received

665-P	CLINICAL IMPACT OF BONE MARROW MORPHOLOGY FOR THE DIAGNOSIS OF ESSENTIAL THROMBOCYTHEMIA: COMPARISON BETWEEN THE BRITISH STANDARDS (BCSH) AND THE WHO CRITERIA	Heinz Gisslinger SINGH	Received

666-P	MYELOPROLIFERATIVE NEOPLASMS AND INFECTIONS; A POPULATION-BASED STUDY ON 9,665 PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS DIAGNOSED IN SWEDEN 1987-2009	Malin Hultcrantz Beers	Received

667-P	UNFAVORABLE KARYOTYPE AND MOLECULAR NEGATIVITY SIGNIFICANTLY INFLUENCE THE INFECTIOUS RISK IN MYELOFIBROSIS: EVALUATION ON 426 PATIENTS	Nicola POLVERELLI marzo	Received

668-P	PRIMARY MYELOFIBROSIS, POST-ET AND POST-PV MYELOFIBROSIS HAVE DISTINCT CLINICAL PROFILES AND SYMPTOMATIC BURDENS: AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG)	Holly Geyer SINGH	Received

669-P	IMPACT OF CALR AND ASXL1 MUTATIONS ON SURVIVAL AND DISEASE COMPLICATIONS IN ESSENTIAL THROMBOCYTHEMIA AND PREFIBROTIC PRIMARY MYELOFIBROSIS STRICTLY DIAGNOSED ACCORDING TO THE WHO-CLASSIFICATION	Heinz Gisslinger Campelo	Received

670-P	RUXOLITINIB PROVIDES CONSISTENT HEMATOCRIT CONTROL IN PATIENTS WITH POLYCYTHEMIA VERA (PV) RESISTANT TO OR INTOLERANT OF HYDROXYUREA	Martin Griesshammer Beers	Received

672-P	SAFETY OF RUXOLITINIB IN PATIENTS WITH POLYCYTHEMIA VERA: RESULTS FROM THE CLINICAL TRIAL PROGRAM	Srdan Verstovsek Beers	Received

673-P	EFFECT OF RUXOLITINIB ON MARKERS OF IRON DEFICIENCY: AN ANALYSIS OF THE RESPONSE TRIAL	Srdan Verstovsek Beers	Received

674-P	RUXOLITINIB REDUCES JAK2P.V617F ALLELE BURDEN IN PATIENTS WITH MYELOFIBROSIS	Srdan Verstovsek Beers	Received

675-P	SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH INTERMEDIATE-1â€"RISK MYELOFIBROSIS (MF) FROM AN OPEN-LABEL, MULTICENTER, SINGLE-ARM EXPANDED-ACCESS STUDY	Pilar Giraldo Beers	Received

676-P	INTERIM ANALYSIS OF A PHASE II PILOT TRIAL OF RUXOLITINIB COMBINED WITH DANAZOL FOR PATIENTS WITH MYELOFIBROSIS SUFFERING FROM ANEMIA	Krisstina gowin Campelo	Received

677-P	BONE MARROW FIBROSIS BY WHO GRADE AND QUANTITATIVE IMAGE ANALYSIS IS REDUCED BY PRM-151 IN PATIENTS WITH MYELOFIBROSIS AND ASSOCIATED WITH IMPROVED BONE MARROW MORPHOLOGY AND INCREASED PLATELET COUNTS	Olga Pozdnyakova Beers	Received

678-P	THE ITALIAN MASTOCYTOSIS REGISTRY: THE FIRST FIVE YEARS	Serena merante marzo	Received

679-P	HIGH RATE OF DISCORDANCY REGARDING DIAGNOSIS AND SUBCLASSIFICATIONOF SYSTEMIC MASTOCYTOSIS ON BONE MARROW BIOPSIESBETWEEN INITIAL LOCAL AND CENTRALIZED REFERENCE HEMATOPATHOLOGY	Mohamad Jawhar Beers	Received

680-P	CLINICAL AND MOLECULAR CHARACTERISTICS OF PATIENTS WITH SYSTEMIC MASTOCYTOSIS AND ASSOCIATED ACUTE MYELOID LEUKAEMIA	Sebastian Kreil Beers	Received

681-P	VALIDATION OF THE SIMPLIFIED PROGNOSTIC SCORE FOR SMZL OF THE SMZLSG (SMZL STUDY GROUP) IN A SERIES OF PATIENTS TREATED WITH RITUXIMAB MONOTHERAPY, AND LONG TERM OUTCOME OF RITUXIMAB RESPONDERS	Gerassimos PANGALIS marzo	Received

682-P	INCIDENCE OF TRANSFORMATION IN FOLLICULAR LYMPHOMA: MULTICENTRE RETROSPECTIVE ANALYSIS OF THE SPANISH GROUP OF LYMPHOMA AND AUTOLOGOUS STEM-CELL TRANSPLANTATION (GELTAMO)	Sara ALONSO Campelo	Received

684-P	MYD-88 L265P IN A SERIES OF CD5(-) CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CD5- CBL)	Gerassimos PANGALIS marzo	Received

685-P	EFFICACY AND SAFETY OF R-COMP REGIMEN IN NON HODGKIN LYMPHOMA PATIENTS WITH CARDIOVASCULAR COMORBIDITIES.	Ombretta Annibali Beers	Received

686-P	THE EFFECTIVENESS OF ANTIVIRAL THERAPY IN PATIENTS WITH HEPATITIS C ASSOCIATED INDOLENT LYMPHOMA (IL + C)	Sergey Lepkov	Received

688-P	TWO DOSES OF POLATUZUMAB VEDOTIN (POV, ANTI-CD79B ANTIBODY-DRUG CONJUGATE) PLUS RITUXIMAB (R) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): DURABLE RESPONSES AT LOWER DOSE LEVEL	Jeff Sharman Beers	Received

689-P	IDELALISIB EFFICACY AND SAFETY IN FOLLICULAR LYMPHOMA PATIENTS FROM A PHASE 2 STUDY	Pier Zinzani	Received

690-P	IDELALISIB MONOTHERAPY RESULTS IN DURABLE RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROMâ€™S MACROGLOBULINEMIA (WM)	Steven Coutre	Received

691-LB	GADOLIN: PRIMARY RESULTS FROM A PHASE III STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE COMPARED WITH BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA	Laurie H. Sehn	Received

691-P	RECURRENT TP53 ALTERATIONS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	Jessica Hoell marzo	Received

692-P	MESENCHYMAL STROMAL CELLS STIMULATE PROLIFERATION AND CYTOKINE PRODUCTION OF GROUP 3 INNATE LYMPHOID CELLS	Marius Munneke	Received

693-P	ENDOTHELIAL CELL MICROPARTICLES-DELIVERY MIR-155 PROMOTES THE DEVELOPMENT OF AGVHD BY MODULATING T CELLS	Qiuling Wu	Received

694-P	PRESENCE OF KIR2DS1 RECEPTOR IN DONORS OF ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION DUE TO MYELOID MALIGNANCIES IMPROVES OVERALL SURVIVAL IN RECIPIENTS WITH HLA-C2 ANTIGENS	Andras Bors Campelo	Received

695-P	ENDOTHELIAL MICROPARTICLE IS INVOLVED IN THE DEVELOPMENT OF ACUTE GVHD AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Dimin Nie Campelo	Received

696-P	SIMPLE, EFFICIENT, AND SAFE PROCESSING OF FROZEN-THAWED UMBILICAL CORD-DERIVED MESENCHYMAL STROMAL CELLS APPLIED FOR THE TREATMENT OF GVHD	Tokiko Nagamura-Inoue Campelo	Received

697-P	THE IMPACT OF NFAT INHIBITION ON NEUTROPHIL EFFECTOR FUNCTIONS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Daniel Teschner	Received

698-P	INHIBITION OF TRANSFORMING GROWTH FACTOR Î´ETA-ACTIVATED KINASE 1 SUPPRESSES ALLOREACTIVITY AND IMPROVES SURVIVAL IN A MURINE MARROW TRANSPLANTATION MODEL	Ayako Kobayashi	Received

699-P	DISTINCT EXOSOMAL MIRNA EXPRESSION OF LATE ONSET GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.	Seiichiro Yoshizawa Campelo	Received

700-P	B LYMPHOCYTES ARE IMPORTANT EFFECTOR CELLS IN ANTI-AML RESPONSES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Marijn Gillissen Campelo	Received

702-P	COMPLEMENT-BINDING DONOR-SPECIFIC ANTI-HLA ANTIBODIES AND RISK OF PRIMARY GRAFT FAILURE IN HEMATOPOIETIC STEM CELL TRANSPLANTATION	Stefan Ciurea	Received

703-P	DURABLE REMISSIONS AFTER SEQUENTIAL TRANSPLANTATION USING T-REPLETE NON-MYELOABLATIVE CONDITIONING FOR RELAPSED/ REFRACTORY ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASIA	Sandra HASSAN Campelo	Received

704-P	SERUM FERRITIN IS INDEPENDENT OF DISEASE RISK INDEX FOR OVERALL SURVIVAL FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION	Lynette Chee marzo	Received

705-P	COMBINATION THERAPY WITH INOLIMOMAB AND ETANERCEPT FOR SEVERE STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE	Lenneke van Groningen	Received

706-P	PURE RED CELL APLASIA IN MAJOR ABO MISMATCHED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH SEVERE PANCYTOPENIA	Fleur Aung Groningen	Received

707-P	DONOR CHIMERISM AS MARKER OF RELAPSES AFTER BONE MARROW TRANSPLANTATION.	Ildar BARKHATOV marzo	Received

708-P	PERIPHERAL BLOOD EOSINOPHIL COUNT AT DAY 28 AS A PROGNOSTIC INDICATOR IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Keisuke Kawamoto SINGH	Received

709-P	AUTOLOGOUS STEM CELL TRANSPLANTATION WITH HIGH-DOSE MITOXANTRONE AND MELPHALAN IN PATIENTS WITH HODGKIN AND NON-HODGKIN LYMPHOMA : LONG-TERM SURVIVAL AND TOXICITY DATA	Yener Koc	Received

710-P	RISK FACTORS FOR TRANSPLANTATION-ASSOCIATED THROMBOTIC MICROANGIOPATHY AND OUTCOME OF PATIENTS, FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Katalin BALASSA Groningen	Received

711-P	REITERATED THERAPEUTIC DRUG MONITORING (TDM) TO BETTER CONTROL TARGETED EXPOSURE TO IV BUSULFAN IN INFANTS AND OLDER CHILDREN UNDERGOING HEMATOPOIETIC STEM-CELL TRANSPLANTATION (HSCT)	Alexandre Amin	Received

712-P	FACTORS DETERMINING THE EFFECTIVENESS OF ACUTE GRAFT VERSUS HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION WITH MULTIPOTENT MESENCHYMAL STROMAL CELLS	Nataliya Petinati SINGH	Received

713-P	IMPACT OF HISTOLOGIC GRADE ON THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMAS	Francesco Maura	Received

714-P	ALPHA/BETA T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION FROM MATCHED RELATED AND UNRELATED DONOR GRAFTS IN PATIENTS WITH HIGH RISK HEMATOLOGICAL MALIGNANCIES.	Moniek de Witte	Received

715-P	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH MDS/MPN OVERLAP SYNDROMES- A SINGLE INSTITUTIONAL EXPERIENCE.	Prashant Sharma marzo	Received

718-P	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PLERIXAFOR + G-CSF VS PLACEBO + G-CSF TO MOBILIZE =5 X 106 CD34+ CELLS/KG IN CHINESE NHL PATIENTS FOR AUTOLOGOUS TRANSPLANTATION	Robin MENG marzo	Received

719-P	INFLUENCE OF CYP3A5 GENE POLYMORPHISMS ON PHARMACOKINETICS OF TACROLIMUS MODIFIED-RELEASE ONCE-DAILY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION.	Takaya Yamashita SINGH	Received

721-P	INTERFERONÎ´: A POTENTIAL EFFECTIVE TREATMENT FOR MINIMAL RESIDUAL DISEASE IN ACUTE LEUKEMIA/MYELODYSPLASTIC SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Xiao-Dong Mo	Received

722-P	INCIDENCE, RISK FACTORS, AND OUTCOME OF EARLY HEMOSTATIC COMPLICATIONS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE MULTICENTER STUDY OF 551 PATIENTS	Depei WU marzo	Received

723-P	A PROSPECTIVE CLINICAL TRIAL OF PROLONGED AUTOLOGOUS ERYTHROPOIETIN (EPO) SECRETION FROM TARGTEPO IN EPO-DEPENDENT END STAGE RENAL DISEASE PATIENTS SHOWED EPO INDEPENDENCE FOR OVER 8 MONTHS	Shany Blum Witte	Received

724-P	ADOPTIVE IMMUNOTHERAPY OF MULTIPLE MYELOMA (MM) WITH ALLOGENIC CAR T-CELLS TARGETING CS1: ENHANCEMENT OF CAR ACTIVITY THROUGH CS1 GENE INACTIVATION IN EFFECTOR CELLS	Roman Galetto Witte	Received

725-P	EVALUATING HUMAN T-CELL THERAPY OF CYTOMEGALOVIRUS ORGAN DISEASE IN HLA-TRANSGENIC MICE	Simone THOMAS SINGH	Received

726-P	NOVEL HUMAN IL-15 SUPERAGONIST PROMOTES LONG-TERM PERSISTENCE AND REACTIVITY OF HUMAN EBV- AND LEUKEMIA-SPECIFIC CD8+ T CELLS WITH STEM CELL MEMORY AND CENTRAL MEMORY PROPERTIES IN HUMANIZED MICE.â€¨â€¨	Udo Hartwig Beers	Received

727-P	DENDRITIC CELL VACCINATION IN POSTREMISSION THERAPY OF AML: RESULTS OF A CLINICAL PHASE I TRIAL AND OF PRECLINICAL STUDIES TESTING COMBINATORIAL APPROACHES	Marion Subklewe Beers	Received

728-P	COMBINATION OF IBRUTINIB AND ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF RELAPSING/REFRACTORY MANTLE CELL LYMPHOMA (MCL)	Marco Ruella Witte	Received

729-P	INTERIM ANALYSIS OF PHASE I/II TRIAL IN HIGH-RISK PEDIATRIC PATIENTS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) TREATED WITH EX VIVO EXPANDED DONOR-DERIVED ADENOVIRUS-SPECIFIC T CELLS	Winnie IP marzo	Received

730-P	LIPOSOME-BASED SPECIFIC TARGETING OF A STAT3-INHIBITOR TO CANCER-PROMOTING MACROPHAGES: A NOVEL THERAPUTIC PARADIGM IN MULTIPLE MYELOMA	Morten Nørgaard Andersen	Received

731-P	ANTIBODY-TARGETED CYCLODEXTRIN NANOPARTICLES DELIVER SIRNA AND ACHIEVE THERAPEUTIC GENE SILENCING IN BLOOD FROM ACUTE MYELOID LEUKAEMIA (AML) PATIENTS	Jianfeng Guo marzo	Received

732-P	CLINICAL GRADE ACTIVATED NATURAL KILLER PRODUCTS FOR ADOPTIVE IMMUNOTHERAPY AGAINST HIGH-RISK MALIGNANCIES	Antonio Pérez Martínez	Received

733-P	IMPROVED SAFETY AND EFFICACY OF A HIGH-AFFINITY A2.1-RESTRICTED SINGLE-CHAIN P53-SPECIFIC TCR FOR ADOPTIVE IMMUNOTHERAPY	Hakim Echchannaoui Andersen	Received

734-P	HYDROXYUREA FOR Î´-THALASSEMIA: A META-ANALYSIS	Ali Algiraigri Beers	Received

736-P	PERICARDIAL EFFUSION IS A MARKER OF INCREASED CARDIAC MORTALITY IN THALASSEMIA MAJOR PATIENTS	Antonella Meloni Martínez	Received

737-P	OUTCOMES OF A COHORT OF CHILDREN WITH HEMOGLOBINOPATHY RECEIVING ORAL IRON CHELATORS FOR TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN TURKEY: RESULTS OF 3-YEAR FOLLOW-UP STUDY	Bulent Antmen Beers	Received

738-P	RARE INHERITED ANAEMIAS: A CLINICAL-GRADE VALIDATED TARGETED RESEQUENCING PANEL YIELDS HIGH DIAGNOSTIC RATES AND IMPROVES TARGETED MANAGEMENT	Noemi Roy Martínez	Received

741-P	ANTIFUNGAL PROPHYLAXIS IN HAEMATOLOGY PATIENTS: FREQUENCY AND DRUG CLASS OF CHOICE ACCORDING TO TYPE OF HAEMATOLOGICAL MALIGNANCY (AFHEM STUDY)	Mauricette Michallet	Received

742-P	INVESTIGATING CYTOPENIA MAY REVEAL BONE MARROW METASTASIS: A SINGLE CENTER EXPERIENCE FROM THE HEMATOPATHOLOGIST POINT OF VIEW	Ambra Paolini Martínez	Received

743-P	DORIPENEM VERSUS MEROPENEM AS THE FIRST-LINE MONO-THERAPY IN HIGH-RISK FEBRILE NEUTROPENIC PATIENTS WITH ACUTE LEUKEMIA: A RANDOMIZED, CONTROLLED TRIAL	Tatsuo Oyake Andersen	Received

744-P	THE RATE OF HUMAN HERPES VIRUS 6 INFECTION IN ACUTE LEUKEMIA AND LYMPHOMA PATIENTS	Tatiana Lobanova SINGH	Received

745-P	IMPACT OF DECTIN-1 POLYMORPHISMS ON SUSCEPTIBILITY OF INVASIVE FUNGAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Ulf SCHNETZKE	Received

746-P	ANTIFUNGAL PROPHYLAXIS WITH POSACONAZOLE IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME PATIENTS TREATED WITH INTENSIVE CHEMOTHERAPY. A MULTICENTER RETROSPECTIVE STUDY OF REAL-LIFE PRACTICE	David Serrano Andersen	Received

747-P	COMMUNITY ACQUIERED RESPIRATORY VIRUS IN ADULTS PATIENTS WITH HEMATOLOGICAL DISEASE: CLINICAL CHARACTERISTICS AND OUTCOME IN RSV AND HPIV INFECTION	Ana García-Noblejas SINGH	Received

748-P	LEVEL OF PENTRAXIN-3 IN PATIENTS WITH ACUTE LEUKEMIA IN SEPTICEMIA AND ITS PROGNOSTIC VALUE	Mohamed El-defrawy SINGH	Received

749-P	IDENTIFICATION OF CLONALITY IN IDIOPATHIC HYPEREOSINOPHILIA USING TARGETED EXOME SEQUENCING	Jee-Soo Lee Andersen	Received

750-P	DEVELOPMENT OF A NOVEL ANTI-NEUTROPENIC FACTOR CLINICAL CANDIDATE FOR HEMATOPOIESIS DEFICIENCIES	Ronald Jubin Beers	Received

751-P	PRECLINICAL PHARMACOKINETIC/PHARMACODYNAMIC RELATIONSHIPS FOR AG-348, AN INVESTIGATIONAL SMALL-MOLECULE ACTIVATOR OF PYRUVATE KINASE	Yue Chen Martínez	Received

752-P	EFFICACY AND SAFETY OF ELTROMBOPAG IN PATIENTS WITH MODERATE, SEVERE AND VERY SEVERE APLASTIC ANEMIA	Danielle Nance Beers	Received

753-P	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: SINGLE CENTER EXPERIENCE	Ersin Toret Beers	Received

755-P	RELATION BETWEEN GLUTATHIONE S TRANSFERASE GENES (GSTM1, GSTT1 AND GSTP1) POLYMORPHISMS AND CLINICAL MANIFESTATIONS OF SICKLE CELL DISEASE IN EGYPTIAN PATIENTS	Hend Ellithy SINGH	Received

756-P	CASES OF SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A SINGLE CENTER EXPERIENCE.	Serap Karaman	Received

757-P	MYCHOPHENOLATE MOFETIL AND SIROLIMUS AS TREATMENT OF AUTOIMMUNE LYMPHOPROLIFERATIVE DISEASE IN CHILDREN: A SINGLE CENTER EXPERIENCE	Maurizio Miano Andersen	Received

758-P	ADULT DISSEMINATED LANGERHANS CELL HISTIOCYTOSIS IN THE US: A POPULATION-BASED STUDY USING THE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) PROGRAM	Mithun Shah Martínez	Received

759-P	MULTICENTRE OBSERVATIONAL PROSPECTIVE COHORT STUDY LOOKING AT CARDIOVASCULAR RISK AND PURE RED CELL APLASIA ASSOCIATED WITH EPOETIN THETA IN 1039 PATIENTS WITH CHRONIC KIDNEY DISEASE	Andreas Lammerich Martínez	Received

760-P	ADJUSTED CORTICOSTEROID RISK FUNCTION OF SEVERE INFECTION IN PRIMARY IMMUNE THROMBOCYTOPENIA ADULTS. A NATIONWIDE NESTED CASE-CONTROL STUDY.	Guillaume Moulis Andersen	Received

761-P	ELTROMBOPAG SAFETY AND EFFICACY FOR PRIMARY CHRONIC IMMUNE THROMBOCYTOPENIA IN CLINICAL PRACTICE	Tomás José	Received

762-P	IDENTIFICATION OF B CELL SUBSETS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA	Eva Schippers Andersen	Received

764-P	THE UNITED KINGDOM IMMUNE THROMBOCYTOPENIA (UK ITP) REGISTRY: PRELIMINARY FINDINGS ON BLEEDING EVENTS EXPERIENCED BY ITS PARTICIPANTS.	Umesh Doobaree	Received

766-P	ELEVATED SERUM THROMBOPOIETIN LEVEL IN IMMUNE THROMBOCYTOPENIA IN PREGNANCY	Xu Zhang González-López	Received

767-P	CHRONIC IMMUNE THROMBOCYTOPENIA IN CHILDHOOD: EVALUATION OF THE DATA OVER 30 YEARS BASED ON THE REVISED CRITERIA OF INTERNATIONAL WORKING GROUP	Begum Koc	Received

768-P	RESPONSE LOSS AND DEVELOPMENT OF NEUTRALIZING ANTIBODIES DURING LONG-TERM TREATMENT WITH ROMIPLOSTIM IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP).	Monica Carpenedo SINGH	Received

770-P	WHOLE EXOME-SEQUENCING TO IDENTIFY GENETIC RISK FACTORS OF INHIBITOR IN KOREAN SEVERE HEMOPHILIA A PATIENTS	Kiyoung YOO Andersen	Received

771-P	SREENING FOR AN ACQUIRED VON WILLEBRAND SYNDROME IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA	Bozena Sokolowska González-López	Received

772-P	INTEREST OF A NEW RAPID COMMERCIAL ASSAY FOR THE ANALYSIS OF VON WILLEBRAND MULTIMERS IN AGAROSE GEL	Marc Vasse Andersen	Received

773-P	DENGUE VIRUS NONSTRUCTURAL PROTEIN 1-INDUCED ANTIBODIES CROSS-REACT WITH HUMAN PLASMINOGEN AND ENHANCE ITS ACTIVATION	Trai-Ming Yeh Beers	Received

775-P	MICROVESICLES ARE A POTENTIAL BIOMARKER FOR THROMBOSIS AND DIC IN ACUTE LEUKEMIC PATIENTS: A CROSS-SECTIONAL STUDY	Damien Gheldof Andersen	Received

777-P	PREVALENCE AND PREDICTIVE MODEL OF MYELOPROLIFERATIVE NEOPLASM-RELEVANT MOLECULAR MARKERS IN ISCHEMIC STROKE PATIENTS,	Yi-Yang Chen González-López	Received

778-P	DENGUE VIRUS NON-STRUCTURAL PROTEIN 1 INDUCES VASCULAR LEAKAGE THROUGH MACROPHAGE MIGRATION INHIBITORY FACTOR SECRETION AND GLYCOCALYX DEGRADATION	Christina Chen Andersen	Received

779-P	PROVOKED VENOUS THROMBOEMBOLISM IN NON-CANCER PATIENTS: ARE THEY THE SAME?	Chong Chyn Chua	Received

780-P	COAGULATION PROCESS AND FIBRINOGEN GENETIC VARIABILITY ARE STRONG RISK FACTORS FOR ATHEROGENESIS, MYOCARDIAL INFARCTION AND THE EXTEND OF THE DISEASE IN SUBJECTS SUSPECTED FOR STABLE ANGINA	Zoi Pallantza	Received

781-P	LONGTERM CANCER RISK AFTER VENOUS THROMBOEMBOLISM	Lisbeth Eischer	Received

782-P	POLYMORPHISM OF GENES INVOLVED IN LIPID METABOLISM AS A RISK FACTOR FOR VENOUS THROMBOEMBOLISM	Svetlana Svitina	Received

783-P	HIGH LEVELS OF FIBRINOGEN, BUT NOT FIBRINOGEN GENETIC VARIANTS PREDICT CORONARY ARTERY DISEASE IN SUBJECTS WITH HYPERTENSION AND DIABETES MELLITUS TYPE 2	Zoi Pallantza	Received

784-P	VENOUS THROMBOEMBOLISM IN NORTHEAST MELBOURNE, AUSTRALIA: EVALUATION OF EPIDEMIOLOGY, RISK FACTORS AND TREATMENT STRATEGIES IN THE WARFARIN ERA	Hui Yin Lim	Received

849-E	FISH-BASED SCREENING FOR TYROSINE KINASE-ACTIVATING FUSION GENES IN CHILDHOOD HIGH-RISK B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL)	Karin Nebral	Received

851-E	THE LNCRNAS MEG3 AND LINC-PINT REGULATE THE EXPRESSION OF HMOX1 IN ALL, SHOWING A POTENTIAL AS A THERAPEUTIC TARGETS FOR THIS DISEASE	Felipe Prosper	Received

852-E	THE ROLE OF NRARP IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATHOGENESIS AND CHEMOTHERAPY SENSITIVITY	Rita Fragoso	Received

853-E	THE INHIBITION OF CHECKPOINT KINASE 1 INCREASES THE EFFECTIVENESS OF CONVENTIONAL CHEMOTHERAPY IN B-/T-ACUTE LYMPHOBLASTIC LEUKEMIA	Andrea Ghelli	Received

855-E	TRD/TRA REARRANGEMENTS OCCUR INFREQUENTLY IN EARLY THYMIC PRECURSOR SUBTYPE OF T LYMPHOBLASTIC LEUKEMIA BY HIGH-THROUGHPUT SEQUENCING	Anna Sherwood	Received

856-E	PROGNOSTIC VALUE OF DELETIONS AND PROMOTER METHYLATION OF CDKN2A AND CDKN2B IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA	Marcin Braun	Received

857-E	MAJOR IMPACT OF AN EARLY CHECKPOINT FOR MINIMAL RESIDUAL DISEASE IN FLOW CYTOMETRY IN CHILDHOOD ALL: A BICENTRIC STUDY	Marion Eveillard	Received

858-E	TARGETING THE P53â€"MDM2 INTERACTION BY THE SMALL-MOLECULE MDM2 ANTAGONIST NUTLIN-3A IN ADULT PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS	Stefania Trino	Received

859-E	CHARACTERIZATION OF IMMUNOPHENOTYPING AND MOLECULAR PROFILE OF FLT3 MUTATIONS IN CHILDHOOD T-CELL LEUKEMIA.	Maria do	Received

860-E	IMPACT OF SMALL MOLECULE INHIBITORS OF SKP2 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Sara Colomer-Lahiguera	Received

861-E	ANTI-CD47 AND METHOTREXATE INDUCE CELL DEATH BY PHAGOCYTOSIS â€" PHAGOPTOSIS â€" OF LEUKAEMIA CELLS, SUGGESTING NOVEL WAYS OF TARGETING CANCER	Lucy Metayer	Received

862-E	CD22 AS A TARGET FOR ELIMINATION OF THE LEUKEMIC BLASTS IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA	Veronika Kanderova	Received

863-E	BONE MARROW STROMAL PRECURSOR CELLS OF THE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED ACCORDING TO THE ALL-2009 PROTOCOL RESTORE THEIR FUNCTIONAL AND BIOLOGICAL POTENTIAL DAMAGED BY THE DISEASE	Tamara Sorokina	Received

864-E	THE PAN-BCL-2-TARGETING DRUG OBATOCLAX (GX15-070) AND THE PI3-KINASE/MTOR-INHIBITOR BEZ235 PRODUCE SYNERGISTIC GROWTH-INHIBITORY EFFECTS ON LEUKEMIC CELLS IN PATIENTS WITH PH+ AND PH- ALL	Gabriele Stefanzl	Received

865-E	GDF15 MODULATES HEPCIDIN-FERROPORTIN AXIS IN LYMPHOBLASTIC LEUKEMIC CELLS	Gao Ju	Received

866-E	PROGNOSTIC SIGNIFICANCE OF THE CYTOGENETIC EVOLUTION AFTER THE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC ACUTE LEUKEMIA	Tatiana Gindina	Received

867-E	SEQUENCE ANALYSIS OF CLONAL IMMUNOGLOBULIN REARRANGEMENTS IN ACUTE LYMPHOBLASTIC LEUKEMIA: PATHEGENESIS AND MECHANISM	Katerina Katsibardi	Received

868-E	NUDT15 GENE POLYMORPHISM RELATED TO MERCAPTOPURINE INTOLERANCE IN TAIWAN CHINESE CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA	Der-Cherng Liang	Received

869-E	HTS COUPLED WITH A BIOINFORMATICS ANALYSIS IN ROUTINE HOSPITAL PRACTICE FOR MULTICLONAL DIAGNOSIS AND MRD FOLLOW-UP IN ALL.	Yann Ferret	Received

870-E	EVALUATION OF INOSINE TRIPHOSPHATE PYROPHOSPHOHYDROLASE 94 C>A, IVS2 + 21 A>C POLYMORPHYSMS IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH 6-MP AND PREDICTION OF ITS MYELOSUPPRESSIVE EFFECTS	Yousef Mortazavi	Received

871-E	COMPARISON OF THREE DIFFERENT PRIMING REGIMENS BASED ON IDARUBICIN, ACLACINOMYCIN OR PIRARUBICIN FOR REFRACTORY/RELAPSE ACUTE LYMPHOBLASTIC LEUKEMIA	Kourong Miao	Received

872-E	INVESTIGATING THE PROGNOSTIC SIGNIFICANCE OF MICRORNA-335 EXPRESSION IN ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA	Joanne Shu	Received

873-E	IDENTIFICATION OF DISTINCT PROGNOSTIC SUBGROUPS IN HIGH-HYPERDIPLOID PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA BY MULTI-TARGET INTERPHASE FISH	Agnes Vojcek	Received

874-E	EARLY CLEARING OF PERIPHERAL BLOOD BLASTS IS AN INDEPENDENT PROGNOSTIC FACTOR IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA	Juliana Schuh	Received

875-E	PHILADELPHIA CHROMOSOME MAY NOT BE AN ADVERSE PROGNOSTIC FACTOR IN THE OLD-AGE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IN THE ERA OF TYROSINE KINASE INHIBITOR	Jung YeonLee	Received

876-E	NELARABINE IN CHILDREN WITH REFRACTORY AND RELAPSED T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Natalia Myakova	Received

878-E	APPLICATION OF SYSTEMS PHARMACOLOGY MODELING FOR EVALUATION OF THERAPIES EFFECT ON BLAST DYNAMICS IN ACUTE LYMPHOBLASTIC LEUKEMIA	Antonina Nikitich	Received

879-E	LACK OF PROGNOSTIC IMPACT OF ABERRANT MYELOID ANTIGEN EXPRESSION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA	Mafalda Alpoim	Received

880-E	OUTCOME OF OLDER ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH HYPERCVAD	Juliana Schuh	Received

881-E	INHIBITION OF AXL KINASE SUPPRESSES RETINOIC ACID METABOLISM THROUGH REGULATION OF CYP26	Clifford Whatcott Xian	Received

882-E	AN EFFICIENT COMPUTATIONAL APPROACH TO EVALUATE THE EXPRESSION PROFILE OF INDIVIDUAL ACUTE LEUKEMIA PATIENTS	Marcus Hansen Xian	Received

884-E	ABSOLUTE QUANTIFICATION OF EVI1 OVEREXPRESSION IN ACUTE MYELOID LEUKEMIA BY RQ-PCR ANALYSIS: A STUDY OF THE ALFA GROUP	Thomas Smol Xian	Received

885-E	THE D816V C-KIT MUTATION HAS HIGHER ABILITY OF JAK-STAT AND SRC FAMILY KINASE THAN N822K C-KIT MUTATION, AND THEREFORE PROLIFERATION ACTIVITY IS HIGH IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA.	Ikuko Omori Xian	Received

886-E	FREQUENCY AND PROGNOSTIC RELEVANCE OF HTERT SPLICED VARIANTS IN AML.	Paolo Bernasconi Xian	Received

887-E	COMPLEMENTARY DYNAMIC BH3 PROFILES PREDICT INDUCTION OF APOPTOSIS BY THE MULTI-KINASE INHIBITOR TG02 IN COMBINATION WITH THE BH3 MIMETIC ABT-199 IN AML CELLS	Monica Pallis Xian	Received

888-E	COMBINED INHIBITION OF HEDGEHOG AND FLT3 SIGNALLING LEADS TO EFFECTIVE ANTI-LEUKEMIC EFFECTS IN ACUTE MYELOID LEUKEMIA	Emily Latuske Xian	Received

889-E	MATURATION-ASSOCIATED IMMUNOPHENOTYPIC CLASSIFICATION OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS	Julia Almeida Xian	Received

890-E	INVOLVEMENT OF HISTONE ACETYLTRANSFERASES IN DEVELOPMENT OF ACUTE PROMYELOCYTIC LEUKEMIA AND RESPONSE TO DIFFERENTIATION-INDUCING COMPOUND	Yoshitaka Sunami Xian	Received

891-E	EFFECTS OF ARSENIC TRIOXIDE ON EVI-1 IN ZEBRAFISH AND IN LEUKEMIA CELLS	Chen Fangyuan Xian	Received

893-E	CRITICAL ROLE OF SOX12 IN LEUKEMOGENESIS IN AML	Haixia Wan Xian	Received

894-E	THE SYK INHIBITORS R788, R406 AND P505-15 COUNTERACT NEOPLASTIC CELL SURVIVAL AND SYNERGIZE WITH MIDOSTAURIN IN PRODUCING GROWTH ARREST IN AML CELL LINES AND PRIMARY AML BLASTS	René Gaupmann Xian	Received

895-E	ACCUMULATION OF THE NPM-1 SPLICE VARIANT R2 ACCOMPANIES AML DEVELOPMENT	Malgorzata Zajac Xian	Received

897-E	NEXT GENERATION SEQUENCING OF MYELOID MALIGNANCIES IDENTIFIED A SPECTRUM OF NOVEL MUTATIONS IN EPIGENETIC REGULATORS â€" CENTER FOR INDIVIDUALIZED MEDICINE CLINIC EXPERIENCE.	Moussab Damlaj Xian	Received

898-E	A COMPREHENSIVE ANALYSIS OF ACCESSIBLE BONE MARROW PROTEINS FOR ANTIBODY-BASED THERAPY OF ACUTE MYELOID LEUKEMIA	Linus Angenendt Xian	Received

900-E	NEXT-GENERATION SEQUENCING AS A TOOL FOR ASSESSING MINIMAL RESIDUAL DISEASE IN AML PATIENTS WITH CEBPA MUTATIONS	Lenka Zejskova Xian	Received

901-E	GRANULOCYTE COLONY-STIMULATING FACTOR INHIBITS CXCR4/SDF-1Î´ SIGNALING AND OVERCOMES STROMAL-MEDIATED DRUG RESISTANCE IN HL-60 CELL LINE	Hua Zhong Xian	Received

902-E	THE ROLE OF CYBB IN MAINTENANCE OF MLL-REARRANGED LEUKEMIA	Chung Fan Lam	Received

903-E	ANALYSIS OF ASXL1 MUTATIONS AND CORRELATION WITH CHROMOSOMAL ALTERATIONS IN ACUTE MYELOID LEUKEMIA	Kalliopi Manola Lam	Received

904-E	TARGETED NEXT GENERATION SEQUENCING (NGS) IN PARALLEL ANALYSES OF CHILDHOOD (CAML) AND ADULT ACUTE MYELOID LEUKEMIA (AAML) PATIENTS	Irena Glumac Lam	Received

905-E	PROGNOSTIC SIGNIFICANCE OF CD34âºCD38LOW/â»CD123âº LEUKEMIC STEM CELLS IN ACUTE LEUKEMIA - A PROSPECTIVE COHORT STUDY	Pawan Kumar Singh	Received

906-E	COOPERATIVE MUTATION STUDY IN KOREAN PATIENTS WITH MLL-REARRANGED ACUTE MYELOID LEUKEMIA USING TARGETED NEXT GENERATION SEQUENCING	So YoungKim Singh	Received

907-E	ASSOCIATION BETWEEN CD117 (C-KIT) AND CD135 (FLT3) RECEPTOR TYROSINE KINASES AND MUTATIONAL STATUS AND CLINICAL FEATURES IN ADULT AML PATIENTS UNDER 60 YEARS	Silvia Bellesi Singh	Received

908-E	ROLE OF DNMT3A MUTATIONS IN INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA PATIENTS: ASSOCIATION WITH PROGNOSIS AND TREATMENT STRATEGIES.	M. Isabel Prieto-Conde	Received

909-E	ACUTE MYELOID LEUKEMIA DISEASE MODELING VIA RNA-GUIDED CRISPRâ€"CAS9 SYSTEM INDUCED SOMATIC MUTATIONS	Oliver Brabetz Prieto-Conde	Received

910-E	VSTM-V1 IS A POTENTIAL MYELOID DIFFERENTIATION ANTIGEN GENE THAT IS DOWNREGULATED IN BONE MARROW CELLS FROM PATIENTS WITH MYELOID LEUKEMIA	Jiao Zhou Prieto-Conde	Received

911-E	THE PI3K GAMMA/DELTA INHIBITOR, IPI-145 (DUVELISIB) INHIBITS ACUTE MYELOID LEUKEMIA BLAST PROLIFERATION AND ADHESION	Genevra Pillinger Prieto-Conde	Received

912-E	IDENTIFICATION OF CYTOGENETIC AND MOLECULAR SUBGROUPS OF ACUTE MYELOID LEUKEMIAS SHOWING L-ASPARAGINASE IN VITRO SENSITIVITY	Salvatore Nicola Bertuccio	Received

913-E	AZACITIDINE FOR THE TREATMENT OF MDS, AML AND CMML: THE SOUTH WALES (UK) EXPERIENCE	Ali Jassem Mahdi	Received

914-E	MIRNA SIGNATURES ASSOCIATED WITH MOLECULAR MARKERS IN ACUTE MYELOID LEUKEMIA	Marta Llop Mahdi	Received

917-E	PIVOTAL BIOMARKER ALTERATIONS IN CYTARABINE-RESISTANT ACUTE MYELOID LEUKEMIA CELL LINES	Jeng-Wei Lu Mahdi	Received

918-E	THE EXPRESSION OF THE DNA REPAIR GENE SETMAR IS HIGHLY CORRELATED TO THE LEVEL OF THE MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA THROUGHOUT THE DISEASE.	Julie Jensen Mahdi	Received

919-E	CORRELATION OF GENOMIC ANALYSIS BY MYAMLâ„¢ WITH IN VITRO HIGH THROUGHPUT DRUG SENSITIVITY TESTING IN NEW DIAGNOSIS AND RELAPSED ACUTE MYELOID LEUKEMIA	Pamela Becker Mahdi	Received

920-E	ANALYSIS OF GENETIC POLYMORPHISMS IN DNA REPAIR GENES IN ASSOCIATION WITH ACUTE MYELOID LEUKEMIA AND ITS SPECIFIC CHROMOSOMAL ABNORMALITIES	Aggeliki Daraki Mahdi	Received

921-E	EXPOSURE TO ROS INDUCES DNA DAMAGE AND INFLUENCES DNA METHYLATION IN NORMAL AND MALIGNANT HEMATOLOGICAL CELL LINES	Ana Cristina Goncalves	Received

922-E	POLYMORPHISM OF FOLATE AND METHIONINE METABOLISM GENES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME	Zhanna Sidorova Goncalves	Received

923-E	SK053, AN INHIBITOR OF ENZYMES INVOLVED IN ALLOSTERIC DISULFIDE BONDS FORMATION, TARGETS EXPRESSION OF HISTONE GENES, SHOWS POTENT ANTI-LEUKEMIC EFFECTS AND INDUCES DIFFERENTIATION OF HUMAN AML CELLS	Justyna Chlebowska Goncalves	Received

924-E	FAVORABLE PROGNOSTIC IMPACT OF NMP1 MUTATION IN ELDERLY PATIENTS WITH NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA	Marijana Virijevic Goncalves	Received

925-E	STUDY OF PLASMA ENDOSTATIN LEVEL IN PATIENTS WITH â€ŽACUTE MYELOID LEUKEMIA	Rasha Haggag	Received

926-E	LONG TERM EFFICACY OF CONSOLIDATION TREATMENT WITH COURSES OF HIGH-DOSE CYTARABINE AND LIMITED AUTOLOGOUS PBSC SUPPORT IN A SERIES OF ADULTS WITH ACUTE MYELOID LEUKEMIA NOT AT HIGH BIOLOGICAL RISK	Erika Borlenghi Goncalves	Received

927-E	HIGH CURE RATE OF YOUNGER AML PATIENTS WITH FLUDARABINE, CYTARABINE AND IDARUBICINE INDUCTION AND RISK ORIENTED CONSOLIDATION: TEN- YEARS REAL LIFE EXPERIENCE	Paola Minetto Goncalves	Received

928-E	IMPACT OF CYTOGENETICS ON CLINICAL OUTCOME IN PATIENTS WITH FIRST RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM VALOR	Norbert Vey Goncalves	Received

929-E	CLOFARABINE AND HIGH-DOSE CYTARABINE ARABINOSIDE (CLARA) FOR PRIMARY REFRACTORY OR RELAPSED ACUTE MYELOID LEUKAEMIA â€" A PROSPECTIVE FOLLOW-UP STUDY OF 60 PATIENTS	Harinder Gill Goncalves	Received

930-E	IDH1 (BUT NOT IDH2) MUTATIONS CAUSE INFERIOR OUTCOME IN PATIENTS WITH AML WITH AN INTERMEDIATE-RISK CYTOGENETICS	Jana Marková Goncalves	Received

931-E	DISTINCT EPIDEMIOLOGIC EXPOSURES AND PROGNOSTIC FACTORS FOR SURVIVAL IN OLDER ADULTS AGE â‰¥70 YEARS RECEIVING LOW INTENSITY THERAPY FOR ACUTE MYELOID LEUKEMIA (AML)	James Foran Goncalves	Received

932-E	CHARACTERISTICS OF ACUTE MYELOGENOUS LEUKEMIA PATIENTS WITH GATA2 MUTATIONS	Hoyoung Maeng Goncalves	Received

933-E	DAY-14 LAIP ON BONE MARROW PREDICTS COMPLETE RESPONSE AND DRIVE EARLY SALVAGE CHEMOTHERAPY IN AML: RESULTS OF MULTIPARAMETER FLOW CYTOMETRY AND WT1-RNA QUANTIFICATION.	Carlo Messina Goncalves	Received

934-E	IDENTIFICATION OF PROGNOSTIC FACTORS RELATED TO THERAPEUTIC OUTCOMES OF CHEMOTHERAPY AND ALLOGENEIC STEM CELL TRANSPLANTATION IN 120 ACUTE MYELOID LEUKEMIA PATIENTS WITH MONOSOMAL KARYOTYPE IN KOREA	Hyunsoo Cho Goncalves	Received

935-E	NO INCREASE IN LEVEL OF FATIGUE AMONG LONG-TERM SURVIVORS WITH ACUTE MYELOID LEUKEMIA	Asa Derolf Goncalves	Received

937-E	RETRO-TRANSCRIPTION LOOP MEDIATED ISOTHERMAL AMPLIFICATION (RT-Q-LAMP) AS A RAPID AND ROBUST MOLECULAR ASSAY FOR THE DIAGNOSTIC DETECTION OF PML-RARA FUSION TRANSCRIPTS	Maria Domenica Divona	Received

938-E	THE ROLE OF AZACITIDINE IN THE TREATMENT OF ELDERLY PATIENTS WITH AML - RESULTS OF A RETROSPECTIVE MULTICENTER STUDY	Anil Tombak Divona	Received

939-E	CORE-BINDING FACTOR IN CHILDHOOD ACUTE MYELOID LEUKEMIA	Olfa Kassar Divona	Received

940-E	PROGNOSATIC RISK SCORE FOR HAEMORRHAGIC EARLY DEATH IN ACUTE PROMYELOCYTIC LEUKEMIA	Mirjana Mitrovic Divona	Received

941-E	THERAPY-RELATED ACUTE MYELOID LEUKEMIA IN ADULTS: IS AGE YOUNGER THAN 40 CLINICALLY RELEVANT?	Deniz Peker Divona	Received

942-E	AZACYTIDINE THERAPY IN PREVIOUSLY UNTREATED ELDERLY AML PATIENTS: COMPARISON WITH CONVENTIONAL CHEMOTHERAPY IN A MATCHED-PAIRED ANALYSIS	Paola Minetto Divona	Received

943-E	COMBINATION OF CLOFARABINE AND CYTARABINE IN THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA	Branimir Spassov Divona	Received

944-E	PROGNOSTIC IMPACT OF WT1 GENE EXPRESSION QUANTIFICATION DURING MINIMAL RESIDUAL DISEASE MONITORING OF ACUTE PROMYELOCYTIC LEUKEMIA	Mirjana Mitrovic Divona	Received

946-E	CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RISK FACTORS, TREATMENT AND OUTCOME	Irena Djunic Divona	Received

947-E	PHASE 1 STUDY: SAFETY AND TOLERABILITY OF INCREASING DOSES OF CB-839, AN ORALLY-ADMINISTERED SMALL MOLECULE INHIBITOR OF GLUTAMINASE, IN ACUTE LEUKEMIA	Marina Y.Konopleva Divona	Received

948-E	PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) EVALUATION OF AG-221, A POTENT MUTANT IDH2 INHIBITOR, FROM A PHASE 1 TRIAL OF PATIENTS WITH IDH2-MUTATION POSITIVE HEMATOLOGIC MALIGNANCIES	Bin Fan Divona	Received

949-E	REDUCED MEDICAL COSTS AND HOSPITAL DAYS WITH ORAL ARSENIC PLUS RETINOIC ACID COMPARED WITH INTRAVENOUS ARSENIC PLUS RETINOIC ACID AS THE FRONT-LINE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA	Xiao-jun Huang Divona	Received

950-E	CLINICAL COURSE OF LEPTOMENINGEAL INVOLVEMENT OF ACUTE MYELOID LEUKEMIA : 14-YEARS SINGLE CENTER EXPERIENCE	Ji Hyun Kwon	Received

951-E	A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA	Richard Noppeney Kwon	Received

952-E	PHASE I/II STUDY OF DFP-10917 GIVEN BY CONTINUOUS INFUSION IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE LEUKEMIA: PHARMACOKINETIC, PHARMACODYNAMICS AND PHARMACOGENOMICS PROPERTIES.	William Plunkett Kwon	Received

954-E	OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR LOW-DOSE CYTARABINE (LDAC) IN THE AZA-AML-001 STUDY	John F.Seymour Kwon	Received

955-E	RETROSPECTIVE ANALYSIS OF OUTCOMES BETWEEN PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO ARE TREATED WITH HEPARIN AND RECOMBINANT HUMAN THROMBOMODULIN THERAPY	Naoki Takezako Kwon	Received

956-E	POST REMISSION MONITORING OF MINIMAL RESIDUAL DISEASE BY WT1 AND LEUKEMIA ASSOCIATED IMMUNOPHENOTYPE PREDICTS RELAPSE IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS .	Michele Malagola Kwon	Received

957-E	TREATMENT WITH LOW-DOSE CYTARABINE (LD-ARAC) IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA (AML): A SINGLE INSTITUTION EXPERIENCE	Mael Heiblig Kwon	Received

958-E	CLINICAL SIGNIFICANCE OF THE DAY 5 PERIPHERAL BLASTS CLEARANCE RATE IN THE EVALUATION OF EARLY TREATMENT RESPONSE AND THE PROGNOSIS FOR AML PATIENTS	Bing Chen Kwon	Received

959-E	PROPHYLACTIC USE OF SORAFENIB IN PATIENTS WITH FLT3-ITD-POSITIVE ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Qifa Liu Kwon	Received

960-E	COMPARISON OF DIFFERENT COMORBIDITY INDICES FOR PREDICTING OUTCOME IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Friederike Hitz Kwon	Received

961-E	CLINICAL OUTCOMES OF ACUTE ERYTHROLEUKEMIA TREATED WITH AZACITIDINE: A RETROSPECTIVE MULTICENTER STUDY	Antonio Almeida Kwon	Received

962-E	CLINICAL FEATURES AND OUTCOMES OF HYPOCELLULAR ACUTE MYELOID LEUKEMIA IN ADULTS: KOREAN AML REGISTRY DATA	Ik Chan Song	Received

963-E	REDUCED-INTENSITY TRANSPLANTATION AS A PART OF STANDARD TREATMENT STRATEGY IN PATIENTS AGED 60 TO 70 YEARS WITH ACUTE MYELOID LEUKEMIA â€" SINGLE CENTRE EXPERIENCE.	Michal Karas Song	Received

964-E	HUMAN MYELOID INHIBITORY C-LECTIN (HMICL):A NOVEL ACUTE MYELOID LEUKEMIA MARKER	Eman Kandeel Song	Received

965-E	CLINICAL OUTCOMES OF AML PATIENTS TREATED WITH AZACITIDINE IN PORTUGAL: A RETROSPECTIVE MULTICENTER STUDY	Antonio Almeida Song	Received

966-E	THE DNMT3A R882 MUTATION WITH FLT3-ITD POSITIVITY IS AN EXTREMELY POOR PROGNOSTIC FACTOR IN PATIENTS WITH NORMAL KARYOTYPE AML AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION	Hyeoung-Joon Kim Song	Received

967-E	LOW-DOSE CYTARABINE AFTER FAILURE OF 5-AZACITIDINE AS PALLIATIVE TREATMENT FOR ELDERLY PATIENTS WITH AML OR HIGH-RISK MDS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY. A RETROSPECTIVE SINGLE CENTER ANALYSIS.	Christian Jakob Song	Received

969-E	CLINICO-BIOLOGICAL CHARACTERISTICS AND OUTCOME OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) CARRYING HEPATITIS B VIRUS OR C VIRUS RECEIVING IMMUNOCHEMOTHERAPY	Miguel Ángel Torrente	Received

970-E	SIL INDEX IS A SIMPLE AND OBJECTIVE PROGNOSTIC INDICATOR IN DIFFUSE LARGE B-CELL LYMPHOMA	Naoto Tomita	Received

971-E	CLINICAL FEATURES AND OUTCOMES IN PATIENTS WITH PRIMARY TESTICULAR LYMPHOMA	Yuki Nakajima Torrente	Received

972-E	STATIN ADMINISTRATION AND THE RISK FOR NON-HODGKIN LYMPHOMA: A NATIONWIDE POPULATION-BASED CASE-CONTROL STUDY	Shih-Feng Cho Torrente	Received

973-E	HIGHLY SUSPECTED LYMPHOMA ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS WITHOUT PATHOLOGICAL EVIDENCE: PET-CT FEATURES AND TREATMENT OUTCOME	Hongxia Qiu Torrente	Received

974-E	HIGH THROUGHPUT TCR SEQUENCING PROVIDES ADDED VALUE IN THE DIAGNOSIS OF CUTANEOUS T-CELL LYMPHOMA	Ilan Kirsch Torrente	Received

975-E	THE CLINICAL IMPLICATION OF THE ACTIVATION OF NF-ÎšB SIGNALING PATHWAY IN DIFFUSE LARGE B CELL LYMPHOMA: PRE- AND POST-RITUXIMAB ERA	Linkun Lee Torrente	Received

976-E	HISTOLOGICAL DISTRIBUTION, TREATMENT AND PROGNOSIS OF PERIPHERAL T-CELL LYMPHOMAS: AN ANALYSIS OF 505 PATIENTS IN TAIWAN	Hsiao-Wen Kao Torrente	Received

977-E	THE INFLUENCE OF TREATMENT FACILITY VOLUME ON SURVIVAL OF DIFFUSE LARGE B-CELL LYMPHOMA	Ronald Go Torrente	Received

978-E	CLINICAL SIGNIFICANCE OF CO-EXPRESSION OF MYC AND BCL2 PROTEIN IN AGGRESSIVE B-CELL LYMPHOMAS TREATED WITH A SECOND LINE IMMUNOCHEMOTHERAPY.	Katsuhiro Miura Torrente	Received

979-E	OUTCOMES OF SPLENECTOMY IN NON-HODGKINâ€™S LYMPHOMAS COMPLICATED BY IMMUNE CYTOPENIAS	Yuriy Yevstakhevych Torrente	Received

980-E	LONG-TERM RESULTS OF TREATMENT OF DIFFUSE LARGE CELL LYMPHOMA ASSOCIATED WITH HEPATITIS C (DLBCL+C).	Sergey Lepkov	Received

981-E	INTERIM 18F-FGD PET/CT MAY NOT PREDICT THE OUTCOME IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS TREATED WITH INTENSIVE METHOTREXATE AND CYTARABINE	Jae-Cheol Jo Torrente	Received

982-E	CLINICAL RELEVANCE OF BONE MARROW HEMOPHAGOCYTOSIS IN THE DIAGNOSIS OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN ADULTS: A SINGLE CENTER, RETROSPECTIVE ANALYSIS	Sung HeeLim	Received

983-E	TOTAL BODY SURFACE AREA (TBSA) AS A NEW PROGNOSTIC VARIABLE IN MYCOSIS FUNGOIDE AND SÃ‰ZARY SYNDROME	Silvana Novelli Torrente	Received

984-E	DIRECT ANTIGLOBULIN TEST POSITIVITY IS A PROGNOSTIC MARKER IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS	Dipti Talaulikar Torrente	Received

985-E	FEATURES OF EBV VIREMIA AND OUTCOMES IN PATIENTS RECEIVED ALLOGENEIC STEM CELL TRANSPLANTATION: A CHINESE MULTICENTER SURVEY	Jia Chen Torrente	Received

986-E	A MODIFIED-INTERNATIONAL PROGNOSTIC INDEX INCLUDING PRETREATMENT HEMOGLOBIN LEVEL FOR EARLY STAGE EXTRANODAL NK/T CELL LYMPHOMA	Liang Wang Torrente	Received

987-E	CARBOPLATIN, ARACTYIN PLUS DEXAMETHASONE WITH OR WITHOUT RITUXIMAB (DHAC+/-R) IS A FEASIBLE AND EFFECTIVE TREATMENT FOR LYMPHOMA PATIENTS	Benoit Tessoulin Torrente	Received

988-E	C-MYC AND BCL2 TRANSLOCATION FREQUENCY IN DIFFUSE LARGE B CELL LYMPHOMAS	Bahar Akkaya Torrente	Received

989-E	R-DA-EPOCH VS R-CHOP IN PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: INTERIM RESULTS OF RANDOMIZED (PROSPECTIVE) MULTICENTER STUDY	Irina Kryachok Torrente	Received

990-E	A PHASE IIA STUDY OF SINGLE-AGENT MOR208, AN FC-OPTIMIZED ANTI-CD19 ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINâ€™S LYMPHOMA	Wojciech Jurczak Torrente	Received

991-E	PROPOSED PROGNOSTIC MODEL FOR PERIPHERAL T-CELL LYMPHOMA: PSU-PROGNOSTIC INDEX FOR T-CELL LYMPHOMA (PSU-PIT) SCORE	Jakrawadee Julamanee Torrente	Received

992-E	RESULTS OF TREATMENT OF LYMPHOBLASTIC LYMPHOMA AT THE CHILDREN CANCER HOSPITAL EGYPT- A SINGLE CENTER EXPERIENCE	Hany Abdelrahman Torrente	Received

993-E	VALIDATION OF THE NCCN IPI IN 70 YEARS AND ABOVE AGGRESSIVE PATIENTS TREATED WITH R-COMP	Adolfo De	Received

994-E	PROSPECTIVE PHASE II TRIAL OF LENALIDOMIDE IN ASSOCIATION WITH CHOP IN ELDERLY PATIENTS WITH ANGIOIMMUNOBLASTIC T CELL LYMPHOMA (AITL): INTERIM ANALYSIS OF A LYSA STUDY.	Violaine Safar La	Received

995-E	SUVMAX ON 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY SCAN IS ASSOCIATED WITH CLINICOPATHOLOGICAL FACTORS AND PROGNOSIS IN NEWLY DIAGNOSED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA	Honghui Huang La	Received

996-E	PROGNOSTIC VALUE OF INTERIM POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY IN 377 PATIENTS WITH NON-HODGKIN LYMPHOMA: A SINGLE INSTITUTIONAL ANALYSIS OVER THE 8 YEARS	Kota Fukumoto La	Received

997-E	LONG-TERM OUTCOME OF ADULTS WITH FIRST-RELAPSED OR REFRACTORYSYSTEMIC ALCL: A LYSA STUDY	Alexandre Morel La	Received

998-E	HIGH-THROUGHPUT SEQUENCING OF BOTH IMMUNOGLOBULIN LIGHT AND HEAVY CHAIN GENE REARRANGEMENTS IMPROVES DETECTION OF NEOPLASTIC CLONES IN MATURE B-CELL LYMPHOMAS	Anna Sherwood La	Received

1000-E	AN INHERITED MUTATION OF THE NOD2 GENE IS ASSOCIATED WITH POOR SURVIVAL OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA.	Magdalena Zawartko	Received

1001-E	MYC/BCL2 DOUBLE EXPRESSION INCREASES A RISK OF RELAPSE OR PROGRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS TREATED WITH INTENSIVE CHEMOTHERAPY M-NHL-BFM-90 PLUS RITUXIMAB	Anna Misyurina	Received

1002-E	CLINICAL FEATURES AND OUTCOMES OF PATIENTS WITH EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE: A PROSPECTIVE MULTICENTER STUDY FROM THE THAI LYMPHOMA REGISTRY	Tawatchai Suwanban	Received

1003-E	CD30 EXPRESSION IN DE NOVO DIFFUSE LARGE B-CELL LYMPHOMA: CLINICAL FEATURES AND OUTCOME	Francesco Gaudio	Received

1004-E	PHASE II STUDY OF SMILE CHEMOTHERAPY FOR RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA	Ritsuro Suzuki	Received

1005-E	GASTROINTESTINAL TRACT POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) AFTER KIDNEY TRANSPLANT: A 17-YEAR BRAZILIAN SINGLE-CENTRE EXPERIENCE	Egyla Cavalcante	Received

1006-E	THE ROLE OF UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HIGH-RISK PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA	Hyunsoo Cho	Received

1007-E	FAVORABLE OUTCOME IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA IN A SINGLE CENTRE: THE PADUA EXPERIENCE.	Silvia Imbergamo	Received

1008-E	HUMAN T-LYMPHOTROPIC VIRUS TYPE I TAX SPECIFIC CYTOTOXIC T-LYMPHOCYTE ANALYSIS OF AGGRESSIVE TYPES OF ADULT T-CELL LEUKEMIA/LYMPHOMA PATIENTS WITH LONG-TERM SURVIVAL AND COMPLETE REMISSION	Tatsuro Jo	Received

1009-E	PROPHYLACTIC USE OF ACETAZOLAMIDE REDUCES WEIGHT GAIN AND AMELIORATES RENAL COMPLICATIONS ASSOCIATED WITH HIGH DOSE METHOTREXATE	Matthew Ku	Received

1010-E	CD30 EXPRESSION IN DLBCL, INCIDENCE AND PROGNOSIS VALUE: A SINGLE-INSTITUTION EXPERIENCE.	Laura García-Sanchis	Received

1011-E	PROPOSAL OF NEW PROGNOSTIC INDEX FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA	Shinkyo Yoon	Received

1012-E	AN INVESTIGATION OF RADIATION THERAPY FOR DLBCL AFTER CHEMOTHERAPY FOR ACHIEVING COMPLETE REMISSION: A SINGLE INSTITUTION EXPERIENCE	Aya Ouchi	Received

1013-E	UNDERWEIGHT AND LOW BODY SURFACE AREAS FOR CHEMOTHERAPY DOSING ARE ASSOCIATED WITH INFERIOR SURVIVAL IN MALE PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A STUDY OF 658 R-CHOP TREATED PATIENTS.	Peter Svenssen Munksgaard	Received

1014-E	18-F FDG PET/CT VERSUS BONE MARROW BIOPSY FOR ASSESSMENT BONE MARROW INVOLVEMENT IN PATIENTS WITH NON-HODGKIN LYMPHOMA	Donka Vassileva Munksgaard	Received

1015-E	INTRAPLEURAL RITUXIMAB FOR THE TREATMENT OF MALIGNANT PLEURAL EFFUSION DUE TO CD20-POSITIVE LYMPHOMA	Man Fai Law	Received

1016-E	LOCALLY ADMINISTERED HAEMOSTATIC DRUG TREATMENT OF DIFFUSE LIFE-THREATENING PULMONARY BLEEDS, REFINING TECHNICAL APPROACH	Anna Selmeczi Law	Received

1017-E	THE USE OF PROTHROMBIN COMPLEX CONCENTRATE FOR INDICATIONS OTHER THAN VITAMIN-K ANTAGONIST REVERSAL: AN ALTERNATIVE AND EFFECTIVE MEANS OF CORRECTING ACQUIRED COAGULOPATHIES	Martin Scott Law	Received

1018-E	VON WILLEBRAND FACTOR DEFICIENCY CORRECTED BY LUNG TRANSPLANTATION.	Ana Lario Law	Received

1020-E	THE P2Y12 H1 HAPLOTYPE IS ASSOCIATED WITH IMPAIRED ADP INDUCED AGGREGATION IN TWO PATIENTS WITH PLATELET-TYPE BLEEDING DIATHESIS.	Giannoula Soufla Law	Received

1021-E	PREGNANCY MANAGEMENT IN VON WILLEBRAND´S DISEASE	Maria Vinogradova Law	Received

1022-E	EFFICACY AND SAFETY PROFILE OF RIVAROXABAN FOLLOWING HIP AND KNEE ARTHROPLASTY	Sheena Patel Law	Received

1023-E	FACTOR V DEFICIENCY IN WEST OF ALGERIA : SINGLE CENTER EXPERIENCE	Moueden Mohamed Amine	Received

1026-E	IN VITRO FACTOR VIII ACTIVITY AFTER RECONSTITUTION WITH DILUENT FLUID FOR CONTINUOUS INFUSION	Kunsoo Lee Amine	Received

1027-E	FREQUENCY AND CHARACTERISTICS OF FACTOR VIII INHIBITORS IN TUNISIAN HEMOPHILIA A : EXPERIENCE OF A SINGLE CENTER	Olfa Kassar Amine	Received

1028-E	12 NOVEL MUTATIONS IDENTIFIED IN PATIENTS OF CONGENITAL AFIBRINOGENEMIA IN PAKISTAN.	Tehmina Nafees Sonia	Received

1029-E	EFFICACY AND SAFETY OF PROPHYLAXIS IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIA A IN IRAN	Mehran Karimi Sonia	Received

1031-E	THE RATIO OF LEUKOCYTE AND RED BLOOD CELL CLONES IN PATIENTS WITH AA/PNH AND THEIR CORRELATION WITH LDH LEVEL	Elena Shilova Sonia	Received

1032-E	VITAMIN D LEVELS OF CHILDREN WITH FANCONI ANEMIA	Canan Albayrak Sonia	Received

1033-E	A PROPOSAL OF CLASSIFICATION FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.	Anna Gaya Sonia	Received

1035-E	A STUDY OF THE MARKERS OF THROMBIN GENERATION AND INFLAMMATION IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN A SUBSET OF PATIENTS SEEN AT A TERTIARY CARE CENTRE IN NORTH INDIA	Rishi Dhawan Sonia	Received

1036-E	ELTROMBOPAG IS BENEFICIAL IN THE TREATMENT OF CHILDREN WITH ACQUIRED APLASTIC ANEMIA	Eleni Atmatzidou Sonia	Received

1037-E	CHARACTERIZATION OF THE DNA-DAMAGE RESPONSE DOWNSTREAM OF B-CELL RECEPTOR SIGNALING IN CLL.	Nadine Nickel Sonia	Received

1038-E	CD69 EXPRESSION POTENTIALLY PREDICTS RESPONSE TO BENDAMUSTINE IN CHRONIC LYMPHOCYTIC LEUKEMIA	Arnau Montraveta Sonia	Received

1039-E	SERUM CHEMOKINES AND CYTOKINES IN CLL PATIENTS TREATED WITH DUVELISIB, AN ORAL DUAL INHIBITOR OF PI3K-DELTA,GAMMA	Mark Douglas Sonia	Received

1040-E	TREG CELLS IN CLL: DEFECTIVE FUNCTION AND HIGH CD39 EXPRESSION	Ozgur Mehtap Sonia	Received

1041-E	ELIMINATION OF MUTATED P53 PROTEIN AND INDUCTION OF P53 DOWNSTREAM GENES IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS USING PRIMA-1MET	Zuzana Jaskova Sonia	Received

1042-E	MICROVESICLES IN CHRONIC LYMPHOCYTIC LEUKEMIA	Giovanni D´Arena Sonia	Received

1043-E	CHANGES IN LYMPHOCYTE SUBSETS, ANGIOGENIC FACTORS AND PLASMA CYTOKINES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA DURING TREATMENT WITH OFATUMUMAB AND LENALIDOMIDE	Candida Vitale Sonia	Received

1044-E	CD49D EXPRESSION IN TRISOMY 12 CLL HAS LITTLE PROGNOSTIC POWER FOR SHORTER OVERALL SURVIVAL.	Pietro Bulian Sonia	Received

1045-E	MESENCHYMAL STROMAL CELLS IMPROVE SURVIVAL OF B-CLL CELLS: ROLE OF CELL-CELL CONTACT AND SOLUBLE FACTORS IN THE MICROENVIRONMENT	Valentina Trimarco Sonia	Received

1046-E	QUANTITATIVE AND QUALITATIVE ANALYSIS OF REGULATORY T CELLS (TREGS) IN B CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL)	Vasiliki Pappa Sonia	Received

1047-E	FCGAMMARIIB HOMMOAGREGATION CAN INDUCE A PROSURVIVAL STATE IN CHRONIC LYMPHOCYTIC LEUKAEMIA CELLS	Rosa Bosch Sonia	Received

1048-E	CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE HIGHLY SUSCEPTIBLE TO DIRECT INHIBITION OF CHECKPOINT KINASE 1	Jana Zemanova Sonia	Received

1049-E	EPIGALLOCATECHIN-3-GALLATE (EGCG) INDUCES APOPTOSIS IN CLL CELLS INVOLVING THE MODULATION OF PI3K/AKT PATHWAY AND INHIBITION OF PROTEASOME ACTIVITY	E. Ponath Sonia	Received

1050-E	REGULATION OF CD38 BY IRF4 IN CHRONIC LYMPHOCYTIC LEUKAEMIA	Helen Marr Sonia	Received

1051-E	13Q DELETION IS PREDOMINANT CYTOGENETIC ABERRATION NEWLY AQUIRED DURING CHRONIC LYMPHOCYTIC LEUKEMIA COURSE IRRESPECTIVE OF DISEASE ACTIVITY AND TREATMENT STATUS	Jana Kotaskova Sonia	Received

1052-E	NOVEL NO-ASA DERIVATIVES ARE NEW PROMISING AGENTS IN THE THERAPY OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND SOLID CANCERS	Hanna Flamme Sonia	Received

1053-E	A RETROSPECTIVE CASE CONTROL STUDY ASSOCIATING CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS SPECIFIC ABERRATIONS WITH CERTAIN RISK FACTORS	Kalliopi Manola Sonia	Received

1054-E	HIGH RESOLUTION MELT (HRM) CURVE ANALYSIS OF P53 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS	Ezzat Elhassadi Sonia	Received

1055-E	ENDOSTEAL AND VASCULAR STRUCTURES OF BONE MARROW STROMA IN CLL	Natalya Semenova Sonia	Received

1056-E	NEW PROGNOSTIC MARKER IN CHRONIC LYMPHOCYTIC LEUKEMIA: PLASMA CCL3 (MIP-1Î´)	Ayse Salihoglu Sonia	Received

1057-E	IMMUNOPHENOTYPE OF CLL CASES WITH STEREOTYPED BCR IS CHARACTERIZED BY DECREASED CD23 EXPRESSION	Vladimir Strugov Sonia	Received

1058-E	CD47 AGONIST PEPTIDES INDUCE PROGRAMMED CELL DEATH IN REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA B CELLS VIA PLCG1 ACTIVATION	Hélene Merle-Béral Sonia	Received

1059-E	FREQUENCY OF CLL-LIKE MONOCLONAL B LYMPHOCYTOSIS IN JAPANESE PEOPLE LIVING IN SAO PAULO, BRAZIL	Mariane Ferreirade Sonia	Received

1060-E	CHARACTERIZATION OF NORMAL AND PATHOLOGICAL LYMPHOID POPULATIONS: VALIDATION OF A 10-COLORS FLOW CYTOMETRY PROTOCOL FOR ROUTINE DIAGNOSIS	Lauren Rigollet Sonia	Received

1061-E	CHEMOTHERAPY EXPOSURE AND SURVIVAL AMONG PATIENTS DIAGNOSED WITH CHRONIC LYMPHOID LEUKEMIA	Patience Musingarimi Sonia	Received

1062-E	REAL-WORLD OUTCOMES OF PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION	Nicole Lamanna Sonia	Received

1064-E	OUTCOMES OF ANTICOAGULANT OR ANTIPLATELET USE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR INDOLENT NON-HODGKINâ€™S LYMPHOMA IN IDELALISIB TRIALS	Peter Hillmen Sonia	Received

1065-E	MODELING THE EPIDEMIOLOGY OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND WALDENSTROM´S MACROGLOBULINEMIA (WM) IN FRANCE	Xavier Troussard Sonia	Received

1068-E	THE OCCURRENCE OF OTHER MALIGNANCIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Milena TodorovicBalint Sonia	Received

1069-E	MINIMAL RESIDUAL DISEASE IN HAIRY CELL LEUKEMIA: DOES IT MATTER?	Abel Santos Carreira	Received

1070-E	ONE OUT OF FOUR TREATMENT-NAÃVE CLL PATIENTS IN TAIWAN CARRY TP53 MUTATIONS: CLINICAL AND PATHOGENETIC IMPLICATIONS	Shang-Ju Wu Carreira	Received

1071-E	RETROSPECTIVE EVALUATION OF 83 PATIENTS WITH HAIRY CELL LEUKEMIA TREATED WITH 3 DIFFERENT TREATMENT MODALITIES IN THE LAST TWO DECADES: A SINGLE CENTER EXPERIENCE	Seniz Ongoren Aydin	Received

1072-E	TWO DECADES OF SINGLE-CENTER EXPERIENCE REGARDING THE TREATMENT, PREDICTORS OF SURVIVAL AND CAUSES OF DEATH IN PATIENTS WITH HAIRY CELL LEUKEMIA	Danijela Lekovic Aydin	Received

1073-E	DETECTION OF BCR-ABL GENE MUTATIONS IN CHRONIC MYELOID LEUKEMIA USING SENSITIVE LOW-DENSITY MICROARRAY APPROACH	Tatiana Nasedkina Aydin	Received

1074-E	ANTIPROLIFERATIVE AND APOPTOTIC EFFECTS OF PONATINIB AND ITS EFFECTS ON MACROMOLECULAR CHANGES IN IMATINIB-SENSITIVE AND â€"RESISTANT CHRONIC MYELOID LEUKEMIA (CML) CELL LINES: A MECHANISTIC APPROACH	Melis Kartal Yandim	Received

1075-E	COMPARATIVE ANALYSIS OF BCR-ABL AND VEGFR2 INHIBITORY ACTIVITIES OF PONATINIB, AXITINIB, AND PF-114	Joseph M Gozgit	Received

1076-E	CD26 ANTIGEN IS SPECIFIC FOR LEUKEMIC STEM CELLS IN CHRONIC MYELOID LEUKEMIA AND DISTINGUISHES PATIENT GROUPS WITH DIFFERENT RATIOS OF LEUKEMIC AND HEALTHY STEM CELLS	Martin Culen Gozgit	Received

1077-E	SPHINGOSINE-1-PHOSPHATE RECEPTOR 2/GQ/PHOSPHOLIPASE C AXIS IS A NOVEL MECHANISM TO OVERCOME NILOTINIB RESISTANCE IN T315I MUTATION EXPRESSING 32DCL3 MURINE CELLS	Aysun Adan Goekbulut	Received

1078-E	SINGLE NUCLEOTIDE POLYMORPHISMS IN APOPTOSIS PATHWAY ARE ASSOCIATED WITH RESPONSE TO IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA	Jieun Uhm Goekbulut	Received

1079-E	THE ROLE OF MICRORNAS IN RESPONSE TO NEW TARGETED THERAPIES IN CHRONIC MYELOID LEUKEMIA	Ana Bela Sarmento	Received

1080-E	A STUDY OF CELL CYCLE KINETICS AND OF KU80 EXPRESSION AS A MARKER OF GENETIC INSTABILITY IN BONE MARROW MESENCHYMAL STEM CELLS OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA	Vasiliki Papadopoulou Sarmento	Received

1081-E	BCR-ABL EXPRESSION IS REDUCED IN THE PRIMITIVE PRECURSOR FRACTION FROM CML TKI-TREATED PATIENTS.	María Sol Ruiz	Received

1082-E	TRIM32 E3 LIGASE AS A TARGET IN CHRONIC MYELOID LEUKAEMIA	Cliona Johnston Ruiz	Received

1083-E	SELECTION OF RUNX1-MUTATED CLONE ASSOCIATED WITH RELAPSE AND BLAST CRISIS IN CHRONIC MYELOID LEUKEMIA PATIENT AFTER ALLO-HSCT AS REVEALED BY TARGETED ENRICHMENT AND DEEP SEQUENCING	Iwona Solarska Ruiz	Received

1084-E	NANOPORE SEQUENCING TO RAPIDLY CHARACTERISE LEUKEMIA-SPECIFIC GENOMIC TRANSLOCATION BREAKPOINTS	Andrew Chase Ruiz	Received

1085-E	THE STUDY OF FUNCTIONAL ACTIVITY OF CD34 CELLS IN CML PATIENTS WITH DIFFERENT RESPONSE TO IMATINIB THERAPY	Tetiana Perekhrestenko Ruiz	Received

1086-E	TYROSINE KINASE INHIBITOR THERAPY INDUCES ALTERATIONS OF CD137 AND CD137L EXPRESSION IN CHRONIC MYELOID LEUKEMIA PATIENTS	Paulo Rodrigues Santos	Received

1087-E	METABOLIC CHARACTERISTICS OF IMATINIB RESISTANT CHRONIC MYELOID LEUKEMIA WITH T315I MUTATION	Jun Young Heo	Received

1088-E	MISSPLICED GSK3Î´ TRANSCRIPT IS UNIVERSALLY EXPRESSED AND CANNOT BE USED TO PREDICT BLAST CRISIS TRANSFORMATION IN CHRONIC MYELOID LEUKAEMIA	Lihui Wang Heo	Received

1089-E	DISCOVERING ALTERNATIVE TARGETS IN CHRONIC MYELOID LEUKEMIA (CML): DETERMINATION OF EXPRESSION LEVELS OF BIOACTIVE SPHINGOLIPID GENES IN NEWLY DIAGNOSED AND DRUG-RESISTANT CML PATIENTS	Melis Kartal Yandim	Received

1090-E	COMPARISON OF TYROSINE-KINASE INHIBITORS AS FIRST-LINE TREATMENT FOR CHRONIC MYELOID LEUKEMIA: RESULTS OF A NETWORK META-ANALYSIS INCLUDING 6314 PATIENTS	Nicole Skoetz Yandim	Received

1091-E	PREDICTIVE FACTORS FOR TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH IMATINIB-TREATED, UNDETECTABLE MOLECULAR RESIDUAL DISEASE: RESULTS FROM THE KID STUDY	Sung-Eun Lee Yandim	Received

1092-E	SUPERIORITY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION TO NILOTINIB & DASATINIB FOR ADULT PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN THE ACCELERATED PHASE	Lan-Ping Xu Yandim	Received

1093-E	ASSESSING RISK FACTORS OF ELECTRONICALLY MEASURED MEDICATION NON-ADHERENCE IN CML PATIENTS: AN OBSERVATIONAL LONGITUDINAL DESIGNâ€" A SUBANALYSIS OF THE TAKE-IT STUDY	Avi Leader Yandim	Received

1094-E	A CRITICAL COMPARISON OF SOKAL, EURO, AND EUTOS RISK SCORES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS	Michele Baccarani Yandim	Received

1095-E	SWITCHING TO NILOTINIB IS ASSOCIATED WITH DEEPER MOLECULAR RESPONSES IN CHRONIC MYELOID LEUKEMIA CHRONIC PHASE WITH MAJOR MOLECULAR RESPONSES ON IMATINIB; STAT1 TRIAL IN JAPAN	Naoto Takahashi Yandim	Received

1096-E	THE LYMPHOCYTE DYNAMICS PREDICTS THE BETTER RESPONSE FOR DASATINIB TREATMENT IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE	Yuho Najima Yandim	Received

1097-E	EVALUATION OF A QUANTITATIVE MULTIPLEX BCR-ABL1 ASSAY ALIGNED DIRECTLY TO THE WHO PRIMARY STANDARD REFERENCE MATERIALS TO REPORT EXPRESSION ON THE INTERNATIONAL SCALE	Justin Brown Yandim	Received

1098-E	IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE: CURRENT INCIDENCE OF CYTOGENETIC REMISSION AND A VERY LONG-TERM AN INTENTION-TO-TREAT ANALYSIS	Oleg Shukhov Yandim	Received

1099-E	CARDIOVASCULAR (CV)-RELATED HOSPITALIZATION IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN SIMPLICITY, A PROSPECTIVE OBSERVATIONAL STUDY	Ron Paquette Yandim	Received

1100-E	ESTIMATED GLOMERULAR FILTRATION RATES OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS (TKIS) IN DASATINIB TRIALS: DASISION (CA180-056), CA180-034, AND CA180-035	Jorge Cortes Yandim	Received

1101-E	NILOTINIB IN JAPANESE PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) WITH SUBOPTIMAL MOLECULAR RESPONSE (MR) TO FRONTLINE IMATINIB: SENSOR FINAL 24-MO ANALYSIS AND BIM POLYMORPHISMS SUBSTUDY	Masafumi Taniwaki Yandim	Received

1102-E	EFFICACY OF NILOTINIB VS HIGH-DOSE IMATINIB VS SUSTAINING STANDARD-DOSE IMATINIB IN EARLY CHRONIC PHASE CML PATIENTS WHO HAVE SUBOPTIMAL MOLECULAR RESPONSE TO FRONTLINE IMATINIB	Soo Young Choi	Received

1103-E	OUTCOMES OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH 10%â‰¤ AND >10% BCR-ABL1 (IS) TRANSCRIPT LEVELS AFTER 3 MONTHS OF GENERIC IMATINIB TREATMENT	Ahmet Emre Eskazan	Received

1104-E	PONATINIB EFFICACY AND SAFETY IN PATIENTS WITH A HISTORY OF STEM CELL TRANSPLANTATION (SCT) IN THE PACE TRIAL	Franck Nicolini Eskazan	Received

1105-E	LONG-TERM BOSUTINIB FOR PHILADELPHIA CHROMOSOMEâ€"POSITIVE (PH+) ADVANCED CHRONIC MYELOID LEUKEMIA (CML) AFTER PRIOR TYROSINE KINASE INHIBITOR FAILURE	Carlo Gambacorti-Passerini Eskazan	Received

1106-E	PATIENT CHARACTERISTICS AND ADVERSE EVENTS (AES) OF TYROSINE KINASE INHIBITORS (TKIS) FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) IN REAL WORLD SETTINGS	Stuart L. Goldberg	Received

1107-E	THE EFFECT OF NILOTINIB IN CHRONIC MYELOID LEUKEMIA TREATMENT DOSE ON FERTILITY AND TERATOGENICITY IN A HEALTHY MOUSE MODEL	Guldane Cengiz Seval	Received

1108-E	DYNAMICS OF RESPONSE AND IMPACT OF SOKAL SCORE IN 3 MONTHS MOLECULAR ´WARNING´ CML PATIENTS. A RETROSPECTIVE STUDY OF GRUPPO TRIVENETO LMC.	Gianni Binotto Seval	Received

1109-E	EVALUATION OF A CENTRALIZED MOLECULAR MONITORING OF CHRONIC MYELOID LEUKEMIA THERAPY IN SOUTH KOREA	Soo Young Choi	Received

1110-E	PREDICTIVE FACTORS TO ACHIEVE DEEP MOLECULAR RESPONSE AND LONG-TERM OUTCOMES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS. A SINGLE CENTER EXPERIENCE IN ARGENTINA.	María José Mela	Received

1111-E	NEW TOOL FOR MONITORING MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA	Talha Badar Mela	Received

1112-E	MULTICENTER STUDY OF COMORBIDITY IN CANARIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS	Maria Saez-Perdomo Mela	Received

1113-E	THE RATE OF BCR-ABL DECLINE AS AN OPTIMIZED PREDICTOR OF OUTCOME FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE ON TREATMENT WITH TYROSINE KINASE INHIBITORS	Mikhail Fominykh Mela	Received

1114-E	IMATINIB TREATMENT DURATION EFFECT ON ESTIMATED GLOMERULAR FILTRATION RATE IN CHRONIC MYELOID LEUKEMIA PATIENTS	Lenka Ruzickova Mela	Received

1115-E	CHRONIC MYELOID LEUKEMIA: IS THE REAL PROGNOSIS OF NEWLY DIAGNOSED PATIENTS REALLY SO GOOD?	Daniela Zackova Mela	Received

1116-E	SIGNIFICANCE OF ANEMIA IN PATIENTS WITH CML AT DIAGNOSIS AND DURING THE TREATMENT WITH IMATINIB OUTSIDE THE CLINICAL TRIALS: CAMELIA REGISTRY EXPERIENCE	Edgar Faber Mela	Received

1117-E	EFFICACY AND SAFETY FOR DASATINIB IN EARLY CHRONIC PHASE CML PATIENTS WITH LATE SUBOPTIMAL RESPONSE TO FRONTLINE IMATINIB. PRELIMINARY RESULTS FROM DASAPOST STUDY	Valentin García-Gutiérrez Mela	Received

1118-E	OPTIMIZATION OF THERAPEUTIC DOSES OF RADOTINIB FOR CHRONIC MYELOID LEUKEMIA BASED ON EXPOSURE-RESPONSE RELATIONSHIP ANALYSES	Hayeon Noh Mela	Received

1119-E	EFFICACY AND SAFETY OF DASATINIB VS. IMATINIB IN LATIN AMERICAN SUBPOPULATION FROM THE DASISION TRIAL IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE (CP)	Alicia Enrico Mela	Received

1120-E	THE EFFICACY AND SAFETY OF GENERIC IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AFTER SWITCHING FROM GLIVEC: UPDATED DATA FROM CERRAHPAÅžA CML COHORT	Ahmet Emre Eskazan	Received

1121-E	GENERIC IMATINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS IN CHRONIC PHASE: UPDATED DATA FROM A TURKISH CML COHORT	Ahmet Emre Eskazan	Received

1122-E	ANALYSIS OF THE RELATIONSHIP BETWEEN DOSE AND BCR-ABL HALVING TIME IN CP-CML PATIENTS TREATED WITH PONATINIB OR IMATINIB	Justin Pritchard Eskazan	Received

1123-E	IL-10/IL-17 DOUBLE-PRODUCING T CELLS: NEW IMMUNOSUPPRESSIVE INSIGHT IN ACUTE MYELOID LEUKEMIA	Silvia Carloni Eskazan	Received

1124-E	HUMAN MEMORY-LIKE NATURAL KILLER CELLS ABLE TO KILL NEOPLASTIC CELLS AS A TOOL FOR A NOVEL APPROACH OF ANTI-TUMOR CELL THERAPY	Daniela Montagna Eskazan	Received

1125-E	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: REVIEW OF 28 CASES	Lucia Guerrero Eskazan	Received

1126-E	HLA-PARTIALLY MATCHED CELLULAR THERAPY (STEM-CELL MICROTRASPLANTATION) IN ACUTE MYELOID LEUKEMIA AND MYELODISPLASTIC SYNDROMES	Maria Esther Martinez-Muñoz	Received

1128-E	UNTOUCHED GMP-GRADE PURIFIED ENGINEERED IMMUNE CELLS	Juergen Kuball Martinez-Muñoz	Received

1129-E	EFFICIENT AND STABLE GENE TRANSFER INTO MESENCHYMAL STEM CELLS	Alexey Bigildeev Martinez-Muñoz	Received

1130-E	IDENTIFICATION OF PREDICTIVE MARKERS OF IMMUNO-SENESCENCE WITH FOCUS ON TUMOR SUPPRESSIVE GENES: HEALTHY DONORS VERSUS PATIENTS DIAGNOSED WITH A LYMPHOPROLIFERATIVE DISEASE	Dominique Bron Martinez-Muñoz	Received

1133-E	REQUIREMENT FOR PHOSPHOLIPASE C GAMMA 1 (PLCG1) IN DEVELOPMENT AND MAINTENANCE OF HEMATOPOIETIC STEM- AND PROGENITOR CELLS	Patricia Arreba Tutusaus	Received

1134-E	THE UTILITY OF FLUORESCENCE LIFETIME IMAGING IN ROUTINE BONE MARROW SMEARS	Irene Lorand-Metze Tutusaus	Received

1135-E	CORD BLOOD STEM CELLS BUT NOT ADULT STEM CELLS AFTER TRANSPLANTATION OVEREXPRESS STEMNESS AND REPROGRAMMING GENES PARTIALLY OVERLAPPING THE SIGNATURE OF INDUCED PLURIPOTENT STEM CELLS (IPS)	Daniela Cilloni Tutusaus	Received

1136-E	STROMAL CELL-DERIVED FACTOR-1 PLAYS IMPORTANT ROLES IN THE REGULATION OF HUMAN EARLY B- AND T/NK-LINEAGE LYMPHOID DIFFERENTIATION IN DIFFERENT MANNERS	Hirohito Minami Tutusaus	Received

1137-E	COMPARISON OF SELF-RENEWAL EXPRESSION IN STROMAL IN VITRO AND IN VIVO MICROENVIRONMENT MODELS â€" CRITICAL DIFFERENCES AND THEIR IMPACT ON HEMATOPOIETIC SUPPORT FUNCTIONS	Gillian Horne Tutusaus	Received

1138-E	BONE MARROW-DERIVED MSCS STIMULATED BY IFN-Î" INHIBITED THE GROWTH OF TOXOPLASMA GONDII VIA UP-REGULATION OF GBP1	Qifa Liu Tutusaus	Received

1139-E	SALVAGE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA WITH BRENTUXIMAB VEDOTIN: THE GREEK EXPERIENCE	Panagiotis Tsirigotis Tutusaus	Received

1140-E	EXPRESSION OF PD-I LIGANDS FOR CLASSICAL HODGKIN LYMPHOMA PROGNOSIS	Irina Kryachok Tutusaus	Received

1141-E	THE ARROVEN STUDY (MA25101): POST-AUTHORISATION OBSERVATIONAL SAFETY STUDY OF BRENTUXIMAB VEDOTIN IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA AND SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA	Kim Linton Tutusaus	Received

1142-E	BRENTUXIMAB VEDOTIN (BV) AN EFFECTIVE TREATMENT FOR TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL)	Simonetta Viviani Tutusaus	Received

1143-E	THE PROGNOSTIC SIGNIFICANCE OF ELEVATED LEVELS OF SERUM FERRITIN PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN LYMPHOMA	Andres ArmandoBorda Tutusaus	Received

1144-E	AUTOMATED IMAGE ANALYSIS REVEALED A HIGH VARIABILITY OF CD30+ HRS CELLS DENSITY IN CLASSICAL NODULAR SCLEROSIS HODGKIN LYMPHOMA	Vit Prochazka Tutusaus	Received

1145-E	HODGKIN LYMPHOMA PATIENTS WITH HIGH NUMBER OF MACROPHAGES IN TUMOR TISSUE - RISK PROFILE AND TREATMENT OUTCOME	Bosko Andjelic Tutusaus	Received

1146-E	LYMPHOMA SURVIVORSHIP AND CARDIOVASCULAR DISEASES: DETECTION OF EARLY CARDIAC DYSFUNCTION	Maria Pina Simula	Received

1147-E	THE CHANGING FACE OF GASTRIC MALT-LYMPHOMA: THE VIENNA UNIVERSITY EXPERIENCE	Markus Raderer	Received

1148-E	INTERIM ANALYSIS OF A PHASE 1B STUDY EVALUATING THE SAFETY OF GS-9820, A SECOND-GENERATION PI3K DELTA-INHIBITOR, IN RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES	Arnon Kater Simula	Received

1149-E	LONG TERM SAFETY AND ACTIVITY OF CLADRIBINE IN MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA (MALT LYMPHOMA)	Barbara Kiesewetter	Received

1150-E	NON-GASTRIC MALT LYMPHOMAS (NG-MALT). CLINICAL CHARACTERISTICS AND OUTCOME IN A SERIES OF 185 PATIENTS: ASSESSING PARAMETERS OF PROGNOSTIC SIGNIFICANCE	Christina Kalpadakis Simula	Received

1151-E	FLUDARABINE TREATMENT FOR WALDENSTROM MACROGLOBULINEMIA-ASSOCIATED NEUROPATHY â€" 20 YEARS EXPERIENCE OF A SINGLE CENTER	Sinziana Radesi -	Received

1152-E	PHARMACOKINETIC DATA, CLINICAL CHARACTERISTICS AND OUTCOME IN FOLLICULAR LYMPHOMA PATIENTS IN MAINTENANCE WITH RITUXIMAB: AN ANALYSIS OF THE FONDAZIONE ITALIANA LINFOMI (FIL)	Alice Di Rocco	Received

1153-E	HYPOGAMMAGLOBULINEMIA AT LONG-TERM AFTER RITUXIMAB/CHEMOTHERAPY TREATMENT FOR LYMPHOMA, AND USE OF INTRAVENOUS IMMUNOGLOBULINS FOR RECURRENT INFECTIONS.	Mariana Ferraro Rocco	Received

1154-E	UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT OPROZOMIB IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES, INCLUDING WALDENSTROM MACROGLOBULINEMIA	David Siegel	Received

1155-E	WHICH GUIDELINES TO TRUST? CRITICAL APPRAISAL OF CLINICAL PRACTICE GUIDELINES FOR MANTLE CELL LYMPHOMA SHOWS HIGH VARIABILITY AMONG RECOMMENDATIONS.	Monia Marchetti	Received

1156-E	CIRCULATING ADAMTS-13 IS REDUCED IN PATIENTS WITH WALDENSTROM´S MACROGLOBULINEMIA AND IS ASSOCIATED WITH INCREASED IGM LEVELS AND DISEASE FEATURES BUT NOT WITH THE LEVELS OF VON WILLEBRAND FACTOR	Efstathios Kastritis Rocco	Received

1157-E	DOES AGE ADJUSTED CHARLSON COMORBIDITY SCORE STRONGLY PREDICT OUTCOME OF THE PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH IMMUNOCHEMOTHERAPY?	Jelena Jelicic Rocco	Received

1158-E	TOXICITY AND EFFICACY OF BENDAMUSTINE IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND INDOLENT LOW GRADE NON-HODGKINS LYMPHOMA (INHL); A MULTI-CENTRE OBSERVATION OF REAL LIFE EXPERIENCE IN THE UK	Duncan Murray Rocco	Received

1159-E	MODELING THE EPIDEMIOLOGY OF FOLLICULAR LYMPHOMA (FL) IN FRANCE	Xavier Troussard Rocco	Received

1160-E	MANAGEMENT OF PRIMARY HEPATIC NON-HODGKINâ€™S LYMPHOMA AND CORRELATION WITH HCV INFECTION : EXCELLENT RESULTS WITH CONVENTIONAL CHEMOTHERAPY	Claudio Cerchione Rocco	Received

1162-E	RITUXIMAB WITH OR WITHOUT CHLORAMBUCIL FOR THE TREATMENT OF EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA: RESULTS OF A MONOCENTRIC STUDY.	Luigi Rigacci Rocco	Received

1163-E	GRANULOCYTE TRANSFUSIONS IN THE TREATMENT OF SEVERE INFECTIONS DURING PROLONGED NEUTROPENIA: SINGLE CENTER EXPERIENCE IN YEARS 2005 - 2014	Edgar Faber Rocco	Received

1164-E	INDUCTION PHASE INFECTIONS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND IMPACT OF STEROID DOSE ON THE INCIDENCE OF INFECTIONS: A RANDOMIZED CONTROLLED STUDY	Turan Bayhan Rocco	Received

1165-E	RELATIVE DOSE INTENSITY OF CHEMOTHERAPY AND PREVENTION OF FEBRILE NEUTROPENIA WITH BIOSIMILAR FILGRASTIM: A MULTICENTRIC OBSERVATIONAL STUDY OF 633 LYMPHOID MALIGNANCY PATIENTS (THE ZOHÃ‰ STUDY).	Philippe Rodon Rocco	Received

1166-E	BK VIRUS-HEMORRHAGIC CYSTITIS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION: CLINICAL CHARACTERISTICS AND UTILITY OF LEFLUNOMIDE TREATMENT	Young Hoon Park	Received

1167-E	A COMPARISON OF ORAL LEVOFLOXACIN AND CEFEPIME IN PATIENTS WITH LOW-RISK FEBRILE NEUTROPENIA BY THE JAPAN FEBRILE NEUTROPENIA STUDY GROUP	Isao Yoshida Park	Received

1168-E	LONGITUDINAL RISK OF HERPES ZOSTER IN PATIENTS WITH NON-HODGKIN LYMPHOMA RECEIVING CHEMOTHERAPY: A NATIONWIDE POPULATION-BASED STUDY	Shih-Feng Cho Park	Received

1169-E	MACROPHAGES FROM SEPSIS SURVIVING MICE PRESENT DIFFERENTIAL GENE EXPRESSION ASSOCIATED WITH AN IMMUNOTOLERANT PROFILE	Eduardo Rego	Received

1170-E	VIRAL RESPIRATORY TRACT INFECTIONS IN CHILDREN WITH MALIGNANCY: ISTANBUL PERSPECTIVE	Zeynep Karakas Park	Received

1171-E	NEUTROPHIL CD64 INDEX AS A BIOMARKER OF EARLY SEPSIS IN MALIGNANT HEMATOLOGIC DISEASE	wang Liru Park	Received

1172-E	FIVE CASES OF PNEUMOCYSTIS PNEUMONIA (PCP) INFECTION IN PATIENTS FOLLOWING TREATMENT WITH BENDAMUSTINE / RITUXIMAB: PROPHYLAXIS SHOULD BE CONSIDERED AS STANDARD PRACTICE	Emma Groarke Park	Received

1173-E	SEVUPARIN DEMONSTRATES ANTI-ADHESIVE EFFECTS IN MALARIA PATIENTS SUGGESTING ITS POTENTIAL CLINICAL BENEFITS IN SEVERE MALARIA AND SICKLE CELL DISEASE	Anna M Leitgeb	Received

1174-E	EFFECTIVENESS OF ANKAFERD BLOOD STOPPER IN PROPHYLAXIS AND TREATMENT OF ORAL MUCOSITIS SEEN IN CHILDHOOD CANCERS AND CORRELATION WITH PLASMA CITRULLINE LEVELS	Turkan Patiroglu Leitgeb	Received

1175-E	SAFETY OF BIOSIMILAR FILGRASTIM IN PATIENTS WITH LYMPHOMA AND MYELOMA UNDERGOING NEUTROPENIA-INDUCING CHEMOTHERAPY: A SUBANALYSIS OF THE NEXT STUDY	Stéphane Lepretre Leitgeb	Received

1176-E	THE EFFICACY OF SERUM GALACTOMANNAN ANTIGEN TEST AS SURVEILLANCE TOOL OF IN-VASIVE PULMONARY ASPERGILLOSIS DURING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH PRIMARY ANTIFUNGAL PROPHYLAXIS	Ryul Kim Leitgeb	Received

1177-E	BIOSIMILAR FILGRASTIM IN PATIENTS UNDERGOING NEUTROPENIA-INDUCING CHEMOTHERAPY: OVERALL RESULTS FROM THE NEXT OBSERVATIONAL STUDY	Frederic Maloisel Leitgeb	Received

1178-E	ORGANIZING PNEUMONIA IN HEMATO-ONCOLOGY PATIENTS: A SOMEWHAT DISREGARDED DIFFERENTIAL DIAGNOSIS	Gil Brás Leitgeb	Received

1179-E	THE EFFICACY OF POLYVINYLPYRROLIDONE â€" ZINC GLUCONATE AND TAURINE GEL (GEL X) IN PROPHYLAXIS AND TREATMENT OF ORAL MUCOSITIS IN CHILDREN TREATED WIH CHEMOTHERAPY	Anca Colita Leitgeb	Received

1180-E	INFECTION AND COLONIZATION BY CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE IN HAEMATOLOGY PATIENTS	Maria Dolores Madrigal	Received

1181-E	INFECTIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA TREATED WITH AZACITIDINE: REPORT FROM A SINGLE CENTER	Angela Maria	Received

1183-E	ANIDULAFUNGIN THERAPY FOR HIGH RISK OF INVASIVE FUNGAL INFECTION HEMATOLOGIC PATIENTS: ITS ROLE IN REAL-LIFE SINGLE CENTER EXPERIENCE.	Sara Lozano Quinto	Received

1184-E	LOW-RISK MYELODYSPLASTIC PATIENTS SUPPORTED WITH ERYTHROPOIETIN PLUS LIPOSOMIAL IRON SHOWS A REDUCED NUMBER OF FEBRILE EPISODES THAN PATIENTS WITH INTRAVENOUS IRON SUPPORT.	Giulio Giordano Quinto	Received

1185-E	RISK FACTORS FOR FEBRILE NEUTROPENIA AND BLOODSTREAM INFECTIONS IN RECIPIENTS OF HEMATOPOIETIC STEM CELL TRANSPLANTS	Igor Stoma Quinto	Received

1186-E	ANALYSIS OF 75 CASES OF ACUTE LEUKEMIA WITH INVASIVE FUNGAL DISEASE	Ye-Hui Tan Quinto	Received

1187-E	ACINETOBACTER BAUMANNII SURVEILLANCE MEASURES IN HAEMATOLOGICAL MALIGNANCIES PATIENTS	Valeria Calafiore Quinto	Received

1188-E	DOES NEUTROPENIA AFFECTS HERPES VIRUS REACTIVATION IN CRITICALLY ILL PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND PNEUMONIA?	Dmitry Tikhomirov Quinto	Received

1189-E	NOCARDIA INFECTION IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION	Maria Stamouli Quinto	Received

1190-E	INFECTIOUS COMPLICATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA TREATED WITH 5-AZACITIDINE	Sofia Ramos Quinto	Received

1191-E	FACTORS AFFECTING THE OUTCOME OF FEBRILE NEUTROPENIA IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES	Rasha Salama Quinto	Received

1192-E	VARIOUS PATTERNS OF HEPATITIS B VIRUS REACTIVATION IN B CELL LYMPHOMA	Aya Nakaya Quinto	Received

1193-E	CAR MEDIATES DIFFERENTIATION AND MIGRATION OF ERYTHROPOIETIC PROGENITOR CELLS AND IS SPECIFICALLY DOWN-REGULATED IN MDS	Karin Bauer Quinto	Received

1194-E	RUNX1 MUTATION AND LOW RUNX1 TRANSACTIVATING ACTIVITY PREDICT HIGHER RISK OF AML TRNASFORMATION AND INFERIOR LEUKEMIA-FREE SURVIVAL IN CHRONIC MYELOMONOCYTIC LEUKEMIA	Ming-Chung Kuo Quinto	Received

1195-E	ABNORMAL MONOCYTE POPULATIONS IN THE PERIPHERAL BLOOD OF PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES	Maria Velegraki Quinto	Received

1196-E	GLUTATHIONE S-TRANSFERASE P1 (GSTP1) PROMOTER HYPERMETHYLATION IN MDS/AML: ASSOCIATION WITH SPECIFIC CHROMOSOME ABBERATIONS	Constantina Sambani Quinto	Received

1197-E	CIRCULATING MICRORNAS IN PLASMA OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES	Michaela Dostalova Merkerova	Received

1198-E	IN VITRO CULTURE OF BM CELLS OF MDS PATIENTS AND CYTC POLYMORPHISMS CAN PREDICT THE â€œIN VIVOâ€ HEMATOLOGICAL RESPONSE OBSERVED DURING IRON CHELATION THERAPY WITH DEFERASIROX	Daniela Cilloni Merkerova	Received

1199-E	MUTATIONAL PROFILE IN MYELODYSPLASTIC SYNDROMES BY HIGH-DEPTH NEXT GENERATION SEQUENCING AND CLINICAL RELEVANCE	Maria Teresa Cedena	Received

1200-E	TS, MTHFR AND XRCC1 GENETIC VARIANTS AFFECT THE CLINICAL COURSE OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK	Federica Loscocco Cedena	Received

1201-E	SIRPB1: BIOMARKER OF RESPONSE TO 5-AZACITIDINE TREATMENT IN MDS AND AML PATIENTS	Viviana Guadagnuolo Cedena	Received

1202-E	RPS14 EXPRESSION IN MYELODYSPLASTIC SYNDROME WITHOUT 5Q DELETION	Keina Susana Quiroz	Received

1203-E	AUTOPHAGY LEVEL WAS ABNORMAL IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES	Huaquan Wang Quiroz	Received

1204-E	CLINICAL RELEVANCE OF IL-6 AND TNF-ALFA IN THE CHARACTERIZATION OF LEUKEMIC STEM CELLS IN MDS PATIENTS	Emília Cortesao Quiroz	Received

1205-E	CONCORDANCE BETWEEN CYTOLOGY AND FLOW CYTOMETRY IN THE DIAGNOSIS OF CHRONIC MYELOMONOCYTIC LEUKEMIA	Isabel González-Gascón y	Received

1207-E	MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS : EVALUATION OF ERYTHROPOIETIC ASPECTS AND ANALYSIS OF RESPONSE	Claudio Cerchione y	Received

1208-E	IMPACT OF TREATMENT WITH RECOMBINANT HUMAN ERYTHROPOIETIN ALPHA ON CARDIAC REMODELING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: RESULTS FROM A PROSPECTIVE STUDY	Arboscello Eleonora y	Received

1209-E	ACUTE MYELOID LEUKEMIA PROGRESSION IN ARGENTINEAN PATIENTS WITH MYELODYSPLASTIC SYNDROMES.	Alicia Enrico y	Received

1210-E	PULMONARY INFECTIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES RECEIVING AZACYTIDINE TREATMENT	Roberto Latagliata	Received

1211-E	HIDDEN MDS: A PROSPECTIVE STUDY TO CONFIRM OR EXCLUDE MDS IN PATIENTS WITH ANEMIA OF UNCERTAIN ETIOLOGY.	Jose María	Received

1212-E	EFFECTIVENESS OF AZACITIDINE COMPARED TO CONVENTIONAL CARE REGIMENS FOR THE TREATMENT OF HIGH-RISK MYELODYSPLASIA IN THE REAL-WORLD: RESULTS FROM THE DUTCH POPULATION-BASED PHAROS MDS REGISTRY	Avinash Dinmohamed Bastida	Received

1213-E	CLINICAL CHARACTERISTICS, TREATMENT AND OUTCOMES OF PATIENTS WITH THERAPY-RELATED MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKAEMIA (T-MDS/AML)	Su Wai Maung	Received

1214-E	CLINICAL FEATURES, TREATMENT DECISIONS AND TREATMENT OUTCOMES OF PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) IN THE REAL-WORLD: RESULTS FROM THE DUTCH POPULATION-BASED PHAROS MDS REGISTRY	Avinash Dinmohamed Maung	Received

1215-E	A NEW PROGNOSTIC INDEX TO PREDICT SHORT-TERM PROGNOSIS IN MDS PATIENTS TREATED WITH AZACITIDINE; COMBINATION OF P53 EXPRESSION AND CYTOGENETICS	Satoshi Nishiwaki Maung	Received

1216-E	DIAGNOSIS, PROGNOSTICATION AND TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS) IN DAILY PRACTICE: RESULTS FROM THE DUTCH POPULATION-BASED PHAROS MDS REGISTRY	Avinash Dinmohamed Maung	Received

1217-E	THE UTILITY OF GRANULOCYTE MATURATION PATTERNS ASSESSED BY FLOW CYTOMETRY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME	Sylvia Meisenberg Maung	Received

1219-E	PROGNOSTIC FACTORS FOR TREATMENT FREE SURVIVAL IN PATIENTS WITH MYELODYSPLASTIC SYNDROME WHO STOPPED HYPOMETHYLATING AGNETS WITHOUT PROGRESSION	Ho Sup Lee	Received

1221-E	HEMATOLOGIC MALIGNANCIES, MOSTLY MYELODYSPLASTIC SYNDROMES AMONG 1740 INFLAMMATORY BOWEL DISEASE PATIENTS: LONG TERM FOLLOW-UP DATA FROM A TERTIARY CENTER	Ayse Salihoglu Lee	Received

1222-E	IMPACT OF AZACITIDINE ON RED BLOOD CELL ALLOINMUNIZATION IN MYELODISPLASTIC SYNDROME	Sebastián Ortiz Zuluaga	Received

1223-E	IRON CHELATION THERAPY IN MYELODYSPLASTIC SYNDROME (MDS) IN ROUTINE CLINICAL SETTING: AN INTERIM ANALYSIS OF THE NON-INTERVENTIONAL STUDY EXSEPT	Forian Nolte Zuluaga	Received

1224-E	HEMOCHROMATOSIS GENE MUTATIONS MAY AFFECT THE SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME	Marko Lucijanic Zuluaga	Received

1225-E	P53 EXPRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT DIAGNOSIS AND FOLLOWING TREATMENT WITH AZACITIDINE	Su Wai Maung	Received

1226-E	SUBGROUP ANALYSES OF A PHASE 3 STUDY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FAILING HMA TREATMENT: IDENTIFICATION OF A HOMOGENEOUS POPULATION WHO BENEFIT FROM RIGOSERTIB THERAPY	Gianluca Gaidano Maung	Received

1227-E	PROGNOSTIC AND PREDICTIVE VALUE OF IPSS-R IN ASSESSING OVERALL SURVIVAL (OS) IN A PHASE III STUDY OF RIGOSERTIB IN SECOND-LINE HIGHER-RISK (HR) MDS PATIENTS	Lewis Silverman Maung	Received

1228-E	INCREASED IMMUNE ACTIVATION AND IMPAIRED CELL SUPPRESSION ON MYELODYSPLASTICS SYNDROMES PROGRESSION	Aline Perazzio Maung	Received

1229-E	IMMUNE EXACERBATION ON MYELODYSPLASTICS SYNDROMES	Aline Perazzio Maung	Received

1230-E	LONG-LASTING HEMATOLOGIC RESPONSE TO AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: UPDATE OF CLINICAL RESULTS FROM A SINGLE INSTITUTION	Carlo Finelli Maung	Received

1231-E	THE EFFICACY OF THE 5-AZACITIDINE IN THE THERAPY-RELATED MYELOID NEOPLASIA: A RETROSPECTIVE MULTICENTRIC EXPERIENCE.	Marta Riva Maung	Received

1232-E	AN ENDOGENOUS RETROVIRUS EXAPTATION EVENT SIGNIFICANTLY CONTRIBUTED TO THE GENERATION OF SOLUBLE RANKL MRNA: IMPLICATIONS ON THE TRANSCRIPTIONAL PROFILE OF THE TRANSCRIPT VARIANT.	Spyros Papamichos Maung	Received

1233-E	IMPACT OF NOVEL THERAPIES ON MULTIPLE MYELOMA SURVIVALâ€"CURRENT AND FUTURE OUTCOMES.	Amar Drawid Maung	Received

1236-E	MET INHIBITION AS A NEW THERAPEUTIC OPTION IN MULTIPLE MYELOMA PATIENTS WITH MET OVEREXPRESSION	Alicia canal Maung	Received

1237-E	INITIAL EVALUATION OF NOVEL DUAL PIM/PI3K AND TRIPLE PIM/PI3K/MTOR INHIBITORS IN MULTIPLE MYELOMA	Mairead Reidy Maung	Received

1238-E	PILOT ASSESSMENT OF PROXIMITY EXTENTION IMMUNOASSAY IN PATIENTS WITH MONOCLONAL GAMMOPATHIES: PARALLEL EVALUATION OF 92 CANCER-RELATED PARAMETERS IN BONE MARROW AND IN SERA	Jiri Minarik Maung	Received

1239-E	THE USE OF MAGE C1 AND FLOW CYTOMETRY TO DETERMINE AND MONITOR THE MALIGNANT CELL TYPE IN MULTIPLE MYELOMA	Kirsty Wienand Maung	Received

1240-E	PERSONAL HISTORY OF INFECTIONS ASSOCIATED WITH AN INCREASED RISK OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) AND MULTIPLE MYELOMA: A POPULATION-BASED NESTED CASE-CONTROL STUDY	Charlene McShane Maung	Received

1241-E	INFLUENCE OF ABC TRANSPORTERSâ€™ GENETIC PROFILES IN THE DEVELOPMENT OF MONOCLONAL GAMMOPATHIES	Ana Bela Sarmento	Received

1242-E	ANALYSIS OF RHOU AND RHOV EXPRESSION IN MULTIPLE MYELOMA REVEALS A POSSIBLE CORRELATION WITH BONE MARROW DEPENDENCE	Sara Nunes Sarmento	Received

1243-E	GRANULOCYTE-LIKE MYELOID DERIVED SUPPRESSOR CELLS (G-MDSC) ARE INCREASED IN MULTIPLE MYELOMA DUE TO IMMUNOLOGICAL DYSREGULATION OF MESENCHYMAL STEM CELLS (MSC)	Cesarina Giallongo Sarmento	Received

1244-E	MICRORNA PROFILE IN BONE MARROW FIBROBLASTS FROM PATIENTS WITH MULTIPLE MYELOMA	Vanessa Desantis Sarmento	Received

1245-E	TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND AND DEATH RECEPTORS: RELEVANCE IN THE PATHOGENESIS OF MONOCLONAL GAMMOPATHIES	Catarina Geraldes Sarmento	Received

1246-E	THE NOVEL MOLECULE STK405759 HAS SELECTIVE CYTOTOXICITY AGAINST MULTIPLE MYELOMA IN VITRO AND IN VIVO.	Gabriela Rozic Sarmento	Received

1247-E	CYTOGENETIC ABNORMALITIES OF UNDETERMINED CLINICAL SINIGICANCE CORRELATE WITH POOR PROGNOSIC FACTORS IN MULTIPLE MYELOMA	Miyoung Kim Sarmento	Received

1248-E	PLASMA CELLS NEGATIVE SELECTION TECHNIQUE IN SAMPLES OF PLASMA CELL DYSCRASIA PATIENTS.	Jose Antonio Perez-Simon	Received

1249-E	CT IS SUPERIOR TO X-RAY IN DIAGNOSING OSTEOLYTIC LESIONS IN THE SPINE AND PELVIS: A PROSPECTIVE STUDY OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.	Maja Hinge Sarmento	Received

1250-E	SEVERE INFECTION IN ELDERLY PATIENTS TREATED WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: ANALYSIS OF THE INTERGROUPE FRANCOPHONE DU MYÃ‰LOME (IFM) 2009 01 PROTOCOL	Philippe Rodon Sarmento	Received

1251-E	IMMUNOGLOBULIN HEAVY/LIGHT CHAIN IMMUNOASSAYS FOR RESPONSE EVALUATION IN MULTIPLE MYELOMA: COMPARISON WITH IMMUNOFIXATION, SERUM FREE LIGHT CHAIN, AND MULTICOLOR FLOW- CYTOMETRY	Yasuhito Suehara Sarmento	Received

1252-E	DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING PARAMETERS CORRELATE WITH ANGIOPOIETIN-1/ANGIOPOIETIN-2 RATIO AND OTHER HIGH-RISK FEATURES IN PATIENTS WITH MULTIPLE MYELOMA	Evangelos Terpos Sarmento	Received

1253-E	SERUM LEVELS OF VON WILLEBRAND FACTOR (VWF) BUT NOT OF ADAMTS-13 PREDICT FOR EARLY DEATH IN PATIENTS WITH AL AMYLOIDOSIS, INDEPENDENTLY OF CARDIAC BIOMARKERS	Efstathios Kastritis Sarmento	Received

1254-E	CHEMOTHERAPY-INDUCED NEUROPATHY AMONG MULTIPLE MYELOMA PATIENTS AND THE INFLUENCE OF CHEMOTHERAPEUTIC AGENTS: RESULTS FROM THE POPULATION-BASED PROFILES STUDY.	Antoinetta Beijers Sarmento	Received

1255-E	FRONTLINE INDUCTION THERAPY FOR MULTIPLE MYELOMA (MM) IN REAL-WORLD CLINICAL PRACTICE: THIRD INTERIM ANALYSIS OF THE MULTINATIONAL, OBSERVATIONAL EMMOS STUDY (NCT01241396)	Mohamad Mohty Sarmento	Received

1256-E	ANALYSIS OF OVERALL SURVIVAL IN MULTIPLE MYELOMA PATIENTS WITH 3 LINES OF THERAPY INCLUDING A PI AND AN IMID, OR DOUBLE REFRACTORY TO A PI AND AN IMID USING REAL WORLD DATA	Saad Usmani Sarmento	Received

1257-E	DETECTING EARLY RELAPSE IN MULTIPLE MYELOMA AFTER ASCT: USEFULNESS OF IMMUNEASSAYS.	Marcio Miguel Andrade	Received

1258-E	MYELOMA MULTIPLE IN PATIENTS AGED â‰¥ 80 YEARS, A GROUP IN CONSTANT GROWTH: EXPERIENCE OF A SINGLE CENTER.	Carolina Villegas Andrade	Received

1259-E	RESPONSE AND EARLY RELAPSE ASSESSMENT IN MULTIPLE MYELOMA TREATED WITH BORTEZOMIB: ROLE OF HEAVY/LIGHT-CHAIN IMMUNEASSAY	Marcio Miguel Andrade	Received

1260-E	MAJOR CARDIOVASCULAR EVENTS AND COMORBIDITIES IN PATIENTS NEWLY DIAGNOSED WITH MULTIPLE MYELOMA	Neil Minton Andrade	Received

1261-E	ASSESSING TREATMENT RESPONSE IN MULTIPLE MYELOMA: IMPLICATIONS OF USING BONE MARROW PLASMA CELL CONTENT AS A MARKER OF DISEASE BURDEN	A. Kamel Abou	Received

1262-E	PATIENT EXPERIENCE WITH LIGHT CHAIN AMYLOIDOSIS: A SURVEY FROM THE AMYLOIDOSIS RESEARCH CONSORTIUM	Isabelle Lousada Abou	Received

1263-E	POMALIDOMIDE + LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: PHASE 1 PHARMACOKINETICS AND SAFETY	Jeffrey Matous Abou	Received

1264-E	ALLOGENEIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: 15-YEAR EXPERIENCE AT A SINGLE CENTER.	Ana Lario Abou	Received

1265-E	TUMOR GROWTH IS ASSOCIATED WITH INCREASED MCD VALUES AND TISSUE EXPRESSION OF ENDOGLIN IN MULTIPLE MYELOMA	Georgios Tsirakis Abou	Received

1266-E	LONG-TERM OUTCOMES OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): MM-024 EXTENDED ACCESS PROGRAM (EAP)	Zhen Cai Abou	Received

1267-E	STAT3 EXPRESSION IS ASSOCIATED WITH POOR SURVIVAL IN YOUNG PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA	Sung-Hoon Jung Abou	Received

1269-E	POTENTIAL THERAPEUTIC TARGETS IN PLASMA CELL DISORDERS: A FLOW CYTOMETRY STUDY.	Katharina Lisenko Abou	Received

1270-E	SERUM LEVELS OF FMS-LIKE TYROSINE KINASE LIGAND IN MULTIPLE MYELOMA PATIENTS ARE CORRELATED WITH MARKERS OF TUMOR PROGRSSION	Michael Alexandrakis Abou	Received

1271-E	THE ROLE OF DIAGNOSTIC DELAY IN MULTIPLE MYELOMA: â€œA DELAY PARADOXâ€	Rafael Ríos-Tamayo Abou	Received

1272-E	SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR RELAPSED MULTIPLE MYELOMA	Beatrice Anna Zannetti	Received

1273-E	BENCE JONES PROTEINURIA IN SMOLDERING MULTIPLE MYELOMA AS PREDICTOR MARKER OF PROGRESSION TO SYMPTOMATIC MULTIPLE MYELOMA	Verónica González de	Received

1274-E	RE-TREATMENT VS CHANGE THERAPY IN FIRST RELAPSE: POST-HOC ANALYSIS OF 476 PATIENTS WITH MULTIPLE MYELOMA (MM) INCLUDED IN TWO PROSPECTIVE TRIALS	Massimo Offidani de	Received

1275-E	AL AMYLOIDOSIS AND QUALITY OF LIFE OUTCOMES	Rahma Warsame de	Received

1276-E	THE ROLE OF INITIAL 18F-FDG PET/CT IN PATIENTS WITH POEMS SYNDROME	Hyunsoo Cho de	Received

1277-E	TRIAL EFFICACY VS REAL WORLD EFFECTIVENESS IN FIRST LINE TREATMENT OF MULTIPLE MYELOMA	Johan Liwing de	Received

1278-E	HEAVY/LIGHT CHAIN IMMUNOPARESIS AS A NOVEL MARKER OF POOR OUTCOMES IN SYSTEMIC AL AMYLOIDOSIS	Ashutosh Wechalekar de	Received

1279-E	ELEVATED FACTOR VIII LEVELS CARRY A POOR OVERALL SURVIVAL IN NEWLY DIAGNOSED SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS PATIENTS.	AD Wechalekar de	Received

1280-E	FIRST REPORT OF A PROSPECTIVE STUDY ON WHOLE-BODY DYNAMIC CONTRAST ENHANCED MRI IN NEWLY DIAGNOSED MYELOMA PATIENTS TREATED WITH UP-FRONT AUTOLOGOUS TRANSPLANTATION: DESCRIPTIVE STUDY AT BASELINE	Karim Belhadj de	Received

1281-E	PROGNOSTIC IMPACT OF SERUM FREE LIGHT CHAIN (SFLC) EVALUATION IN PATIENTS WITH NEWLY DIAGNOSED SYMPTOMATIC MULTIPLE MYELOMA (MM) RECEIVING BORTEZOMIB (BTZ) -BASED REGIMENS	Paola Tacchetti de	Received

1282-E	EVALUATION OF THE CHROMOSOMAL ABERRATION PATTERN IN IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS	Min-Young Lee de	Received

1283-E	IMPACT OF NF-KB EXPRESSION IN THE PROGNOSIS OF MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB IN FRONTLINE REGIMENS	Catarina Geraldes de	Received

1284-E	CIRCULATING BCMA BINDING TO ITS LIGAND BAFF PREVENTS NORMAL ANTIBODY PRODUCTION IN MULTIPLE MYELOMA PATIENTS	James Berenson de	Received

1285-E	BORTEZOMIB CONSOLIDATION FOLLOWING ASCT FOR MULTIPLE MYELOMA (MM) IMPROVES RESPONSE DEPTH, WITH ACCEPTABLE TOXICITY AND PRESERVED QUALITY OF LIFE	Neil Rabin de	Received

1287-E	IMPACT OF SERUM ALPHA 1-ACID GLYCOPROTEIN (AAG), A POTENTIAL PATIENT SELECTION MARKER FOR FILANESIB, ON SURVIVAL AND RESPONSE TO CONVENTIONAL THERAPIES IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA (RMM)	Brian Tunquist de	Received

1288-E	BORTEZOMIB FOR THE TREATMENT OF MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS	Kathleen Scott de	Received

1289-E	CAN OVERALL SURVIVAL BE IMPROVED IN ELDERLY MULTIPLE MYELOMA PATIENTS?	Bart M.S.Heeg de	Received

1290-E	PROGNOSTIC IMPACT OF CIRCULATING PLASMA CELLS ON SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA	Miquel Granell de	Received

1291-E	A POPULATION BASED STUDY OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS IN LATVIA (2007-2009 YEARS)	Daiga Auzina de	Received

1292-E	OUTCOME OF NEWLY DIAGNOSED SYMPTOMATIC MULTIPLE MYELOMA IN VERY ELDERLY PATIENTS (AGED 80 YEARS OR MORE)	Nicola Sgherza de	Received

1293-E	INTENTION TO TREAT VS AGE OF DIAGNOSIS. ANALYSIS OF BENEFITIAL EFFECT OF NEW AGENTS IN THE TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)	Belen Ballina de	Received

1294-E	SUBCUTANEOUS VERSUS INTRAVENOUS BORTEZOMIB: A REAL-LIFE STUDY ON MULTIPLE MYELOMA PATIENTS	Silvia Mangiacavalli de	Received

1295-E	THE AMPLIFICATION OF 1Q21 IS AN ADVERSE PROGNOSTIC FACTOR IN CHINESE PATIENTS WITH MULTIPLE MYELOMA	Lijuan Chen de	Received

1296-E	USE OF EARLY CHANGES IN GENE EXPRESSION OF PLASMA CELLS MAY PREDICT RESPONSE TO BORTEZOMIB IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA	Konstantinos Liapis de	Received

1297-E	ANTI-GRP78 MONOCLONAL ANTIBODY PAT-SM6 IN REFRACTORY AND EXTRAMEDULLARY MULTIPLE MYELOMA: PRECLINICAL AND CLINICAL EVIDENCE FOR A COMBINATORIAL STRATEGY WITH NOVEL AGENTS	Leo Rasche de	Received

1298-E	ACCURACY OF THE SERUM TOTAL LIGHT CHAIN RATIO AS A PREDICTOR OF ABNORMAL SERUM FREE LIGHT CHAIN RATIOS	Marta-Isabel Pereira de	Received

1299-E	CLINICAL FEATURES, PROGNOSIS AND TREATMENT OUTCOME OF THE OF THE EXTRAOSSEUS PLASMA CELL NEOPLASIA: PLASMACYTOMA, MULTIPLE MYELOMA AND PRIMARY PLASMA CELL LEUKEMIA	Jelena Jelicic de	Received

1300-E	HIGH PREVALENCE OF RAS PATHWAY MUTATIONS IN CMML PATIENTS WITH HIGH COLONY GROWTH	Klaus Geissler de	Received

1301-E	ACQUIRED UNIPARENTAL DISOMY OF CHROMOSOME 14 IN MYELOID MALIGNANCIES TARGETS THE IMPRINTED MEG3-DLK1 LOCUS	Andrew Chase de	Received

1302-E	CIRCULATING ENDOTHELIAL CELLS (CEC) AS A SURROGATE MARKER FOR EVOLUTION IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS.	Mercedes Rodriguez-Calvillo de	Received

1304-E	SUPERVISED MULTI-CLASSIFIER SEPARATION OF THE PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS	Vibe Skov de	Received

1305-E	SERUM LEVELS OF MATRIX METALLOPROTEINASES AND THEIR TISSUE INHIBITORS ARE ELEVATED IN JAK2V617F MUTATED COMPARED TO CALR MUTATED MYELOFIBROSIS AND TRIPLE NEGATIVE ESSENTIAL THROMBOCYTEMIA PATIENTS	Luciene Terezina Lima	Received

1306-E	THE MUTATION OF THE SPLICING GENE SRSF2 PERFORMED BY HRM SCREENING IN THE DIAGNOSIS OF CMML.	Melissa Torres Ochando	Received

1307-E	FINDING MOLECULAR/EPIGENETIC SIGNATURES IN PHILADELPHIA NEGATIVE MPNS: A NOVEL TOOL FOR STRENGTHENING DISEASE STATUS CLASSIFICATION AND TAILORING PERSONALIZED DRUG STRATEGIES	Miguel Martin Ochando	Received

1308-E	TNIP1 AS A NOVEL REARRANGEMENT PARTNER FOR 5Q32 PDGFRB IN EOSINOPHILIA-ASSOCIATED MYELOID NEOPLASM	Arjan Buijs Ochando	Received

1309-E	ACTIVATED STAT5 AS NOVEL STEM CELL TARGET IN JAK2 V617F POSITIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)	Emir Hadzijusufovic Ochando	Received

1310-E	PROGRESSION TO MYELOPROLIFERATIVE NEOPLASMS WAS ASSOCIATED WITH MUTATIONS OF THE JAK2 AND CALR GENES IN PATIENTS WITH IDIOPATHIC LEUKOCYTOSIS AND THROMBOCYTOSIS	Naoki Mori Ochando	Received

1311-E	TO TAKE HOME: HOW MUCH VALUE IS LOW BURDEN OF JAK2 V617F ALLELE MUTATION?	Laura Torres Miñana	Received

1312-E	CHRONIC INFLAMMATION BIOMARKERS IN MYELOPROLIFERATIVE NEOPLASMS	Vladan Cokic Miñana	Received

1313-E	THE PRESENCE OF THE JAK2V617F POINT MUTATION AFFECTS OSTEOCLAST FUNCTION IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS.	Emmanouil Spanoudakis Miñana	Received

1314-E	INTERLABORATORY EVALUATION OF TARGETED NEXT GENERATION SEQUENCING FOR MYELOPROLIFERATIVE NEOPLASMS ASSOCIATED MUTATIONS	Emmanuelle Verger Miñana	Received

1315-E	A 7- GENE SIGNATURE DEPICTS THE BIOCHEMICAL PROFILE OF EARLY PREFIBROTIC MYELOFIBROSIS	Vibe Skov Miñana	Received

1316-E	PLATELET ANALYSIS INCREASES THE DETECTION OF MUTATIONS IN TRIPLE-NEGATIVE ESSENTIAL THROMBOCYTHEMIA PATIENTS	Anna Angona Miñana	Received

1317-E	BONE MARROW STROMA MEDIATED PROTECTION OF MPN CELLS FROM RUXOLITINIB- AND VORINOSTAT-INDUCED APOPTOSIS REQUIRES MAPK-JNK AND PI3K-AKT/PKB SIGNALING PATHWAY ACTIVATION	Antonio Almeida Miñana	Received

1318-E	FREQUENCY AND ALLELE BURDEN OF CALR MUTATIONS IN CHINESE WITH ESSENTIAL THROMBOCYTHEMIA AND PRIMARY MYELOFIBROSIS WITHOUT JAK2 V617F OR MPL MUTATIONS	Guo-Rui Ruan Miñana	Received

1319-E	GENE AND PROTEIN EXPRESSION ANALYSES OF THE MTOR SIGNALING PATHWAY IN MYELOPROLIFERATIVE NEOPLASMS	Vladan Cokic Miñana	Received

1320-E	THE ANTIPROLIFERATIVE EFFECT OF SIMVASTATIN IS ASSOCIATED WITH EPIGENETIC MECHANISMS IN NEOPLASTIC MAST CELLS	Heidrun Karlic Miñana	Received

1321-E	CD30 EXPRESSION ON NEOPLASTIC MAST CELLS IN SYSTEMIC MASTOCYTOSIS â€" CORRELATION OF ASSESSMENT BY IMMUNOHISTOCHEMISTRY AND MULTIPARAMETER FLOW CYTOMETRY WITH RESPECT TO CLINICAL PARAMETERS	Frauke Bellos Miñana	Received

1322-E	INCIDENCE OF CALR MUTATIONS IN PATIENTS WITH CEREBRAL VENOUS THROMBOSIS WITHOUT OVERT CHRONIC MYELOPROLIFERATIVE NEOPLASM	Emmanuelle Verger Miñana	Received

1323-E	COMPARISON OF THREE DIAGNOSTIC METHODS TO DETECT CALRETICULIN MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS	Francois Girodon Miñana	Received

1324-E	ALTERNATIVE SPLICING VARIANT COULD BE RESPONSIBLE OF MORGANA UNDER-EXPRESSION IN ACML	Cristina Panuzzo Miñana	Received

1325-E	MUTATION ANALYSIS OF JAK2, MPL, CALR, ASXL1, TET2, IDH1, IDH2, DNMT3A, AND SF3B1 IN MYELOPROLIFERATIVE NEOPLASM	Jee Hyun Kong	Received

1327-E	JAK2V617F MUTATION IN COMBINATION WITH ASXL1, DNMT3A, TET2, U2AF1 AND RUNX1 VARIANTS IS ASSOCIATED WITH SEVERE CLINICAL PHENOTYPES IN PRIMARY MYELOFIBROSIS	Chieh Lee Wong	Received

1328-E	GATA-1, BUT NOT FOG-1, FLI-1 OR CALR, IS UP-REGULATED IN ESSENTIAL THROMBOCYTHEMIA INDEPENDENTLY FROM JAK2 AND CALR MUTATIONS.	Ciro Rinaldi Kong	Received

1329-E	PEGYLATED INTERFERON TREATMENT IMPROVES SURVIVAL IN POLYCYTHEMIA VERA PATIENTS: A SINGLE CENTER EXPERIENCE	Elena CrisÃ Kong	Received

1330-E	TERT RS2736100_C POLYMORPHISM AS PREDISPOSITION FACTOR FOR MYELOPROLIFERATIVE NEOPLASMS	Katalin Piroska Kiss	Received

1331-E	PATIENT SELF-CARE INTERVENTIONS: DO THEY IMPACT MPN-RELATED FATIGUE?	Robyn Scherber Kiss	Received

1333-E	ULTRA-DEEP SEQUENCING (UDS) ALLOWS MORE SENSITIVE DETECTION OF THE D816V AND OTHER KIT GENE MUTATIONS IN SYSTEMIC MASTOCYTOSIS	Caterina De Benedittis	Received

1334-E	RUXOLITINIB VS BEST AVAILABLE THERAPY IN PATIENTS WITH POLYCYTHEMIA VERA TREATED IN THE RESPONSE STUDY: A SUBGROUP ANALYSIS OF HYDROXYUREA- AND NON-HYDROXYUREAâ€"TREATED PATIENTS	Francesco Passamonti Benedittis	Received

1335-E	RISK OF PREGNANCY COMPLICATIONS AND EFFECT OF DIFFERENT TREATMENTS IN WOMEN WITH ESSENTIAL THROMBOCYTHEMIA: A RETROSPECTIVE MONOCENTER ANALYSIS OF 62 PREGNANCIES.	Silvia Betti Benedittis	Received

1336-E	ANALYSIS OF PHENOTYPE AND OUTCOME IN ESSENTIAL THROMBOCYTHEMIA WITH CALR AND JAK2 MUTATIONS	Carla Al Assaf	Received

1337-E	MUTATIONAL STATUS AND CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH STRICTLY WHO 2008-DIAGNOSED ESSENTIAL THROMBOCYTHEMIA: A MONOCENTRIC STUDY	Irene Bertozzi Assaf	Received

1338-E	CLINICAL SIGNIFICANCE OF CIRCULATING MICROPARTICLES IN PH- MYELOPROLIFERATIVE NEOPLASMS (MPN)	Yue Han Assaf	Received

1339-E	MATRIX METALLOPROTEINASE 2,3,9,10 AND 13 GENE MUTATIONS IN MYELOPROLIFERATIVE DISEASES	Senem Maral Assaf	Received

1340-E	KARYOTYPE OF CIRCULATING PROGENITOR CELLS OF MYELOID LINEAGE COULD BE RELATED TO CLINICAL COURSE OF MYELOFIBROSIS	Rosyslav Lozynskyy Assaf	Received

1341-E	IPSET-THROMBOSIS BETTER IDENTIFIES THROMBOSIS FREE SURVIVAL	Omuer Goekmen Sevindik	Received

1342-E	EFFICACY OF RUXOLITINIB IN MYELOID NEOPLASMS WITH PCM1-JAK2 FUSION GENE	Ilaria Carola Casetti	Received

1343-E	CLINICAL FEATURES OF JAPANESE POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA PATIENTS HARBORING CALR, JAK2V617F, JAK2EX12DEL, AND MPLW515L/K MUTATIONS	Masahiro Okabe Casetti	Received

1344-E	BONE MINERAL DENSITY IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA	Sarah Farmer Casetti	Received

1345-E	PREVALENCE OF EOSINOPHILIAS (EOS), IDIOPATIC HYPEREOSINOPHILIA AND HYPEREOSINOPHILIC SYNDROME (HES) IN A LARGE (ONE MILLION) POPULATION IN NORTH ITALY (THE ROMAGNA GREATER AREA)	Michela Rondoni Casetti	Received

1346-E	A SCORING SYSTEM BASED ON LEUKOCYTE ALKALINE PHOSPHATASE ACTIVITY AND PERIPHERAL GRANULOCYTE PRECURSOR PERCENTAGE PREDICTS JAK2 V617F MUTATION IN PATIENTS WITH PRIMARY MYELOFIBROSIS	Rosangela Invernizzi Casetti	Received

1347-E	RUXOLITINIB IN CHRONIC MYELOMONOCYTIC LEUKEMIA AND SYMPTOMATIC SPLENOMEGALY	Klaus Geissler Casetti	Received

1348-E	CLINICAL DIFFERENCES IN ESSENTIAL THROMBOCYTHEMIA PATIENTS WITH AND WITHOUT THROMBOTIC COMPLICATIONS	Anastasiia Zherniakova Casetti	Received

1349-E	LONG-TERM RESULTS OF PREDNISONE TREATMENT FOR THE ANEMIA OF MYELOFIBROSIS	Juan-Carlos Hernandez-Boluda Casetti	Received

1350-E	CLINICAL CHARACTERISTICS OF CALR MUTATIONS IN JAPANESE PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA	Yuka Sugimoto Casetti	Received

1351-E	SIMULATION IN CONTINUING EDUCATION: IMPROVING HEMATOLOGIST EVIDENCE-BASED DECISIONS FOR MYELOPROLIFERATIVE NEOPLASM MANAGEMENT	Emily Van Laar	Received

1352-E	CLINICAL CHARACTERISTICS OF POLYCYTHEMIA VERA PATIENTS, RECEIVING DIFFERENT TYPES OF THERAPY.	Dzhariyat Shikhbabaeva Laar	Received

1353-E	COMPLETE HEMATOLOGIC CONTROL WITH RUXOLITINIB IN PATIENTS WITH POLYCYTHEMIA VERA (PV) RESISTANT TO OR INTOLERANT OF HYDROXYUREA	Claire Harrison Laar	Received

1354-E	XRCC1 399GG GENOTYPE PREDICTS LONG LASTING CR AND SIGNIFICANTLY LONGER OVERALL SURVIVAL IN RESISTANT LYMPHOMA TREATED WITH BENDA-BEAM AND ASCT	Giuseppe Visani Laar	Received

1356-E	DESIGN AND DEVELOPMENT OF A NOVEL, HIGHLY POTENT AND SELECTIVE PI3K-DELTA INHIBITOR, CPL-302-215, AS POTENTIAL TREATMENT OF HEMATOLOGIC MALIGNANCIES	Aleksandra Stanczak Laar	Received

1357-E	NR4A1 AND NR4A3 POSSESS FUNCTIONAL REDUNDANCY BY REGULATING PRO-APOPTOTIC GENES IN AGGRESSIVE LYMPHOMAS.	Alexander Deutsch Laar	Received

1358-E	CD3+/CD8+/CD16+/CD56-/CD57+ T-LGLL REPRESENTS A DIFFERENT SUBSET WITH DISTINCT CLINICAL AND BIOLOGICAL FEATURES	Gregorio Barila	Received

1359-E	STAT5B MUTATION ANALYSIS IN A COHORT OF T-LGL LEUKEMIA PATIENTS	Antonella Teramo	Received

1360-E	B-CELL CLONALITY IN BONE MARROW IS PREDICTOR OF OUTCOME IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS TREATED WITH HIGH-DOSE CHEMOTHERAPY.	Olga Gavrilina	Received

1361-E	SILENCING PROGRESSION OF TUMOR SUPPRESSIVE MICRORNAS ESSENTIALLY CONTRIBUTES TO DEVELOP AGGRESSIVE T-CELL LYMPHOMA	Akihiro Kitadate	Received

1362-E	AKT GENE EXPRESSION IS REGULATED BY THE AP-1 TRANSCRIPTION FACTORS JUNB AND CJUN IN ALK+ ANAPLASTIC LARGE CELL LYMPHOMA (ALCL): A NOVEL CROSSTALK MECHANISM	George Rassidakis	Received

1363-E	IDENTIFICATION OF LEUKEMIC STEM CELL CANDIDATES IN AN ATL MOUSE MODEL OF HBZ TRANSGENIC MICE	Wakako Kuribayashi	Received

1364-E	A NEW MOUSE MODEL FOR MATURE B-CELL LYMPHOMA REVEALING REQUIREMENT FOR FAS DOWNREGULATION IN LYMPHOMAGENESIS	Eiji Sugihara	Received

1365-E	MOLECULAR DIAGNOSIS BY GENE EXPRESSION PROFILING IN FORMALIN FIXED PARAFFIN EMBEDDED TISSUE - BURKITT LYMPHOMAS WITH EXPRESSION OF BCL2	Neus Masqué-Soler	Received

1366-E	PROTEIN KINASE CK2 IN DIFFUSE LARGE B-CELL LYMPHOMA: DEFINING ITS ROLE TO SHAPE NEW THERAPIES	Elisa Mandato	Received

1367-E	INHIBITORS OF MTOR/PI3K/AKT PATHWAY EXTEND THERAPEUTIC OPPORTUNITY IN WALDENSTROMS MACROGLOBULINEMIA CELLS THAT DISPLAY RESISTANCE TO BOTH ABT-199 AND IBRUTINIB.	Kasyapa Chitta	Received

1368-E	HIGH THROUGHPUT IN VITRO COMBINATION SENSITIVITY SCREEN IN HEMATOLOGIC MALIGNANCIES WITH DUVELISIB, A DUAL PI3K-DELTA,GAMMA INHIBITOR	Kerrie Faia	Received

1370-E	ARTISAN PCR: HIGHLY RELIABLE IDENTIFICATION OF FULL-LENGTH B-CELL RECEPTOR SEQUENCES	Marvyn Koning	Received

1371-E	NFKBIE MUTATIONS OCCUR IN 15% OF GCB DLBCL AND IN VARIOUS OTHER LYMPHOID MALIGNANCIES.	Daniel Noerenberg	Received

1372-E	NK CELLS CYTOTOXICITY IS AFFECTED BY VARIOUS BTK INHIBITORS	Marta Siernicka	Received

1373-E	VDJH USAGE IN TRANSFORMED FOLLICULAR LYMPHOMA	Maria Garcia	Received

1374-E	GENOME-WIDE DNA COPY NUMBER IMBALANCES ASSOCIATED WITH HIV POSITIVE PLASMABLASTIC LYMPHOMAS	Pascale Willem	Received

1375-E	EFFICACY OF THE PAN PI3K-INHIBITOR COPANLISIB COMPARED TO SELECTIVE PI3K-Î´, -Î´, -Î" INHIBITORS IN MANTLE CELL LYMPHOMA (MCL)	Anna Zoellner	Received

1376-E	WALDENSTROM MACROGLOBULINEMIA CELLS WITH PLASMACYTIC-PREDOMINANT FEATURES ARE INSENSITIVE TO DISRUPTION OF B-CELL RECEPTOR SIGNALING BUT RETAIN HEIGHTENED SENSITIVITY TO PROTEOTOXIC STRESS.	Kasyapa Chitta	Received

1377-E	EVALUATION OF GENOMIC IMBALANCES AND MIRNA EXPRESSION IN PATIENTS WITH MYCOSIS FUNGOIDES	Fuad Huaman	Received

1378-E	MULTIPLE INJECTIONS OF ANTIBODY-RADIONUCLIDE-CONJUTAGES TARGETING CD37 INCREASES TOLERABILITY IN NUDE MICE BEARING NON-HODGKIN LYMPHOMA XENOGRAFTS	Helen Heyerdahl	Received

1379-E	OFATUMUMAB OVERCOMES CD59-DEPENDENT RESISTANCE TO COMPLEMENT-DEPENDENT CYTOTOXICITY IN HUMAN B-CELL LYMPHOMA MODEL	Michal Dwojak	Received

1380-E	THE EXPRESSION OF FOXO4 REGULATES LYMPHOMA STEM CELL-LIKE CHARACTERISTICS AND RESISTANCE TO TREATMENT IN B-CELL NON-HODGKIN LYMPHOMA	Kyung JuRyu	Received

1382-E	IMMUNOPHENOTYPIC CHARACTERIZATION AND CLINICAL BEHAVIOUR IN CD19+CD5+ (NON-CLL) LYMPHOPROLIFERATIVE DISORDERS MUTATED AND UNMUTATED WITH AND WITHOUT T(11,14)	Lucia Lopez-Anglada	Received

1383-E	ANALYSIS OF THE IGVH SOMATIC MUTATIONS IN SPLENIC MARGINAL ZONE LYMPHOMA	Hunan Julhakyan	Received

1384-E	FLOW CYTOMETRY IMMUNOPHENOTYPING AND CYTOLOGICAL ANALYSES OF CSF: A COMPARISON OF PERFORMANCES FOR LYMPHOMATOUS CELL DETECTION	Myrto Costopoulos	Received

1385-E	EXPRESSION OF SOXC CLUSTER AND MIR-17-92 POLYCISTRON IN MANTLE CELL LYMPHOMA PATIENTS.	Alejandro Roisman	Received

1386-E	THE IMPACT OF MUTATION STATUS OF SOCS1 IN PATIENTS WITH HIGH-GRADE DIFFUSE LARGE B-CELL LYMPHOMA.	Olga Gavrilina	Received

1387-E	FLOW CYTOMETRIC CHARACTERIZATION OF LEUKOCYTE SUBPOPULATIONS IN BONE MARROW FROM UNTREATED PATIENTS WITH GAUCHER DISEASE TYPE 1: PRONOUNCED T-CELL RESPONSE AND STEM CELL DEFECT?	Monika Klimkowska Garaicoa	Received

1388-E	FREQUENCY OF AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME IN CHILDREN WITH CHRONIC IMMUNE CYTOPENIAS AND NEWLY DIAGNOSED LYMPHOMA	Zuehre Kaya Alvarez	Received

1389-E	PLASMA LEVELS OF PRESEPSIN (SOLUBLE CD14-SUBTYPE) AS A NOVEL PROGNOSTIC MARKER FOR HEMOPHAGOCYTIC SYNDROME	Satoru Nanno Alvarez	Received

1390-E	INFECTIONS IN CHILDREN WITH CHRONIC NEUTROPENIA-A 13-YEAR EXPERIENCE IN A TERTIARY CARE CENTER	Madalina Schmidt Garaicoa	Received

1391-E	OUTCOME OF LANGERHANS CELL HISTIOCYTOSIS IN CHILDREN UNDER THE AGE OF 24 MONTHS- LCH-III PROTOCOL	Maria Moschovi Alvarez	Received

1392-E	HYPERTRYPTASEMIA OF UNCERTAIN SIGNIFICANCE: A NOVEL CONDITION DETECTED IN A SCREEN OF 1330 UNSELECTED CASES IN A HEMATOLOGY CENTER	Katharina Blatt Alvarez	Received

1393-E	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME IN A FAMILY WITH PYRUVATE KINASE DEFICIENCY	Marina Economou Alvarez	Received

1394-E	THE RESEARCH PARAMETER NEUT-X IN VITAMIN B12 DEFICIENCY	Athanasia Agorasti Alvarez	Received

1395-E	CHRONIC NEUTROPENIA IN CHILDHOOD â€" EXPERIENCE FROM A SINGLE CENTER	Tuba Hilkay KarapÄ±nar	Received

1396-E	STUDY OF ALPHA HEMOGLOBIN STABILIZING PROTEIN EXPRESSION IN PATIENTS WITH Î´ THALASSEMIA AND SICKLE CELL ANEMIA AND ITS IMPACT ON CLINICAL SEVERITY	Marwa Deghedy KarapÄ±nar	Received

1397-E	HEMOPHAGOCYTIC SYNDROMES IN SAUDI CHILDREN: SINGLE CENTER EXPERIENCE	Azzah Alzahrani KarapÄ±nar	Received

1399-E	SUSTAINED INFLAMATORY CYTOKINES IN NAÃVE GAUCHER DISEASE: A LINK WITH MULTIPLE MYELOMA?	Marcio Miguel Andrade	Received

1400-E	AUTOIMMUNE HEMOLYTIC ANEMIA: DESCRIPTIVE STUDY OF 100 CASES.	Kmira Zahra Andrade	Received

1401-E	PROSPECTIVE STUDY OF PLASMA BIOMARKERS ASSOCIATED WITH THE INFLAMMATORY RESPONSE IN TYPE 1 GAUCHER DISEASE PATIENTS TREATED DURING ONE YEAR WITH VELAGLUCERASE ALFA.	Marcio Andrade-Campos Andrade	Received

1403-E	USEFULLNESS OF SERUM FERRITIN LEVEL > 10,000 NG/ML TO DIAGNOSIS HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) IN ADULTS.	Ernesto ColoradoLedesma Andrade	Received

1404-E	EFï¬CACY OF HIGH-DOSE METHYLPREDNISOLONE AS A ï¬RST-LINE THERAPY IN ADULT PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA	Emel Gurkan	Received

1405-E	ELTROMBOPAG MAY BE USEFUL IN SECONDARY ITP PATIENTS IN CLINICAL PRACTICE	Tomás José	Received

1406-E	ITP PATIENTS IN THE ASIA PACIFIC: ARE THEY DIFFERENT?	Beng Chong	Received

1407-E	CLINICAL FEATURES OF PATIENT WITH SEVERE ACQUIRED ADAMTS13 DEFICIENCY IN THROMBOTIC THROMBOCYTOPENIC PURPURA	Doyeun Oh	Received

1408-E	A PERSONALIZED REFERENCE INTERVAL FOR PLATELET COUNT REDUCES THE PREVALENCE OF UNEXPLAINED THROMBOCYTOPENIA AND INCREASE THAT OF REACTIVE THROMBOCYTOSIS IN ELDERLY PEOPLE	Patrizia Noris	Received

1409-E	ROLE OF ASHWELL-MORELL RECEPTOR MEDIATED HEPATIC CLEARANCE OF PLATELET IN IMMUNE THROMBOCYTOPENIA (ITP): PLATELET KINETIC STUDIES AND AUTOANTIBODY TYPE DATA IN CLINICAL PRACTICE	Monica Carpenedo	Received

1410-E	DIAGNOSIS AND MANAGEMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN AUSTRALIA - FINDINGS FROM THE FIRST FIVE YEARS OF THE AUSTRALIAN TTP REGISTRY (2009-2014)	Piers Blombery	Received

1411-E	RECENT TIME TRENDS IN THE UPTAKE OF SPLENECTOMY IN ADULTS DIAGNOSED WITH CHRONIC IMMUNE THROMBOCYTOPENIA: A NATIONWIDE HISTORICAL COHORT STUDY IN DENMARK, 1996-2012	Sally Wetten	Received

1413-E	THE ROLE OF REGULATORY T CELLS IN IMMUNE THROMBOCYTOPENIA OF CHILDHOOD	Maria Stratigaki	Received

1414-E	INCIDENCE OF MALIGNANCY IN ADULT PATIENTS WITH AUTOIMMUNE THROMBOCYTOPENIC PURPURA: A 12 YEAR SINGLE CENTER EXPERIENCE	Mahmoud Ayesh	Received

1417-E	EFFECT OF THROMBOPOIETIN RECEPTOR AGONISTS ON COAGULATION AND PLATELET ACTIVATION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA	Lamya Garabet	Received

1418-E	SPLENECTOMY IN THE TPO MIMETIC ERA â€" STILL REASONABLE APPROACH?	Eva Konirova	Received

1419-E	ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN SOME IMMUNOREGULATORY GENES WITH IMMUNE THROMBOCYTOPENIA	Marica Pavkovic	Received

1420-E	SWITCHING THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) IN ADULT IMMUNE THROMBOCYTOPENIA (ITP) PATIENTS: A RETROSPECTIVE CASE SERIES	Monica Carpenedo	Received

1421-E	A STUDY OF HUMAN KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR(KIR) AND MULTI-DRUG RESISTANCE (MDR )GENE POLYMORPHISMS IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA	Nancy Elbarbary	Received

1422-E	ROMIPLOSTIM AS A PREPARATION TREATMENT BEFORE SPLENECTOMY IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA.	Eva Burnasheva	Received

1423-E	GLANZMANN THROMBASTHENIA IN CHILDREN : TWENTY FIVE YEARS FOLLOW-UP	Zafer Salcioglu	Received

1424-E	DIAGNOSTIC VALUE OF TESTS USED AT IMMUNE THROMBOCYTOPENIA DIAGNOSIS TO DETECT ASSOCIATED DISEASES. A PROSPECTIVE MULTICENTER COHORT STUDY.	Guillaume Moulis	Received

1425-E	STUDY OF ADAMTS13 LEVELS IN PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) DURING PREGNANCY	Francesca Piras	Received

1426-E	SYMPTOMS, QUALITY OF LIFE AND HEALTH CARE UTILISATION IN MULTIPLE MYELOMA â€" A LONGITUDINAL STUDY OF PREDICTIVE DEMOGRAPHIC AND CLINICAL FACTORS	Christina Ramsenthaler Yousef	Received

1427-E	NET SURVIVAL AND EXCESS MORTALITY AFTER A FOLLICULAR OR DIFFUSE LARGE B CELL LYMPHOMA: TREND BY EUROPEAN AREA.	Morgane Mounier Yousef	Received

1428-E	IMPLEMENTATION OF â€œLEANâ€ WORKING PRACTICES AND AN INTEGRATED ECP SYSTEM RESULTED IN A 50% INCREASE IN PATIENT TREATMENTS WITH THE SAME NUMBER OF NURSES EMPLOYED IN THE UNIT	Paul Button Yousef	Received

1429-E	PROGNOSTIC VALUE OF NEURO-PSYCHOLOGICAL PARAMETERS IN CLINICALLY FIT OLDER PATIENTS WITH HEMATOLOGICAL MALIGNANCIES	Dominique Bron Yousef	Received

1430-E	NOA PROGRAM INFLUENCING SURVIVAL IN CML PATIENTS FROM RESOURCE CONSTRAINT SETTINGS	Uday Yanamandra Yousef	Received

1431-E	A MULTI-CENTRE COST COMPARISON OF INTEGRATED VERSUS â€œOFF-LINEâ€ SYSTEMS FOR PERFORMING EXTRACORPOREAL PHOTOPHERESIS PROCEDURES	Paul Button Yousef	Received

1433-E	IMPACT OF CARFILZOMIB ON HEALTH-RELATED QUALITY OF LIFE: RESULTS FROM A PHASE 2 POST-HOC ANALYSIS OF SINGLE-AGENT CARFILZOMIB (PX-171-003-A1) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA	David S. Siegel	Received

1434-E	PATIENTSâ€™ PERCEPTIONS OF RECEIVING A DIAGNOSIS OF A HAEMATOLOGICAL MALIGNANCY, FOLLOWING THE SPIKES PROTOCOL	Lauren Dixon Siegel	Received

1435-E	IMPACT OF BURDEN OF THALASSEMIA MAJOR ON HEALTH RELATED QUALITY OF LIFE IN OMANI CHILDREN	Surekha Mevada Siegel	Received

1436-E	QUALITY OF LIFE IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA TREATED WITH ELTROMBOPAG: INTERIM RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED PROSPECTIVE TRIAL.	Esther Natalie Oliva	Received

1437-E	MEDICAL AND SOCIO-ECONOMIC IMPACT OF A FREE HEALTHCARE POLICY ON MIGRANTS WITH ACUTE MYELOID OR LYMPHOID LEUKEMIA	Anne Marie Ronchetti	Received

1438-E	KNOWLEDGE ASSESSMENT AND EDUCATIONAL INTERVENTION AT A PATIENT CENTERED CANCER SYMPOSIUM	Ruben Mesa Ronchetti	Received

1439-E	COST-EFFECTIVENESS OF IDELALISIB IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN PORTUGAL	Maria Gomes Silva	Received

1440-E	QUALITY OF LIFE OF ANTICOAGULATED PATIENTS: SURVEY SATISFACTION	Jesus Loza Silva	Received

1441-E	QUALITY OF LIFE EQ-5D RESULTS FROM THE AETHERA TRIAL: A PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN CONSOLIDATION FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT FOR HL	Scott Ramsey Silva	Received

1442-E	ON DEATH AND DYING: CULTURAL END-OF-LIFE ISSUES IN MULTIPLE MYELOMA	Marta-Isabel Pereira Silva	Received

1443-E	UTILITY VALUES FOR PATIENTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL) IN TOP FIVE EUROPEAN COUNTRIES (EU-5)	Magali Cognet Silva	Received

1444-E	THE IMPACT OF PALLIATIVE RADIOTHERAPY ON QUALITY OF LIFE IN MULTIPLE MYELOMA PATIENTS WITH PAINFUL BONE DESTRUCTIONS	Milda Rudzianskiene Silva	Received

1446-E	QUALITY OF LIFE IN MULTIPLE MYELOMA: VALIDATION OF THE TURKISH VERSION OF THE QLQ-MY20 INSTRUMENT	Inci Alacacioglu Silva	Received

1448-E	BRENTUXIMAB VEDOTIN IN PATIENTS AT INCREASED RISK OF HODGKIN LYMPHOMA PROGRESSION POST AUTOLOGOUS STEM CELL TRANSPLANT: EVALUATION OF HEALTHCARE RESOURCE UTILIZATION IN THE AETHERA TRIAL	Vijayveer Bonthapally Silva	Received

1449-E	COST-EFFECTIVENESS AND QUALITY ASSURANCE IN BONE MARROW ANALYSIS: AN AUDIT OF SAMPLING TECHNIQUE AND SPECIALISED HAEMATOLOGICAL TEST REQUESTING AT A HAEMATO-ONCOLOGY CENTRE	Paul Greaves Silva	Received

1450-E	BLOOD AND PLATELET TRANSFUSIONS FOR HAEMATOLOGY PATIENTS REQUIRING PALLIATIVE CARE: WHAT CAN UK HOSPICES PROVIDE?	Samual Ackroyd Silva	Received

1451-E	COST-EFFECTIVE ANALYSIS OF PROPHYLAXIS WITH LAVIVUDINE FOR PREVENTION OF REACTIVATION IN OCCULT HEPATITIS B (OBI) IN PATIENTS WITH NON HODGKIN LYMPHOMA CD20+ UNDERGOING CHEMOTHERAPY	Claudio Cerchione Silva	Received

1452-E	DEMAND MANAGEMENT OF ANALYTICAL REQUEST IN ERYTHROPATHOGY SECTION OF A TERTIARY HOSPITAL.	María De La	Received

1453-E	MICRO-COSTING STUDY OF RITUXIMAB SUBCUTANEOUS INJECTION VERSUS INTRAVENOUS INFUSION IN DUTCH SETTING	Jovan MihajloviÄ‡ La	Received

1454-E	BIOSIMILAR FILGRASTIM FOR THE PREVENTION OF FEBRILE NEUTROPENIA IN ELDERLY DLBCL PATIENTS HAS COST EFFECTIVENESS COMPEERED WITH ORIGINAL FILGRASTIM	Naoki Takezako La	Received

1455-E	IS CLINICAL TRIAGE EFFECTIVE? AN AUDIT OF OUTPATIENT REFERRALS TO THE HAEMATOLOGY DEPARTMENT AT NORTHWICK PARK HOSPITAL, LONDON NORTHWEST NHS TRUST	Marquita Camilleri La	Received

1456-E	PROGRESSION-FREE SURVIVAL AS THE PRIMARY ENDPOINT IN ONCOLOGY TRIALS: ITS VALUE AND CREDIBILITY FROM DIFFERENT STAKEHOLDERSâ€™ PERSPECTIVES	Casey Quinn La	Received

1457-E	IMBALANCES IN THE ANNUAL EHA CONGRESS. THE FUTURE OF HAEMATOLOGY.	Jesus Loza La	Received

1458-E	HEMATOLOGY AND SOCIAL MEDIA: COMMUNICATION AND EDUCATION IN THE MODERN ERA	Emily Graves La	Received

1460-E	HEMOGLOBINOPATHIES WITH HIGH OXYGEN AFFINITY	Williana Torres	Received

1461-E	TRANSFUSION-DEPENDENT HEREDITARY SPHEROCYTOSIS AND COMPLETE DISTAL RENAL ACIDOSIS: THE FIRST CASE WITH A HOMOZYGOUS EXON 12 C.1430C>A (P.SER477X) MUTATION OF THE SLC4A1 GENE	Leo Kager	Received

1462-E	CHARACTERIZATION OF 6 HEMOGLOBINOPATHIES OCCURRING WITH CYANOSIS AND/OR LOWERING THE OXIGEN SATURATION	Williana Torres	Received

1463-E	IDENTIFICATION OF TWO NEW MISSENSE MUTATIONS AND A 5BP DELETION IN THE ERYTHROID-SPECIFIC PROMOTOR OF THE PKLR GENE IN TWO UNRELATED PATIENTS WITH NON-SPHEROCYTIC HEMOLYTIC ANEMIA	Leo Kager	Received

1464-E	HB PUERTA DEL SOL, HB VALDECILLA, HB GRAN VÃA, HB MACARENA, AND HB EL RETIRO: DESCRIPTION OF 5 NEW HEMOGLOBINOPATHIES	Felix De	Received

1466-E	THE CLINICAL FEATURES AND TREATMENT OF IRON OVERLOAD IN PYRUVATE KINASE DEFICIENCY (PKD): DATA FROM THE PKD NATURAL HISTORY STUDY (NHS)	Rachael Grace La	Received

1467-E	THE QUESTIONING OF THE NEED FOR MONTHLY MONITORING OF PROTENURIA AMONG PATIENTS WITH BETA THALASSEMIA MAJOR USING DEFERASIROX	Fatma gumruk La	Received

1468-E	CAUSES OF NEWLY DIAGNOSED ANAEMIA IN GENERAL PRACTICE: THE RELEVANCE OF MCV	Karlijn Stouten La	Received

1469-E	USEFULNESS OF LASER ASSISTED OPTICAL ROTATIONAL CELL ANALYZER (LORRCA) IN THE DIAGNOSIS OF HEREDITARY HAEMOLYTIC ANAEMIAS	Paola Bianchi La	Received

1470-E	IDIOPATHIC AND CONGENITAL ERYTHROCYTOSIS: A STUDY OF A LARGE COHORT.	Maria Luigia Randi	Received

1471-E	LEFT VENTRICULAR GLOBAL FUNCTION INDEX AND LEFT VENTRICULAR MASS VOLUME RATIO BY CMR: ASSOCIATION WITH HEART FAILURE AND ARRHYTHMIAS IN THALASSEMIA MAJOR PATIENTS	Alessia Pepe Randi	Received

1472-E	SIGNIFICANT IMPROVEMENT OF SURVIVAL BY T2* MRI IN THALASSEMIA MAJOR	Alessia Pepe Randi	Received

1473-E	A NON-INTERVENTIONAL OBSERVATIONAL STUDY ASSESSING SAFETY OF DEFERASIROX IN PATIENTS WITH HEMOGLOBINOPATHIES AND TRANSFUSIONAL IRON OVERLOAD: RESULTS FROM THE â€œENERGYâ€ STUDY	Ersi Voskaridou Randi	Received

1474-E	DESCRIPTIVE ANALYSES OF DEFERASIROX SAFETY AND EXPOSURE IN PATIENTS AGED >65 VERSUS 18 TO â‰¤65 YEARS	Maria Domenica Cappellini	Received

1475-E	SERUM CYSTATIN C IN SICKLE CELL DISEASE: RELATION TO CARDIOVASCULAR DYSFUNCTION AND SICKLE CELL NEPHROPATHY	Azza Tantawy Cappellini	Received

1476-E	DEFERASIROX IMPROVES LIVER FIBROSIS IN Î´ THALASSAEMIA MAJOR PATIENTS. A 5 YEARS FOLLOW UP STUDY.	Efthimia Vlachaki Cappellini	Received

1477-E	PREMATURE ATHEROSCLEROSIS IN CHILDREN WITH BETA- MAJOR THALASSEMIA: NEW DIAGNOSTIC MARKER	Laila Sherief Cappellini	Received

1478-E	ASSESSMENT OF LIVER IRON CONCENTRATION IN PATIENTS WITH THALASSEMIA MAJOR USING MRI TECHNOLOGY: FINAL RESULTS OF A PROSPECTIVE COMPARATIVE STUDY BETWEEN T2* AND FERRISCAN	Ersi Voskaridou Cappellini	Received

1479-E	25-OH VITAMIN D DOWN-REGULATES IN VITRO PRODUCTION OF ANTI-ERITHROCYTE ANTIBODIES IN AUTOIMMUNE HAEMOLYTIC ANAEMIA	Bruno Fattizzo Cappellini	Received

1480-E	A CROSS-SECTIONAL STUDY COMPARING DIFFERENT HEMATOLOGICAL AND BIOCHEMICAL DISEASE MARKERS FOR CLINICAL DIAGNOSIS OF IRON DEFICIENCY	Dietmar Enko Cappellini	Received

1481-E	CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE III AND PRIMARY HEMOCHROMATOSIS; COEXISTENCE OF MUTATIONS IN KIF23 AND HFE.	Maria Liljeholm Cappellini	Received

1482-E	ERYTHROCYTE-DERIVED MICROVESICLE RELEASE DURING EX-VIVO CARDIOPULMONARY BYPASS PROCEDURES	Rick Huisjes Cappellini	Received

1483-E	HS-TROPONINE T RELATES WITH MYOCARDIAL IRON OVERLOAD IN TRANSFUSION DEPENDENT THALASSEMIC PATIENTS	Calogero Vetro Cappellini	Received

1484-E	COMPARISON OF IRON CHELATION EFFECTS OF DEFEROXAMINE, DEFERASIROX, AND COMBINATION OF DEFEROXAMINE AND DEFERIPRONE ON LIVER AND CARDIAC T2* MRI IN THALASSEMIA MAIOR	Shahla Ansari Cappellini	Received

1485-E	MRI PROSPECTIVE SURVEY ON CARDIAC AND HEPATIC IRON AND CARDIAC FUNCTION IN TRANSFUSION-DEPENDENT THALASSEMIA INTERMEDIA PATIENTS TREATED WITH DESFERRIOXAMINE, DEFERIPRONE AND DEFERASIROX.	Alessia Pepe Cappellini	Received

1486-E	TISSUE DOPPLER IMAGING IN CHILDREN WITH SICKLE CELL DISEASE: EVALUATION OF PULMONARY HYPERTENSION	Ilham Youssry Cappellini	Received

1487-E	TOWARD BETTER PATHOPHYSIOLOGICAL CHARACTERIZATION AND THERAPEUTIC SOLUTION IN BETA-THALASSEMIA TRAIT PATIENTS WITH IRON OVERLOAD. PRELIMINARY REPORTS FROM AN ONGOING STUDY.	Fabiana Busti Cappellini	Received

1488-E	DIAGNOSIS OF FUNCTIONAL IRON DEFICIENCY: HEPCIDIN AS NOVEL BIOMARKER VERSUS CONVENTIONAL CLINICAL BIOMARKERS	Dietmar Enko Cappellini	Received

1490-E	EVALUATION OF EMERGENCY CARE FOR ADULT SICKLE CELL PATIENTS: A MONOCENTRIC STUDY	Marie-Agnes Azerad Cappellini	Received

1491-E	IMPROVING MACROCYTOSIS DIFFERENTIAL DIAGNOSIS BY RDW-SD	Telma Nascimento Cappellini	Received

1492-E	PROSPECTIVE STUDY ON THE EFFECT OF FOK-I GENE POLYMORPHISM ON BONE HEALTH IN YOUNG PATIENTS WITH B-THALASSAEMIA MAJOR	Marina Economou Cappellini	Received

1493-E	GROWTH DIFFERENTIATION FACTOR-15 AND CARDIOVASCULAR DISEASE IN THALASSEMIA INTERMEDIA	Azza Tantawy Cappellini	Received

1494-E	SOLUBLE FMS LIKE TYROSINE KINASE-1 (SFLT-1) : AN EARLY MARKER FOR GLOMERULAR DYSFUNCTION IN SICKLE CELL NEPHROPATHY	Ilham Youssry Cappellini	Received

1495-E	ORAL IRON-BASED PHOSPHATE BINDER, FERRIC CITRATE, INCREASES IRON MEASURES IN DIALYSIS-DEPENDENT AND NON-DIALYSIS DEPENDENT PATIENTS WITH CHRONIC KIDNEY DISEASE	Lisa Loram Cappellini	Received

1496-E	THE SPECTRUM OF Î´-THALASSEMIA AND Î´â€"THALASSEMIA MUTATIONS IN SOUTH WEST IRAN	Bijan Keikhaei Cappellini	Received

1497-E	DO WE HAVE TO CHELATE PATIENTS WITH THALASEMIA MAJOR HAVING FERRITIN LEVELS < 500 ÎœG/L ?	Gonul Aydogan Cappellini	Received

1498-E	KLF10 GENE EXPRESSIONÂ AS A SECONDARY MODIFIER IN BETA THALASSEMIA AND SICKLE CELL DISEASE (SCD) PATIENTS AND A PHARMACOGENOMIC BIOMARKER FOR HYDROXYCARBAMIDE TREATMENT RESPONSE	Mohsen S Elalfy	Received

1499-E	THINKING OF HEREDITARY XEROCYTOSIS: THE FIRST STEP TO THE DIAGNOSIS	Mónica Santos Elalfy	Received

1500-E	EFFECTIVENES OF MAGNETIC RESONANCE IMAGING FOR MEASURING OF PITUITARY IRON OVERLOAD IN PATIENTS WITH THALASSEMIA	Yesim Oymak Elalfy	Received

1501-E	ACTIVATION OF MONOCYTES AND DENDRITIC CELLS IN PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Eva Hofmann	Received

1502-E	COMPARISON OF CONDITIONING REGIMENS FOR RELAPSED / REFRECTORY LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION: BEAM VS HIGH DOSE ICE	Ahmet Kursad	Received

1503-E	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-MALIGNANT HEMATOLOGICAL DISORDERS	Yasser Elnahass	Received

1504-E	FERTILITY IN OUR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS: RESULTS FOR 23 YEARS OF EXPERIENCE	Pervin Topcuoglu	Received

1506-E	PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND EFFICACY STUDY OF PLERIXAFOR IN CHINESE PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL)	Huan CHEN	Received

1507-E	THE ROLE OF STEM CELL TRANSPLANTATION FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT TO TYROSINE KINASE INHIBITORS WITH BCR-ABL KINASE DOMAIN MUTATION T315I.	Julia Vlasova	Received

1508-E	GRANZYME B EXPRESSION IN T-REGULATORY CELLS ON DAY +14 AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IS A STRONG PREDICTOR OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD)	Mikhail Drokov	Received

1509-E	THE ROLE OF TREGS AND TIM3 IN HEMATOPOIETIC STEM CELL TRANSPLANTATION	Caixia Li	Received

1510-E	SUCCESSFUL STEM CELL MOBILIZATION AND AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER PRETREATMENT CONSISTING OF BENDAMUSTINE, PREDNISONE AND BORTEZOMIB IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA	Wolfram Poenisch	Received

1512-E	HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY IMMUNE DEFICIENY DISEASES: A SINGLE CENTER EXPERIENCE	Turkan Patiroglu	Received

1513-E	DECITABINE BRIDGING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE TREATMENT OF MDS RETROSPECTIVE EFFICACY ANALYSIS	Chengcheng Fu	Received

1514-E	THE OUTCOMES OF HAPLOIDENTICAL HEMATOPOETIC STEM CELL TRANSPLANTATION PERFORMED WITH UNMANIPULATED DONOR STEM CELLS AND POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HIGH RISK CHILDREN	M. Akif	Received

1515-E	THE EBMT RISK SCORE CAN PREDICT THE OUTCOME AFTER ALLOGENEIC HEMATOPOIETC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA AMONG EGYPTIAN PATIENTS	Samah Desoukey	Received

1516-E	FACTORS AFFECTING SURVIVAL IN PATIENTS WITH ACUTE LEUKEMIA WHO RECEIVED DONOR LYMPHOCYTE INFUSION IN THE TREATMENT OF FIRST RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	Fatih Kurnaz	Received

1518-E	HBV CLEARANCE IN HBSAG+ PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IS HERALDED BY GVHD OF LIVER	Tran-Der Tan	Received

1519-E	OUTCOMES OF CORD BLOOD TRANSPLANTATION WITH NON-TOTAL BODY IRRADIATION CONDITIONING REGIMEN CONSISTING OF FLUDARABINE AND BUSULFAN FOR PATIENTS WITH ADVANCED HEMATOLOGYIC MALIGNANCIES	Kenji Tsuda	Received

1520-E	A PORTABLE MICROSCOPIC CELL COUNTER (ADAM II) FOR ENUMERATING CD34+ CELLS	Jong HyunOh	Received

1521-E	LONG-TERM OUTCOMES FOLLOWING REDUCED-INTENSITY STEM CELL TRANSPLANTATION: THE CRITICAL IMPORTANCE OF THE DEVELOPMENT OF GRAFT-VERSUS-HOST DISEASE	Emilie Nevill	Received

1522-E	AUTOLOGOUS STEM CELL TRANSPLANT IN AL AMYLOIDOSIS: AN EFFECTIVE TREATMENT FOR SELECTED PATIENTS	Mariella D´Adda	Received

1524-E	A BENDAMUSTINE CONTAINING FLUDARABIN-BASED REDUCED INTENSITY CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN REFRACTORY/RELAPSED CLASSICAL HODGKIN LYMPHOMA	Natalia Mikhaylova	Received

1525-E	EFFICACY OF ORAL GLUTAMINE IN THE PREVENTION OF MUCOSITIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION. EXPERIENCE OF A SINGLE CENTER.	Ana Santamaria	Received

1526-E	THIOTEPA FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN SOLID TUMORS	Ritsuro Suzuki	Received

1527-E	DELAYED RECONSTITUTION AND IMMATURE PHENOTYPE OF NATURAL KILLER(NK) CELLS FOLLOWING POSTRANSPLANT CYCLOPHOSPAMIDE IN 30 UNMANIPULATED HAPLOIDENTICAL TRANSPLANTATION PATIENTS. A PROSPECTIVE ANALYSIS	Ana Maria	Received

1528-E	UTILITY OF CHIMERISM ANALYSIS IN DETECTION OF POST-TRANSPLANT DISEASE RELAPSE IN PATIENTS WITH MYELOID NEOPLASMS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION	Mehrdad Hefazi	Received

1529-E	BUSULFAN THERAPEUTIC DRUG MONITORING IS NEEDED IN POPULATIONS WITH GENETIC HETEROGENEITY UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION	Murtadha Al-Khabori	Received

1530-E	HEMATOLOGICAL RECOVERY AFTER INTRA-BONE MARROW CORD-BLOOD TRANSPLANT WAS ENHANCED THROUGH LOCAL ENGRAFTMENT OF INJECTED SITE. A SINGLE CENTER PROSPECTIVE PHASE I/II TRIAL IN JAPAN.	Naoki Kurita	Received

1531-E	EXCELLENT LONG-TERM OUTCOME OF AUTOLOGOUS TRANSPLANTATION WITH INTERMEDIATE-DOSE INTENSIVE MELPHALAN (100 MG/M2, MEL100) FOR MULTIPLE MYELOMA: A SINGLE CENTRE STUDY.	Kentaro Fukushima	Received

1532-E	IMPACT OF DONOR AGE ON PERIPHERAL BLOOD AND BONE MARROW HEMATOPOIETIC STEM CELL HARVEST	Hyunsoo Cho	Received

1533-E	BASELINE PERIPHERAL BLOOD CD34+ CELL COUNT DOES NOT INFLUENCE PLERIXAFOR SUCCESS RATE	Ana Ferreira	Received

1534-E	AUTOLOGOUS PERIPHERAL BLOOD CD34+ CRYOPRESERVED WITH 5% DIMETHYL SULFOXIDE COMPARED TO 10%: BETTER VIABILITY OF CD34+ AND NO NEUROLOGICAL SIDE EFFECTS	Vincenzo Pavone	Received

1535-E	SINGLE VERSUS TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA â€" RETROSPECTIVE STUDY	Patrícia Silva	Received

1536-E	IS ALLOGENEIC STEM-CELL TRANSPLANTATION AN OPTION FOR PATIENTS WITH ACUTE LEUKEMIA AND MYELODISPLASTIC SYNDROME TRANSPLANTED WITH ACTIVE DISEASE? A CENTER EXPERIENCE	Sara Alonso	Received

1537-E	RETROSPECTIVE AUDIT OF A SINGLE CENTRE USE OF FRESH FROZEN PLASMA WITH OR WITHOUT PLASMA EXCHANGE TO REDUCE ISOAGGLUTININ TITRES PRIOR TO MAJOR ABO MISMATCHED HAEMATOPOIETIC STEM CELL TRANSPLANTS	Moon Ley	Received

1538-E	BONE MARROW EOSINOPHILIA CORRELATES WITH TREATMENT OUTCOMES BOTH AFTER AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Yanitsa Georgieva	Received

1540-E	IMMUNOPHENOTYPIC CHARACTERIZATION OF HUMAN MOBILIZED HEMATOPOIETIC STEM AND PROGENITOR CELLS: BIOLOGICAL AND CLINICAL IMPLICATIONS.	Valentina Giai	Received

1541-E	EXPRESSION OF TH17/TREGS AXIS ASSOCIATED REGULATORY FACTORS IN PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE	Qifa Liu	Received

1543-E	SCA1+ MESENCHYMAL STROMAL CELLS INHIBIT GRAFT-VERSUS-HOST DISEASE IN MICE AFTER BONE MARROW TRANSPLANTATION	Fan Wen	Received

1544-E	IN VITRO EXPANDED HUMAN CD4+CD25+FOXP3+ REGULATORY T CELLS IN NUTRIENT-DEPRIVED MEDIUM AS A POTENTIAL ARMAMENT IN THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE	Tzeon-Jye Chiou	Received

1545-E	PROGNOSTIC SIGNIFICANCE OF IMMUNOLOGIC RECOVERY AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMAS	Maria Cioch	Received

1546-E	COMPARISON BETWEEN HEALTHY DONOR-DERIVED BONE MARROW MESENCHYMAL STEM CELLS BM-MSCS AND HUMANDERMAL FIBROBLASTS: IMPACT ON CLINICAL APPLICATIONS OF HMSCS.	Mohammed Al	Received

1547-E	COMPARISON OF RED BLOOD CELL AND PLASMA DEPLETION EFFICIENCIES OF TWO METHODS FROM CORD BLOOD: AUTOMATED SEPAX (BIOSAFE) AND MANUAL CELLEFFIC (KANEKA)	Pinar Yurdakul	Received

1549-E	SOLUBLE FMS-LIKE TYROSINE KINASE-1 IN CHILDREN AND ADOLESCENTS WITH THALASSEMIA INTERMEDIA: RELATION TO PULMONARY VASCULOPATHY AND SUBCLINICAL ATHEROSCLEROSIS	Azza Tantawy	Received

1550-E	ASSOCIATION OF THE DYNAMIC STATUS OF COAGULATION FACTORS WITH L-ASPARAGINASE ADMINISTRATION IN THE INDUCTION PHASE OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA	Yasuo Kubota	Received

1551-E	UPPER AND LOWER EXTREMITY DEEP VEIN THROMBOSIS IN CHILDREN:A SINGLE CENTER EXPERIENCE	Mualla Cetin	Received

1552-E	RECURRENCES AFTER SPLANCHNIC VENOUS THROMBOSIS: RISK FACTORS AND EFFECT OF DIFFERENT TREATMENTS IN A RETROSPECTIVE MONOCENTER COHORT OF 154 PATIENTS.	Valerio De	Received

1553-E	THROMBIN INDUCES VASCULAR LEAKAGE THROUGH MACROPHAGE MIGRATION INHIBITORY FACTOR AND AUTOPHAGY DURING SEPSIS	Chiao-Hsuan Chao	Received

1555-E	ADAMTS-13 A NOVAL MARKER LINKING BETWEEN MICRO AND MACRO- VASCULAR DISEASE IN YOUNG TYPE -1 DIABETES PATIENTS	Azza Tantawy Stefano	Received

1556-E	PROGNOSTIC SIGNIFICANCE OF THE ABSOLUTE MONOCYTE COUNTS IN LUNG CANCER PATIENTS WITH VENOUS THROMBOEMBOLISM	Gyeong-Won Lee Stefano	Received

1557-E	PREDICTIVE POTENTIAL OF MARKERS OF COAGULATION, FIBRINOLYSIS AND ANGIOGENESIS IN CANCER PATIENTS	Elina Beleva Stefano	Received

1558-E	DURABLE LONG TERM REMISSIONS WITH EARLY USE OF RITUXIMAB IN PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)	Shahid Iqbal Stefano	Received

1559-E	ASSESSMENT OF LOW MOLECULAR WEIGHT HEPARIN ANTICOAGULANT EFFECT IN CHILDREN USING THROMBODYNAMICS GLOBAL HEMOSTASIS ASSAY	Pavel Zharkov Stefano	Received

1560-E	CRP, D-DIMER, LEUKOCYTE, BLAST AND PLATELET COUNTS AT THE TIME OF ALL DIAGNOSIS AS POSSIBLE BIOMARKERS FOR EARLY CEREBRAL VEIN THROMBOSIS	Saara Mertanen Stefano	Received

1561-E	CHILDREN WITH CEREBRAL INFARCT DUE TO CRANIOCERVICAL ARTERIAL DISSECTION IN A SINGLE CENTER	Selin Aytac Stefano	Received

1562-E	A BESPOKE â€˜APPâ€™ FOR THE INVESTIGATION AND MANAGEMENT OF DEEP VEIN THROMBOSIS	Sheena Patel Stefano	Received

1563-E	EFFICACY OF THROMBOPROPHYLAXIS IN THE PREVENTION OF THROMBOSIS IN PREGNANCY. EFFECTS ON THE INCIDENCE OF MISCARRIAGES.	Carolina Miranda Castillo	Received

1564-E	THROMBIN GENERATION (TG) POTENTIAL AND ACTIVATED PROTEIN C (APC) RESISTANCE IN PATIENTS ON CHRONIC ORAL ANTICOAGULANT THERAPY WITH VITAMIN K ANTAGONIST (VKA)	Cristina Verzeroli Castillo	Received

1565-E	POLYPHARMACY IN PATIENTS TREATED WITH NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS (NOACS) AND THEIR IMPLICATION IN THE PERIOPERATIVE SETTING. RESULTS FROM THE â€œREAL LIFEâ€ COHORT	Inés Valcarce Castillo	Received

1566-E	IMMOBILIZATION AS A RISK FACTOR IN VENOUS THROMBOEMOLISM. DIFFERENCES BY SEX AND AGE	Aránzazu García Raso	Received

1567-E	PROPHYLAXIS FOR VENOUS THROMBOEMBOLIC DISEASE IN PREGNANCY AND POSTPARTUM PERIOD.	Sofia Grille Raso	Received

1569-E	LMWH PROPHYLAXIS THROMBOTIC EVENTS IN HODGKIN LYMPHOMA PATIENTS	Alexander Poletaev Raso	Received

1570-E	CATALASE Ð¡âˆ´262Ð¢ GENE POLYMORPHISM AS A POSSIBLE RISK FACTOR FOR VENOUS THROMBOEMBOLISM IN THE POPULATION OF NORTH-WESTERN RUSSIA	Sergey Kapustin Raso	Received

1571-E	EVALUATION OF ABO BLOOD GROUP DISCREPANCIES IN A TERTIARY CARE CENTRE IN SPAIN	Maria Tenorio	Received

1572-E	USE OF A PEGYLATED CARBOXYHEMOGLOBIN BOVINE IN SEVERE LIFE-THREATENING ANEMIA	Ronald Jubin	Received

1573-E	CLINICAL COURSE AND OUTCOME OF NEWLY DIAGNOSED ACUTE LEUKEMIA PATIENTS PRESENTED WITH HYPERLEUKOCYTOSIS IN THAILAND: A 10-YEAR SINGLE-CENTER RETROSPECTIVE STUDY	Archrob Khuhapinant	Received

1574-E	DETECTION OF UNEXPECTED RED CELL ALLOANTIBODIES BY THE ENZYME/NACL GEL TEST ONLY	Aspasia Argyrou	Received

1575-E	SUCCESSFUL COMPATIBLE PHENOTYPE TRANSFUSION PROTOCOL TO PREVENT ALLOIMMUNIZATION IN SICKLE CELL DISEASE.	Ana Maria	Received

1576-E	THE MIRNA PROFILE OF PLATELETS STORED IN A BLOOD BANK AND ITS RELATION TO CELLULAR DAMAGE FROM STORAGE	Thais Pontes	Received

1577-E	MONITORING HEMOSTATIC POTENTIAL OF PLATELETS DURING STORAGE OF PLATELET CONCENTRATES FOR TRANSFUSION	Cinzia Giaccherini	Received

1578-E	INDIVIDUALIZED GCSF/PLERIXAFOR PBSC MOBILIZATION SCHEDULE ALLOWS SUCCESSFUL HARVEST ALSO IN POOR MOBILIZERS LYMPHOMA PATIENTS	Manuela Rizzo	Received

1579-E	GENETIC RISK FACTORS IN HUMORAL IMMUNE RESPONSE TO PLATELET ANTIGENS HLA AND HPA SYSTEMS IN MULTITRANSFUSED HEMATOLOGICAL PATIENTS	Larisa Golovkina	Received

1580-E	STUDY OF AN ALTERNATIVE PYROGEN TEST FOR BLOOD PRODUCTS USING MONOCYTE ACTIVATION TEST.	Ji Hye	Received

1581-E	INFILTRATION OF PLATELET RICH PLASMA OBTAINED IN OPEN SYSTEM IN PATIENTS WITH EPICONDILITIS	Aránzazu García Raso	Received

2075-LB	FAVORABLE OUTCOME OF PATIENTS WITH NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA HARBORING FLT3-ITD AND TREATED WITH CLADRIBINE ADDED TO DAUNORUBICIN AND CYTARABINE INDUCTION.	Wieslaw WIktor Jedrzejczak	Received

2076-LB	A NOVEL HOTSPOT FOR IKZF1 WHOLE GENE DELETIONS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA	Mariana Emerenciano Jedrzejczak	Received

2077-LB	PROGNOSTIC IMPACT OF TRANSPORTER GENE POLYMORPHISMS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA ADULTS	Juan Eduardo Megías	Received

2078-LB	NQO1 C609T VARIANTS ARE ASSOCIATED WITH TYPE I AND II MUTATIONS IN PEDIATRIC ACUTE MYELOID LEUKEMIA	Francianne Gomes Andrade	Received

2080-LB	REACTIVATION OF HEPATITIS B INFECTION IN HAEMATOLOGY PATIENTS RECEIVING RITUXIMAB THERAPY: EVIDENCE OF SUB-CLINICAL ALT FLARES IN HBSAG-/HBCAB+ PATIENTS	Strachan Mackenzie Andrade	Received

2081-LB	USING PET/CT TO ASSESS FDG NODAL UPTAKE AND IMPACT OF VIRAEMIA IN HIV-POSITIVE PATIENTS: A COMPARISON OF REACTIVE LYMPHADENOPATHTY, MULTICENTRIC CASTLEMAN DISEASE AND HIV-RELATED LYMPHOMA	Strachan Mackenzie Andrade	Received

2082-LB	EXPRESSION ANALYSIS OF GENES LOCATED IN THE COMMON REGION OF AMPLIFICATION IN PEDIATRIC B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA WITH INTRACROMOSSOMAL AMPLIFICATION OF CHROMOSOME 21	Mariana Emerenciano Andrade	Received

2084-LB	PREVALENCE AND TRENDS OF HBV, HCV, AND HIV SEROLOGICAL AND NAT MARKERS AND PROFILES IN SAUDI BLOOD DONORS	Wafa Elbjeirami Andrade	Received

2085-LB	ELEVATED PIM-2 GENE EXPRESSION IS ASSOCIATED WITH POOR SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA	Katarzyna Kapelko-Slowik	Received

2087-LB	DUSP4-MEDIATED ACCELERATED T-CELL SENESCENCE IN IDIOPATHIC CD4 LYMPHOPENIA	Karl Balabanian Andrade	Received

2088-LB	SEVERE NEONATAL JAUNDICE DUE TO A DE NOVO GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENT CLASS I MUTATION	Rafael Del Orbe	Received

2089-LB	ASSESSMENT OF THE EFFECTS OF ANEMIA ON CARDIOVASCULAR FINDINGS IN OBESE ADOLESCENTS	Hale Oren Orbe	Received

2090-LB	ANTIMICROBIAL-RESISTANT GRAM-NEGATIVE BACTERIA IN BLOODSTREAM INFECTIONS IN PATIENTS WITH PEDIATRIC HEMATOLOGY & ONCOLOGY AND PEDIATRIC BONE MARROW TRANSPLANTATION UNIT	Arzu Akcay	Received

2091-LB	PHASE 1/2, DOSE-ESCALATION STUDY OF ORAL NS-018 IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (POST-PV MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MF(POST-ET MF)	Tomonori Uno	Received

2093-LB	PLASMA EXCHANGE FOR ACUTE HUMORAL REJECTION OF RENAL ALLOGRAFT AFTER ABO-MATCH KIDNEY TRANSPLANTATION: 5-YEAR EXPERIENCE IN A UNIVERSITY HOSPITAL.	Ingrid Parra Salinas	Received

2094-LB	FINALLY A METHOD FOR ROUTINE DIAGNOSIS OF SOUTH-EAST ASIAN OVALOCYTOSIS	Pamela McLaughlin Salinas	Received

2095-LB	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH HEMOPHAGOCYTIC SYNDROME: SINGLE CENTER EXPERIENCE	Arzu Akcay	Received

2096-LB	POST TRANSPLANT ERYTHROCYTOSIS IN ELEVEN CASES	Pinar Ataca Salinas	Received

2097-LB	EVANS SYNDROME SECONDARY TO CHRONIC LYMPHOCYTIC LEUKAEMIA IS ASSOCIATED WITH ADVERSE BIOLOGICAL FEATURES AND OUTCOME.	Giuseppe CARLI	Received

20th Congress of EHA

11-14 June 2015 Vienna

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 11/06/2015 TO 12/06/2015

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.20eha.2015



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access